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Sporadic CJD is a rare but universally fatal neurodegenerative disease of unknown aetiology that
occurs worldwide. This study aims to characterise UK sCJD cases between 1993 and 2004 looking for
evidence of change over time. Transmission of cattle BSE to humans, with subsequent development of
variant CJD, has raised concerns that other novel phenotypes of human prion disease may develop with
potentially major public health implications. This study addresses this by reviewing suspect sCJD
patients referred before and after the identification of vCJD, by evaluating the phenotype of young
onset compared to older onset sCJD and by comparing UK cases with the sCJD databases in France
and other predominantly European countries with lower BSE exposure.
This study also aims to review the WHO sCJD diagnostic criteria and hence explore the differential
diagnosis of sCJD in the UK.
Methods
All suspected sCJD cases referred to the NCJDSU between 1993 and 2004 were evaluated by
retrospective case note review using the NCJDSU archives. A more detailed analysis of clinical
phenotype was performed on patients referred in 1993, 1994, 2003 and 2004, all cases with a negative
14-3-3 result and all patients aged 50 or less at disease onset. MRI, CSF, EEG and pathology results
were analysed. UK data were compared with European sCJD data extracted from the EUROCJD
database. Suspect sCJD cases that ultimately received an alternative, non CJD diagnosis were
reviewed, and the WHO sCJD criteria were evaluated.
Results and Conclusions
There is no evidence to support emergence of a novel, BSE related phenotype of human prion disease.
The sCJD demographic data and clinical phenotype are reassuringly similar between 1993/4 and
2003/4, between young and older onset cases and between UK and other European cases. The small
number of changes that have been observed can largely be attributed to alterations in data collection
and investigation use, plus improved case ascertainment. There is a suggestion that the proportion of
PRNP MM cases is decreasing in the UK and France, most likely related to improved identification of
atypical presentations. However, continued close observation ofPRNP trends is important.
The current WHO diagnostic criteria for sCJD are a useful tool, both for research purposes and
clinicians in daily practise. Incorporation of CSF 14-3-3 into the Probable sCJD classification has
resulted in improved sensitivity of 72% but at the expense of moderate reduction in specificity to 79%.
The positive predictive value remains high of 89%. Currently there is insufficient evidence to support
inclusion of MRI in the diagnostic criteria.
The differential diagnosis of sCJD is wide but Alzheimer's disease is the condition most commonly
mistaken for sCJD. However, a significant minority of individuals initially suspected of having CJD
never receive a diagnosis, sometimes even after neuropathological studies. Accurate disease
surveillance remains a priority, not only to ensure that atypical sCJD presentations are not
misdiagnosed, but also to assess putative risk factors for developing sCJD and to identify any novel
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Chapter 1: Introduction
A. Aims and Objectives
The primary aim of this study is to evaluate the characteristics of UK cases of
sporadic Creutzfeldt-Jakob disease (sCJD) and assess whether they have changed over
a ten year period, and to evaluate possible explanations for any disparities.
The emergence of variant CJD has heightened concerns that we may be missing other
human cases of prion disease, either related to BSE transmission or potentially from
other animal TSEs. All vCJD cases to date have been homozygous for methionine at
codon 129 of the prion protein gene, but we know that vCJD has been transmitted to a
methionine valine heterozygote by blood transfusion and we do not know what the
clinical picture might be in this context. It is possible that non methionine
homozygotes might display a novel BSE phenotype. This study aims to analyse
suspected sCJD patients in the UK before and after the identification of vCJD,
searching for any evidence that might support emergence of a novel human prion
phenotype. UK data will also be compared with European data extracted from the
EUROCJD database to assess if any observed changes are restricted to the UK or
reflect a more general Europe - wide shift. The BSE epidemic was maximal in the UK
with far smaller numbers of cases elsewhere in Europe, and the majority of vCJD
cases have also occurred in the UK. Any changes in sCJD characteristics that are
confined to the UK and correlate with BSE exposure are of particular interest. French
data is analysed separately as France occupies a position midway between the UK and
the other EUROCJD nations with respect to BSE and vCJD. Whilst it did not
experience a major BSE epidemic it had significant exposure to BSE via the UK
export market and has had more vCJD cases than any other country with the
exception of the UK (21 French vCJD cases as of February 2007).
Young onset suspected sCJD referrals are analysed in particular detail because vCJD
tends to occur in younger individuals than sCJD. Therefore the differential diagnosis
is particularly relevant in young adults with rapidly progressive dementia or other
features suggesting prion disease. Whilst we cannot be sure that a novel human
presentation of BSE would predominantly affect young adults it is reasonable to
examine this group particularly closely.
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The second principal aim of this study concerns the validity of the diagnostic criteria
for sCJD. This is addressed by comparing National CJD Surveillance Unit referrals
where a diagnosis of sCJD has been confirmed with those where an alternative
diagnosis has been made. Thus the differential diagnosis of sCJD is reviewed. This is
of interest for a number of reasons. On a practical, day-to-day basis the differential
diagnosis of sCJD is what matters to the clinical neurologist, particularly the
reassurance that a treatable alternative has not been overlooked. Secondly knowledge
of the sensitivity and specificity of sCJD diagnostic criteria is useful for clinicians and
relatives alike, to guide decisions regarding further investigation and to provide
families with a measure of diagnostic certainty. Thirdly it is vital to assess the final
diagnoses attributed to suspected sCJD referrals to ensure that potential novel CJD
phenotypes are not being missed. This is especially relevant since a definitive
neuropathological diagnosis is never made in a proportion of NCJDSU referrals in
which sCJD is ultimately excluded.
The objectives of the study are as follows:
• To evaluate sCJD referrals for the period 1993 to 2004 inclusive and assess
trends in absolute numbers, demographics and referral process.
• To perform more detailed analysis of all sCJD referrals in 2003/4 compared to
1993/4 with respect to clinical phenotype, referral process and investigations.
• To review the alternative diagnoses in non sCJD cases and identify which
clinical features and investigations are most discriminating between sCJD and
non-cases.
• To evaluate the current World Health Organisation (WHO) diagnostic criteria
for sCJD and assess whether modifications are indicated in light of changes in
diagnostic tools or the disease itself.
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• To review all sCJD cases aged fifty or less at onset that were referred between
1993 and 2004 and compare their clinical phenotype and investigation results
with a control older sCJD cohort.
• To compare UK data with European data to identify any changes in the
characteristics of sCJD in the UK which may correlate with BSE exposure.
B. Introduction
1.1 Introduction to Transmissible Spongiform Encephalopathies
Sporadic CJD is a neurodegenerative, uniformly fatal human disease characterised
pathologically by spongifonn change within the brain. It is a member of a larger
family of transmissible spongiform encephalopathies (TSE), which affect a variety of
mammalian species (table 1.1). The aetiology of the different TSEs varies but in all
cases the causative infective agent is believed to be a prion, a host encoded protein
devoid of nucleic acid (1). It is notable for its small size and resistance to degradation
by physical agents including heat, irradiation and chemicals. TSEs share three key
pathological features, namely spongiform change, neuronal loss and astrocytosis. In
addition amyloid plaque formation may occur within the brain. A pathological
hallmark of TSEs is central nervous system deposition of an insoluble, protease
resistant, cellular protein termed PrPSc (Sc for scrapie). A key feature distinguishing
prion diseases from other neurodegenerative conditions is their ability to be
transmitted, both experimentally and sometimes naturally.
23
Table 1.1 (2) Transmissible spongiform encephalopathies












Cattle epidemic UK; peak
1992. Small number of
native cases elsewhere
including the majority of
European countries, USA,
Canada and Japan.
Imported cases only in
Falklands, Oman.
Goat: France 2005.
Source of infection unknown:
? sporadic BSE, ? scrapie.






Cattle Atypical BSE first
identified in French cattle




























USA, Canada Unknown - not clearly linked








? scrapie infected feed
Kuru Humans Highlands of Papua New
Guinea
Perpetuated by cannibalism,
origin of index case unknown
sCJD Humans Worldwide Unknown
vCJD Humans Predominantly UK, smaller







Humans Worldwide but higher
incidence in Slovakia, Italy,
Israel
Mutation in PRNP gene
Iatrogenic CJD Humans Variable; hGH cases most
frequent in France and UK,
dura mater in Japan. 4 cases
or transfusion transmission
of vCJD in the UK
CJD infected pituitary




*BASE bovine amyloidotic spongiform encephalopathy
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1.2 Transmission experiments
The prototypical TSE, scrapie, was the first to be experimentally transmitted to a
previously healthy sheep by inoculation of scrapie infected spinal cord in 1936.
Further support for scrapie transmission came from a scrapie outbreak in sheep that
had been vaccinated against the disease, louping ill, using a preparation containing
brain from sheep exposed to natural scrapie (6). Hadlow, an American veterinary
surgeon, noted the pathological similarity between kuru and scrapie in 1959 (7). This
observation stimulated the successful transmission of kuru into chimpanzees by
intracerebral inoculation in 1966 (8). Two years later CJD was transmitted to
chimpanzees (Gibbs 1968) (9) and since then there have been numerous TSE
transmission experiments including Gertsmann Straussler Scheinker syndrome to
mice and Fatal Familial Insomnia to mice (10,11, 12).
The species barrier refers to the increased difficulty in transmitting infection between
species as opposed to within a species (13). In prion disease this is by no means
absolute, as demonstrated by BSE spreading to humans, ungulates and cats. The
barrier is usually reflected in an increase in incubation time but, on some occasions, in
failure of transmission altogether. E.g. BSE has failed to transmit to dogs, and rabbits
appear completely resistant to experimental infection (14). However, if successful
transmission occurs then sequential passage through the new species appears to allow
the incubation time to shorten and stabilise (15). Ease of inter species transmission is
believed to relate to PrP structure, with greater homology between donor and host PrP
reflected in greater ease of TSE transfer. E.g. transgenic mice expressing hamster PrP
are highly susceptible to infection with hamster prions unlike wild type mice (16).
This property of transmission is a key feature of prion diseases but such experiments
are time consuming and expensive, even using mouse models with relatively short
incubation periods. Therefore new techniques have been developed to diagnose and
research TSEs, utilising detection of protease resistant PrP in infected tissue.
1.3 Prion hypothesis
Alper was first to suggest that the scrapie infective agent might lack nucleic acid
following an experiment in 1957 where scrapie infectivity persisted despite high dose
ionizing radiation. (17). Almost 20 years later this information was resurrected and
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Stanley Prusiner postulated the prion hypothesis (18). He won the Nobel prize for
medicine and physiology for his work in 1997, despite the fact it was controversial
and not fully validated. The term prion derives from proteinaceous infectious particle
(with the i and o reversed for ease of pronunciation), referring to the absence of
nucleic acid in prions. PrP is encoded by a chromosomal gene in the host rather than
nuclear DNA within the infecting particle itself, and PrP mRNA levels do not increase
throughout the course of prion infection. These observations challenge conventional
theories of infectivity. The normal PrP protein is PrPc, a 33 - 35 kD protease sensitive
protein that is structurally rich in a helices. It is anchored to the cell surface by a
glycosyl phosphotidyl tail. PrPc is present throughout most mammalian tissues but is
particularly concentrated in the brain. Its normal role remains incompletely
understood but interestingly PrP knock out mice appear relatively normal, with
normal life expectancies although in one study circadian rhythm and sleep wake cycle
were disrupted (19).
According to the prion theory an abnormal isoform of PrP termed PrPSc is derived by
a post-translational process involving conformational change. One possibility is that
spontaneous fluctuations in PrPc structure could create a partially unfolded
intermediate isoform (PrP*) and this might either degrade, revert to PrPc or
occasionally undergo further conformational change to PrPSc. The disease associated
PrPSc is rich in P pleated sheets and relatively protease resistant (20). It acts as a
template for conversion ofmore PrPc to PrPSc. It is believed that PrPSc is the principle
and possibly the only agent required to catalyse this process. Each type of human
prion disease can potentially be explained by this hypothesis. E.g. In sporadic CJD the
initial formation of PrPSc is a rare, stochastic event; in acquired CJD (iatrogenic and
variant) a seed of PrPSc is introduced acting as a catalyst for more to form; in genetic
CJD underlying mutations mean PrPc is inherently less stable and therefore more
likely to form PrPSc (21).
There is some evidence to support this biologically eloquent hypothesis. PrPc and
PrPSc have identical amino acid sequences when analysed by mass spectrometry, but
spectroscopy confirms they have different structures with respect to the proportion of
a helices and p pleated sheets. Fluorescence and circular dichroism spectroscopy
experiments have provided some support for an intermediate PrP isoform (284, 285).
In another study mice inoculated with recombinant PrP died of neurological
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dysfunction and brain extracts were positive for protease resistant PrP. Subsequently
these brain extracts transmitted the disease to wild type mice with the creation of a
novel prion strain, providing supportive evidence that prions alone are the infective
agent (22). As predicted animals devoid of PrPc are resistant to prion disease and fail
to propagate infection. (23, 24, 25). The unique protein only explanation for prion
propagation means that prions differ from all other known infectious agents.
However, many questions remain unanswered, not least how accumulation of PrPSc
(or less likely absence of PrPc) causes disease, and how PrPSc can catalyse
conformational change. There is ongoing controversy as to whether PrPSc is really the
infectious agent. Recently mouse models have demonstrated high infectivity in the
absence of PrPSc in brain tissue (26), and conversely not all PrPSc is associated with
infectivity. The prion theory also fails to satisfactorily explain the many strains of
TSEs with the different, strain specific phenotypes. Therefore, the validity of the
prion hypothesis continues to be debated (27, 28).
1.4 TSE strain variation
TSE strain variation refers to the fact that numerous different prion strains have been
identified, mainly by mouse transmission experiments. Individual strains differ
primarily in terms of incubation period and neuropathological lesion profile, but also
in some cases by ease of transmission, clinical features and susceptibility to
inactivation. The extent of strain variation in natural as opposed to experimental TSEs
is less clear, and the number of different strains varies depending on the type of prion
disease. For instance over 20 scrapie strains have been determined experimentally in
mice whereas BSE is caused by a single strain whose features have remained
constant, even after transmission into 7 species. Hence there appears to be strain
specific information, which is independent of the host PrP genotype (15). What is
remarkable is that prions, apparently composed of the same protein, can result in
phenotypically distinct transmission states. The basis of prion strain variation at the
molecular level is not completely understood nor adequately explained by the prion
hypothesis but appears to relate to differences in PrP conformation and glycosylation
(29, 30). However, PrP type may be a surrogate marker for TSE strain rather than the
true determining factor.
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1.5 Historical perspective on human prion disease
The CJD story dates from 1920 when H.G. Creutzfeldt, a German clinician with
neuropathology training, described the case of a 22 year old female with a 6 year
history of mild incoordination, culminating in 18 months of progressive dementia,
spasticity, myoclonus and finally status epilepticus. Post mortem revealed moderate
atrophy with degeneration of pyramidal tracts and scattered areas of partial necrosis.
Over the next 3 years A Jakob, a neuropathologist, described 5 further cases which
shared some clinical features with Creutzfeldt's original patient and which he
believed shared a common, novel clinical syndrome. They demonstrated a variable
combination of dementia, pyramidal, extrapyramidal, cerebellar and psychiatric signs
with death occurring between 6 and 13 months after illness onset. Pathologically all
showed diffuse neuronal degeneration and, in some instances, astrocyte proliferation.
Jakob denoted the clinical triad of cortical dysfunction, extrapyramidal signs and
spastic-paretic pyramidal signs as 'spastic pseudosclerosis' (31).
In retrospect Creutzfeldt's patient probably did not represent a case of CJD, neither
meeting the current clinical or major histological criteria. However, at least 2 of
Jakob's 5 original cases are believed to be CJD, based on evidence of spongiform
change on review of the pathology, with the remaining three probably representing
forms ofmotor neurone disease and two toxic or metabolic encephalopathies. (32).
The eponymous term Creutzfeldt - Jakob Disease was first suggested in 1922 by
Spielmeyer, a colleague of Creutzfeldt's, to describe these and similar cases.
However, ongoing debate about the characteristic phenotype, pathology and aetiology
led to a proliferation of synonyms including disseminated encephalomyelopathy
(Jakob 1921), cortico-pallido-spinal degeneration (Davison 1932), presenile dementia
with cortical blindness - Heidenhain's syndrome (Meyer et al 1954) and subacute
spongiform encephalopathy attributable to vascular dementia (Nevin et al 1960 (33)).
The term CJD only attained widespread acceptance in the 1960s following the
seminal papers by Nevin and Jones (34).
Historically, cases with a combination of dementia and prominent lower motor
neurone signs were thought to have an amyotrophic variant of sCJD, but this is no




Kuru is a human TSE confined to the Fore tribe in the highlands of Papua New
Guinea. It was first formally described by Gajdusek in 1957 but historically probably
existed from the early 20th century (36). In the Fore language kuru means shiver,
referring to the tremor which characterises this disease (37). Typically it presents with
unsteadiness, followed by increasing ataxia, tremor, dysarthria, rigidity, involuntary
movements and emotional lability (hence the term 'laughing death') (38). Frank
dementia is believed to be unusual. Death usually occurs within a year, often with
mutism being present in the final stages (39). Neuropathologically there is cerebellar
atrophy, astrocytosis, mild spongiform change and, in over 70%, of cases striking PrP
positive amyloid plaques, particularly concentrated in the cerebellum.
Kuru is believed to have been propagated by ritualistic cannibalism, which was
practised amongst the Fore people in the first part on the 20th century, resulting in
gastrointestinal, mucosal and skin exposure to CNS tissue. It is postulated that the
index case may have been a chance occurrence of sporadic CJD but there is no
evidence to support or refute this, although sCJD is certainly recognised in Papua
New Guinea (40). The disease was more common in women and children (41),
probably reflecting cultural practice where men were less exposed to CNS tissue
during cannibal rituals (39).
Cannibalism was forbidden by the Australian government in 1954 and since then the
incidence of kuru has markedly declined, although it has not, as yet, disappeared
completely. 11 cases were identified between 1996 and 2004 and for these individuals
the estimated incubation period ranged from 34 to 56 years (42). These recent cases
were predominantly methionine valine heterozygous (MV) at codon 129 on PRNP
analysis. The MV genotype is associated with reduced susceptibility to kuru
compared with methionine homozygotes, but with a prolonged incubation period (43)
(see section 1. 8 for discussion of effect of codon 129 genotype).
1.7 Creutzfeldt-Jakob disease
Prion diseases are unique in that they exist in sporadic, genetic and infectious forms.
There are four distinct types of human CJD; sporadic, genetic, variant and iatrogenic.
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Sporadic and variant CJD are described in detail later in this introduction (sections 1.9
and 1.10).
Genetic TSEs are associated with mutations in the prion protein gene (PRNP) and
comprise genetic CJD, Gerstmann Straussler Scheinker syndrome (GSS) and fatal
familial insomnia (FFI). However, increasingly genetic cases are being defined by the
precise mutation as this is the dominant factor influencing clinical and pathological
phenotype. For example the E200K insertion presents in a manner typical for sCJD
(44) whereas codon 102 and codon 105 point mutations usually produce the GSS
phenotype, characterised by a slowly progressive cerebellar syndrome with late
cognitive decline (45). FFI occurs when a point mutation at codon 178 is coupled
with methionine at codon 129 of the mutant allele (cis - 129 M). Clinically insomnia
and dysautonomia are prominent features of FFI, associated with predominantly
thalamic pathology (46, 47). Although particular mutations are associated with
characteristic phenotypes there may be variability, even within a single family.
Genetic TSE inheritance is autosomal dominant and penetrance varies dependant on
the mutation but is generally high. Despite this only one third to one half of inherited
cases have a family history (44) and this may relate to non paternity, relatives dying
of alternative causes prior to CJD onset or de novo mutations (as recently reported in
some UK and other European families with the classic GSS P102L mutation (286)).
This emphasises the need to offer PRNP gene sequencing in all suspected CJD
individuals, irrespective of family history. Genetic TSEs are recognised throughout
the world but the incidence varies, with Slovakia, Italy and Israel having particularly
high levels (48, 49, 50). Overall it remains an extremely rare condition, comprising
about 10% of all CJD cases (44).
Iatrogenic CJD is caused by inadvertent transmission of infection during medical or
surgical procedures. The first reported case related to cadaveric corneal graft
transplantation (51) but iatrogenic CJD is most commonly a result of human dura
mater grafts or human pituitary growth hormone. Other implicated mechanisms
include human pituitary gonadotrophin, neurosurgical instrumentation and depth
electrodes (52, 53). The majority of the dura-related cases have been Japanese,
probably reflecting their high use of dura mater during neurosurgical procedures (54).
The resultant clinicopathological phenotype of iatrogenic CJD depends partly on the
route of infection. Peripherally acquired growth hormone cases are associated with a
progressive cerebellar syndrome and typically survive for over a year (55), whilst
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intracranial infection sources such as dura mater cases are more variable in their
clinical onset and duration. Some have cerebellar presentations (53, 56) whereas
others have focal onsets, often corresponding to the site of dural graft placement (57).
Illness duration in UK dura cases has ranged from 2 to 33 months (57). Incubation
period is also influenced by route of infection. In growth hormone - related CJD the
peak risk is estimated to occur 20 years after first exposure (58). In dura - related
iatrogenic CJD the incubation period has ranged from 45 to 177 months with a mean
of 7.75 years (93 months)(57). PRNP codon 129 genotype influences susceptibility
and is discussed below (section 1.8).
1.8 Codon 129 polymorphism and CJD
The codon 129 locus of the human PRNP gene is a variable region encoding either
methionine or valine. Thus three possible combinations exist: methionine
homozygous (MM), valine homozygous (VV) and methionine valine heterozygous
(MV). This locus has been identified as having a significant impact on disease
susceptibility and expression in CJD.
All three codon 129 genotypes are potentially susceptible to sCJD but an excess of
cases are MM suggesting this combination increases susceptibility (table 1.2). In
addition codon 129 influences phenotype; atypical sCJD presentations are more likely
to be non MM cases. All vCJD patients thus far have been MM. It remains unknown
whether MV and W individuals are resistant to vCJD or have a longer incubation
period and therefore have yet to present. However, vCJD has been transmitted to a
non MM patient. An individual heterozygous for methionine and valine was exposed
to vCJD via blood transfusion and died 5 years later without CJD symptoms. PrPSc
was detected in the lymphoreticular tissue (spleen) but not in the brain (59).
Homozygosity for either methionine or valine is a risk factor for the development of
iatrogenic CJD (53, 60). In genetic CJD codon 129 influences disease expression. E.g.
Characteristically the combination of VV and a mutation at codon 178 results in a
sCJD - like phenotype whereas the same mutation co-segregating with methionine at
codon 129 results in FFI (61), with slight variation in disease duration and phenotype
depending on whether the individual is homozygous or heterozygous for methionine
(62). However, genotype / phenotype studies on Spanish D178N cases suggest the
clinical picture may be less distinct, with a typical sCJD phenotype being recognised
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in MM and MV patients. This suggests that factors other than codon 129
polymorphism influence disease expression of the codon 178 mutation (63).
Table 1.2 (64). Codon 129 distribution in the normal UK population and in sporadic
and variant CJD
Codon 129 genotype % MM % MV % VV
Normal UK population 39 50 11
sCJD (1990-2001) 69 15 17
vCJD 100 0 0
1.9 Sporadic CJD
Sporadic CJD has an annual incidence of 1 - 2 cases / million people and this figure is
fairly constant between countries with an active surveillance system (65). An
exception is Switzerland where the incidence has been unusually high at 2.2- 2.6
cases / million since 2001, although it is now declining to the norm (66, 67). There is
no clear explanation for this and it may reflect an excellent surveillance system or a
true increase in sCJD frequency, although no comparable rises have been reported in
neighbouring countries such as Austria (68). Switzerland did have a higher incidence
of BSE than the rest of continental Europe between 1995 and 1998 but none of their
cases were clinically or pathologically suggestive of vCJD (66).
The mean age of sCJD disease onset is 66 years (69) and the majority of cases occur
between the ages of 50 and 75, although patients as young as 14 and as old as 86 have
been recognised (70, 71). There is no significant gender difference. Disease duration
is typically short with a median of 6 months from onset to death. Only 14% of cases
survive longer than a year and only 5% live for two years or more (72).
The aetiology of sporadic CJD remains unknown. It occurs in a worldwide
distribution with no sustained, statistically significant clustering to suggest particular
environmental factors (73, 74). Numerous risk factor studies have been performed but
recall bias is often a problem and no convincing risk factors have been identified (75,
76, 77, 78). It is postulated that it is caused by the spontaneous formation of PrPSc in
the brain but if this were the case one might expect the incidence to increase with age,
yet it decreases in the very elderly, although this may partially reflect limited case
ascertainment in the elderly (69, 71).
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1.9.1 Clinical Features of Sporadic CJD
The characteristic clinical picture in sCJD is one of rapidly progressive dementia with
associated neurological features, particularly cerebellar ataxia, pyramidal signs and
myoclonus. Visual disturbance, ocular movement disorders, extrapyramidal signs and
hallucinations are all well recognised. The final stages are often characterised by an
akinetic mute state. The illness may be preceded by a non specific prodrome including
fatigue, low mood, weight loss, personality change and headaches. Some of these
symptoms may reflect the early stages of dementia but potentially some may relate to
recall bias.
Various studies have reviewed the clinical characteristics of sCJD and their findings
are summarised in tables 1.3 and 1.4. The figures vary slightly from study to study but
many of the inconsistencies are explicable on the basis of different definitions of
symptoms and signs, and different methods of data collection (e.g. retrospective or
prospective, proportion of cases seen in life).
Table 1.3 Clinical characteristics of sCJD: symptoms at presentation (expressed as
percentage) (79)
Study Eng and Wales France USA UK
1970-79 1968-77 1963-93 1990-94
(n = 124) (n = 124) (n = 232) (n = 144)
Dementia 21 29 48 19
Ataxia 19 29 33 39
Behavioural 18 30 29 15
disturbance
Dizziness 11 8 13 n/a
Visual 9 17 19 10
Involuntary 5 1 4 2
movements
Dysphasia 5 n/a n/a 4
Sensory 4 2 6 n/a
Headache 3 10 11 n/a
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Table 1.4: Clinical characteristics of sCJD: signs during course of illness (expressed
as percentage) (79)












Dementia 100 100 100 100
Myoclonus 82 84 78 85
Pyramidal 79 44 62 62
Dysphasia 62 n/a n/a 58
Cerebellar 42 56 71 85
Akinetic mutism 39 n/a n/a 75
Primitive
reflexes
30 n/a n/a 58
Cortical
blindness
13 n/a n/a 52
Extrapyramidal 3 60 56 34
Lower motor
neurone
3 12 12 17
Seizures 9 9 19 13
The commonest sCJD presentation is with a rapidly progressive dementia but other
onsets are recognised, including extrapyramidal, psychiatric and stroke - like
presentations. Two clinical subtypes of sCJD deserve particular mention.
The Heidenhain variant presents with isolated visual disturbance and is named after
Heidenhain who first described this phenotype in 1928 in an article describing three
cases of CJD including two patients with prominent, early visual symptoms (80). The
eponymous term was not coined until 1954 (81). Initial symptoms can be as diverse as
pallinopsia, tunnel vision, peripheral field defects or simple blurring (82, 83). These
visual problems persist in the absence of cognitive impairment for days to weeks.
Then a typical sCJD course follows with rapid decline associated with dementia,
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usually myoclonus and cortical blindness. Heidenhain cases are invariably methionine
homozygous at codon 129 of the prion protein gene. They are rare representing less
than 5% of all sCJD cases (82)
Brownell - Oppenheimer variant refers to the pure cerebellar presentation of sCJD
where isolated cerebellar symptoms may persist for several weeks before dementia
and a more typical CJD picture ensues (84). It was first described in the literature in
1955 under the heading 'The ataxic - cerebellar form of CJD' (85). Brownell and
Oppenheimer went on to describe the clinical and pathological features in 1965, hence
the historical eponymous name for this sCJD type (86).
The rapidity of deterioration in sCJD usually helps distinguish it from other dementias
and neurodegenerative conditions.
1.9.2 Investigations in sporadic CJD
(i) Blood tests
There are no specific findings on blood tests in sCJD and their primary value is to
exclude other diagnoses. Attempts are being made to identify a diagnostic blood test
for sCJD (87) but no such test is currently available, although PrPSc has been detected
in blood samples from hamsters with scrapie (88).
(ii) Cerebrospinal fluid
Routine examination of CSF in sCJD is usually unremarkable with normal glucose
and no cells although protein may be modestly elevated (usually less than lg /1) (89,
90). The most valuable CSF test is 14-3-3 analysis. 14-3-3 refers to a family of acidic,
low molecular weight proteins that exist in mammalian tissue in 7 isoforms, 5 of
which are present in neuronal cells. They have diverse roles including regulation of
neuronal development, cell - cell signalling and production of neurotransmitters. In
1986 2 proteins entitled pi30 and p 131 were detected in the CSF of 21 sCJD patients
(91). Subsequently they were identified as members of the 14-3-3 family and a
diagnostic test for sCJD was developed utilising SDS / PAGE and immunoblotting
techniques (92, 93). 14-3-3 analysis was introduced to the UK in Dec 1996. The
World Health Organisation (WHO) diagnostic criteria for sCJD were modified in
1998 to include CSF 14-3-3, with a positive result classifying a possible case as
probable (94). The assay sensitivity is 90 - 97% (95, 96, 97) and those cases with a
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negative result appear to be clinically and pathologically atypical, often with a
younger age of onset and prolonged disease duration (98). This may reflect the fact
they are more likely to have unusual codon 129 - prion protein isotypes such as MM2
and MV2 (see section 1.9.4 for classification based on codon 129 - PrP isotype).
However, 14-3-3 detection in CSF is not unique to sCJD and is recognised in
association with acute neuronal damage in diverse conditions including stroke,
paraneoplastic disease, inflammation and post seizure activity (table 1.5) (99, 101).
The value of the test is diminished when used as a screening tool for unselected
patients with dementia (100, 101). The specificity of 14-3-3 in diagnosing sCJD
varies depending on the population assessed but has been reported to be 87 - 100% in
the context of CJD surveillance (96, 97, 99, 101). The aetiology of a positive 14-3-3
result is incompletely understood but it is assumed to relate to massive neuronal
damage with leakage of brain proteins into the CSF (93, 101). The false positive 14-3-
3 results seen in certain inflammatory conditions and following cerebral infarction
would support this theory.
Other CSF proteins have also been investigated as diagnostic tools in sCJD. S-100
and neuron-specific enolase (NSE) are both elevated but are less specific or sensitive
than 14-3-3. (102, 103, 104). A recent paper suggested tau has comparable sensitivity
to 14-3-3 in sCJD diagnosis (104) and there is ongoing work assessing the sensitivity
and specificity of total tau and phosporylated tau levels (105).
(iii) Magnetic Resonance Imaging
MRI is primarily performed to exclude alternative diagnoses but there is now
evidence it can support the diagnosis of sCJD. The characteristic finding is
hyperintensity of the putamen and caudate head (fig 1.1), usually present bilaterally
but occurring asymmetrically in 10 - 20%. Sensitivity is reported at 60 - 80% with a
specificity of around 90% (106, 107, 108, 109, 110). FLAIR and DWI sequences
appear most sensitive, with DWI being particularly good at detecting early changes
(111, 112). The hyperintensity is recognised most easily on axial views. The
differential diagnosis for basal ganglia high signal includes Wilson's disease, carbon
monoxide poisoning, mitochondrial disorders, haemolytic uraemic syndrome and
variant CJD (although in the latter the posterior thalamic hyperintensity is more
pronounced than the caudate / putamen signal change). However, most of these
conditions should be readily clinically distinguishable.
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Other radiological findings in sCJD include cortical hyperintensity (fig 1.2)( 113),
periaqueductal grey matter signal change, hippocampal hyperintensity and atrophy
(probably correlating with disease duration).
Currently the WHO diagnostic criteria for sCJD do not include MRI features, because
of limited information on specificity.





The typical EEG in sCJD shows periodic, triphasic sharp wave complexes occurring
at about 1 / second, usually generalised throughout the trace (fig 1.3). Occasionally
periodic lateralised epileptifonn discharges (PLEDS) are seen initially but these are
have a much wider differential diagnosis (114). Objective criteria have been published
(115) and when these are applied sensitivity of the EEG is 64 - 67% and specificity 74
- 91% (115, 116, 117). However, sensitivity varies depending on the underlying
codon 129 genotype / prion protein isotype combination with periodic complexes
being detected most frequently in MM1 and MV1 cases and only rarely in valine
homozygotes (118, 119, 120, 121). Sequential EEGs may be required to detect the
typical pattern, but the triphasic complexes may disappear as the disease advances.
The EEG is rarely if ever truly normal in established sCJD.
An apparently typical EEG even in the presence of dementia does not guarantee a
diagnosis of CJD and false positive EEGs are recognised in Alzheimer's disease,
Lewy Body dementia, vascular dementia (122, 123, 124), plus other less confusing
clinical scenarios such as lithium toxicity (125).
Table 1.5. The differential diagnosis of basal ganglia hyperintensity on MRI, periodic
complexes on EEG and a positive 14-3-3 CSF result
Differential diagnosis of a
positive 14-3-3 result
Radiological differential






Acute stroke Wilson's disease Alzheimer's disease
Post seizure Mitochondrial disease Lewy body dementia
Variant CJD Variant CJD (but pulvinar
brighter)
SSPE
Paraneoplastic encephalitis Huntingdon's disease Lithium toxicity
Meningoencephalitis Encephalitis ECT




Intracerebral malignancy Hypoxic brain damage
Alzheimer's disease Carbon monoxide poisoning






1.9.3 Neuropathology of sporadic CJD
Macroscopically the sCJD brain may look normal but more often is atrophic, either
diffusely or focally, although the hippocampi are usually spared in contrast to other
degenerative dementias, particularly Alzheimer's disease. The three key
histopathological features of sCJD are spongiform change, neuronal loss and gliosis,
(astrocytes and microglia) (126). Neuronal loss and gliosis occur in many
neurodegenerative conditions but spongiform encephalopathy is more specific and
therefore a more useful diagnostic finding. Spongiform change is characterised by the
presence of vacuoles in the neuropil of the deep cortical layers, cerebellar cortex or
subcortical grey matter (fig 1.4). The vacuoles may become confluent, disrupting the
cortical cellular architecture. The distribution of spongiform change is variable in
sCJD but the most constant affected region is the head of the caudate nucleus whereas
spinal cord and brainstem are rarely involved. The white matter can be involved but
extensive white matter degeneration with necrosis distinguishes the 'panencephalic'
variant of sCJD (127). This is rare outwith Japan. The regional distribution of
spongiform change has been shown to be influenced by PrP glycotype and PRNP
codon 129 genotype (128).
Fig 1.4
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sCJD: confluent spongiform change
However, spongiosus is not specific to CJD. Focal changes indistinguishable from
spongiform change in CJD are occasionally seen in Alzheimer's disease and diffuse
Lewy Body dementia. Superficial 'spongy' alterations are associated with Pick's
disease, and perineuronal vacuolation can occur secondary to hypoxia. Status
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spongiosus can be the end result of extensive neuronal loss of various aetiologies
including long duration sCJD and other, non PrP dementias (129).
Immunohistochemical identification of PrPSc has become a useful tool for diagnosis
of sCJD. Normal brain contains only PrPc which is fully degraded by proteinase K.
PrPSc is either deposited in a diffuse, synaptic pattern, a patchy, perivacuolar
distribution or in plaques (figs 1.5, 1.6, 1.7). True kuru like plaques are seen in only
10 - 15% of sCJD cases (130) and may be visible without immunohistochemistry,
predominantly in the cerebellar cortex. Plaque-like PrP deposits are more common
and require immunochemical staining to be visualised. There is increasing evidence
that microglial cells play a crucial role in PrP plaque formation (131, 132). Similar to
spongiform change the pattern and distribution of PrP is influenced by codon 129
genotype and PrP glycotype (120,128).
Fig 1.5
** •















9 ~ i * ''





Western blot reveals two possible isoforms of PrPSc in sCJD, types 1 and 2A,
differing in terms of electrophoretic mobility. This is determined by relative
molecular mass, reflecting the degree of proteinase K-mediated truncation of PrP at
the N terminus, (type 1 21 kDa, type 2A 19 kDa). PrP profile can be characterised
further by glycosylation pattern on immunoblot. Diglycosylated, monogylcosylated
and non glycosylated PrP occur but in sCJD the monoglycosylated protein
predominates. A definite neuropathological diagnosis of sCJD requires either
evidence of spongiform encephalopathy in cerebral and / or cerebellar cortex and / or
subcortical grey matter, or an encephalopathy with PrP immunoreactivity. (133).
1.9.4 Sporadic CJD classification
It has been proposed that sCJD phenotypes are determined by the combination of host
PRNP genotype and PrPSc isotype (characterized by molecular mass) (134, 135).
Subsequently Parchi et al defined a classification system for sCJD subtypes,
identifying six phenotypic variants with differing clinical features and neuropathology
from a study of three hundred confirmed sCJD cases (120) (table 1.6).
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Table 1.6. sCJD classification based on codon 129 genotype and PrP isotype (Parchi
classification)
Codon 129 / PrP isotype Clinical profile Neuropathology




















MV2 Prominent ataxia and
dementia
Kuru plaques and plaque
like PrP deposits
VV2 Early ataxia, dementia
often late
Similar to MV2 without
kuru plaques
The commonest sCJD phenotype is associated with MM1 or MV1, accounting for
70% of cases. Such patients usually have the classic sCJD triad of rapidly progressive
dementia, myoclonus and a typical EEG. The Heidenhain presentations are also
contained within this subgroup. The second most frequently encountered phenotype
(seen in 16%) occurs with VV2, the so called ataxic variant. The other codon 129 /
prion protein isotypes combinations are all rare and are associated with long disease
duration. MM2 has two characteristic phenotypes with different PrP gylcosylation
ratios; MM - thalamic which is indistinguishable from fatal familial insomnia, and
MM - cortical with prominent dementia. However, it should be noted that the
pathological and particularly the clinical phenotypes associated with each codon 129 /
PrP type are not absolute and are generalisations only. In fact other studies have
shown only weak correlation between codon 129 / prion protein isotype and clinical
phenotype and there is likely to be considerable overlap in clinical features between
different Parchi subtypes (136).
To confuse matters further there are two other sCJD classification systems in use,
both subdividing Parchi group MM1 into two. Collinge et al's system identifies three
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rather than two PrPSc types, distinguished by gel electrophoretic mobility. Thus
Collinge types 2 and 3 correspond to Parchi PrPSc types 1 and 2 respectively, but
Collinge type 1 has a higher molecular mass than any PrP in the Parchi system and
clinically it is suggested that Collinge type MM1 is phenotypically distinct with a
shorter disease duration than Collinge defined MM2 sCJD (29, 128). Zanusso et al
also identify two subtypes within Parchi sCJD MM1, in their case based on different
pH dependant PrPSc gel migration and differences in disease duration (137). However,
a recent study has re-evaluated these findings and the different classification systems
and did not feel subdivision of Parchi sCJD MM1 was clinically, neuropathologically
or experimentally justified (although admittedly the authors included Parchi and
Gambetti, proposers of the original system) (138). In this thesis the Parchi system will
continue to be used as it is currently the most widely accepted sCJD classification.
Codon 129 / PrP type also influences sensitivity of CJD investigations. EEG is most
often typical in MM1 / MV1 patients. CSF 14-3-3 is positive in the majority of cases
but the infrequent negatives are usually seen in association with PrP 2 (139, 140,
119). The relationship between MRI findings and PRNP / PrP type is less
straightforward. The frequency of basal ganglia hyperintensity varies with molecular
subtype but is recognised in all six Parchi types. Cortical hyperintensity is probably
seen most commonly with MM1 and MM2 (141). Thalamic high signal has been
associated with MV2, MM2 and VV2 (142, 143, 144).
Occasionally a mixture of PrP 1 and 2 is detected and recent evidence suggests that
the harder you search for multiple PrP types the more likely you are to find them,
although the true prevalence of multiple types is unknown (145). Conventional
western blot analysis for the detection of PrP types is quantitatively limited and it is
likely that the prevalence of PrP 1 / 2 co-occurrence is underestimated. Newer
techniques using specific antibodies are proving more successful in detecting each
PrP type. It is likely that as experimental techniques become more sensitive more
sCJD patients will be identified as having both PrP type 1 and 2. This casts doubt on
the current sCJD classification system based on the PRNP polymorphism and one or
other PrP type. However, one PrP subtype usually predominates and this often
correlates with the neuropathology and clinical presentation. (146, 147), but there is
emerging evidence that when large sCJD cohorts are studied those cases with mixed
PrPSc types may have a different clinical phenotype (121).
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To date no sCJD case has been associated with PrP type 2B which is characteristic of
vCJD (whereas it is type 2A in sCJD due to the different glycosylation pattern).
1.9.5 Diagnostic criteria for sporadic CJD
Diagnostic criteria for sCJD were first proposed in 1979 by Masters et al and have
subsequently been revised three times (148). The current criteria were established in
1998, incorporating the CSF 14-3-3 result (94).
CurrentWHO criteria: Rotterdam 1998
I Rapidly progressive dementia
II A) Myoclonus
B) Visual or cerebellar problems
C) Pyramidal or extrapyramidal features
D) Akinetic mutism
III Typical EEG
1.0 Definite: Neuropathologically / immunocytochemically confirmed
2.0 Probable: I + 2 of II + III or I + 2 of II + positive 14-3-3 CSF protein
3.0 Possible: I + 2 of II + duration < 2 yrs
4.1 Unclear diagnosis, not meeting sCJD criteria
4.2 Clinical diagnosis not sCJD
4.3 Pathological diagnosis not sCJD
1.10 Variant CJD
1.10.1 BSE and vCJD
Variant CJD was first identified as a new disease entity in 1996 following
identification in 1995 of three individuals under the age of thirty with an unusual
clinical phenotype for sCJD and atypical pathology characterised by extensive
amyloid plaque formation (149). As more cases followed and genetic CJD and
alternative diagnoses were excluded it became apparent this was a novel phenotype,
initially unique to the UK. Incidence continued to rise until a peak in 1999 and,
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although there have been fewer cases since this time, new patients are still presenting
each year (fig 1.8). To date (April 2007) there have been 199 cases worldwide, with
162 in the UK, 22 in France, 4 in Ireland, 3 in the USA, 2 in the Netherlands and
single cases in Italy, Portugal, Spain, Canada, Japan and Saudi Arabia (150).
Fig 1.8
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There is convincing evidence that the aetiological agent of vCJD is BSE. The origin
of BSE in cattle is unclear with theories ranging from a sporadic onset, genetic
mutation, via feed contaminated by a TSE - infected exotic ungulate or originating
from scrapie. Scrapie strains can change their characteristics on transmission through
a new species but currently strain studies do not provide positive evidence for scrapie
as the source of BSE. Irrespective of its origin it seems likely BSE was propagated by
the use of meat and bone meal in cattle feed (151). An alteration in the rendering
process around 1980 probably allowed the infective agent in carcasses to survive and
contaminate the feed, with subsequent recycling of the TSE. BSE was formally
recognised as a novel disease in the UK in 1986 (152), although in retrospect the first
cow died in December 1984. A full scale epidemic ensued, affecting nearly 200,000
cattle in total. The epidemic was slowly brought under control by the introduction of
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the ruminant feed ban in 1988 and the specific bovine offal ban a year later. In
addition the public were further protected in 1996 by the 30 month rule whereby
asymptomatic cattle over this age were pre-emptively destroyed (153). Numerous
other countries have been affected by BSE but in far smaller numbers and probably as
a result of imported livestock or food supplements.
The BSE epidemic immediately raised concern regarding the theoretical possibility of
human transmission. This stimulated the reinstitution of active CJD surveillance in the
UK in 1990 looking for evidence of a change in the pattern of CJD which might
reflect a link to BSE. The evidence associating BSE and vCJD is three fold. In
epidemiology terms the high incidence of vCJD in the UK compared to countries with
similar surveillance systems mirrors the BSE problem and is consistent with the BSE
theory. More convincingly transmission experiments inoculating mice with vCJD
brain result in a similar incubation period and lesion profile as mice inoculated with
BSE from cattle, confirming a common strain. (154, 155, 156). At a molecular level
strain typing of vCJD has confirmed that the responsible agent is indistinguishable
from that seen in BSE (29). This BSE glycoprotein 'signature' is a constant feature of
vCJD and can therefore be used to distinguish it from other types of CJD.
BSE is believed to have entered the human food chain via beef products contaminated
with central nervous system tissue e.g. meat pies and sausages containing
mechanically recovered meat that is obtained by carcass compression and extraction
and potentially contains spinal cord (157).
1.10.2 Clinical features of vCJD
The mean age at onset of vCJD is significantly younger than sCJD at 28 years and the
mean disease duration is longer at 14 months (150, 158). The longest surviving case
to date is 5 years and 7 months (April 07).
The clinical phenotype is remarkably stereotyped, consistent with the proposed
aetiology from a single strain of infective agent. Typically the illness begins with non
specific psychiatric symptoms including anxiety, loss of interest and behavioural
change, often prompting referral to psychiatry (159, 160, 161, 162, 163). Around one
third have early, persistent sensory symptoms such as dysaesthesia and numbness
(162). A minority (around 15 - 30%) have a pure neurological onset (158, 162).
Neurological features inevitably develop at some stage in all cases. Classically the
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patient becomes ataxic and develops a movement disorder, most frequently
myoclonus but sometimes dystonia, chorea or tremor (161). Other common late
features include hallucinations, visual impairment and upper motor neurone signs.
Progressive cognitive decline is universal, culminating in death. The possibility of a
distinct vCJD neuropsychological profile has been explored, but ultimately most
patients have global cognitive impairment with cortical and subcortical features (165,
166). Evaluation is limited by the fact many vCJD patients are unable to cope with the
demands of rigorous neuropsychological testing.
1.10.3 Investigations in vCJD
(i) Blood tests
As with sCJD no prion specific blood test exists for vCJD and bloods are usually
normal and not diagnostically helpful.
(ii) CSF
In variant as with sporadic CJD routine CSF examination is unremarkable with no
lymphocytosis but possibly mildly elevated protein. 14-3-3 protein is positive in 40 -
50% of variant cases (167, 104, 161), making it a less useful diagnostic tool than in
sporadic CJD, and it is postulated this relates to the slower disease course of vCJD. A
positive result may be supportive but a negative assay by no means excludes the
diagnosis. Various other CSF proteins including S100, Tau and neuron-specific
enolase, have been evaluated in vCJD but to date none are sufficiently sensitive or
specific for routine diagnostic use. Tau appears most promising with sensitivity
greater than 90% in some studies, but it is frequently elevated in other
neurodegenerative diseases limiting its utility as a specific diagnostic test for vCJD
(167).
(iii) Magnetic resonance imaging
MRI is the most useful non-invasive investigation in the diagnosis of vCJD and is
included in the diagnostic criteria, allowing a clinically possible case to be classified
as probable (2). The characteristic finding is hyperintensity in the posterior thalamic
nuclei relative to the basal ganglia, the so called 'pulvinar' sign (168). It was first
described in 1996 on proton density and T2 sequences (169, 170) but FLAIR has been
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found to be the most sensitive sequence (greater than 90% sensitivity) (171). A
retrospective review in 2000 found the pulvinar sign was actually missed in 60% of
cases at the referring centre (172), although this may well have improved with
increasing awareness of the MRI findings in vCJD. Specificity is high at greater than
95% and many of the alternative causes of pulvinar hyperintensity are clinically
readily distinguishable diseases. Also the hyperintensity often involves the thalamus
generally rather than specifically the pulvinar nuclei. Alternative causes of thalamic
hyperintensity include familial and sporadic CJD (172, 173) Alper's syndrome (174),
Fabry' disease (but seen on Tl-weighted images) (175), post infectious
encephalopathy (176), idiopathic intracranial hypertension (177), 'tip of basilar'
syndrome, Wernicke's encephalopathy (178), bithalamic glioma and paraneoplastic
limbic encephalitis (179).
(iv) EEG
The EEG in vCJD usually shows non specific changes such as focal or generalised
slow waves, and it can be entirely normal, particularly in the early stages of illness
(161, 163). The typical sCJD pattern of periodic complexes has been reported in 2
cases of vCJD in Italy and Japan late in the clinical course but is not the usual finding
(180, 181).
(v) Tonsil Biopsy
In vCJD PrP can be detected in the lymphoreticular system (LRS), in contrast to other
human prion diseases where lymphoid PrP is undetectable by comparable methods.
PrPSc is believed to replicate and accumulate in the LRS prior to neuroinvasion of the
central nervous system, and this raised the possibility that lymphoid biopsy might
provide an early diagnostic tool. Spleen, tonsil, appendix and lymph node have all
been positive for PrPSc in vCJD at post mortem, and tonsil biopsy has proved to be a
valuable diagnostic test in clinical practice (182). Analysis by western blot and
immunohistochemistry demonstrates proteinase K digestion fragments identical in
size to those in vCJD brain, but the glycoprotein ratios are slightly different. This
probably reflects the role of tonsillar tissue in glycosylation, but the predominant type
is still diglycosylated protein as in vCJD brain, as opposed to the monoglycosylated
form in sCJD(183).
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To date no definite or probable vCJD patients who have undergone tonsil biopsy have
had a negative result (provided adequate tissue was available for analysis). Equally
importantly no false positive tonsil biopsy assays have yet been identified. Like MRI
tonsil biopsy is part of the current diagnostic criteria for vCJD.
However, there are a number of caveats related to tonsil biopsy. It is an invasive test
with risks including haemorrhage, and may not be necessary in the face of a typical
clinical picture and positive pulvinar sign on MRI. If the diagnosis of vCJD is really
in doubt a tonsil biopsy can only confirm or refute this whereas a brain biopsy can
potentially provide an alternative definitive diagnosis. It is not known how early tonsil
specimens are positive for PrPSc but an appendix has been positive 8 months prior to
symptom onset (184). Therefore lymphoid tissue could potentially be used as a
presymptomatic screening test although this would not be indicated currently given
the low disease incidence and lack of curative treatment. A retrospective study has
evaluated PrPSc accumulation in tonsil and appendix tissues to guide estimates of
vCJD prevalence. It identified 3 positive appendices out of over 12,000 appendix /
tonsil specimens, giving an estimated prevalence of 237 per million (185). However,
questions have been raised regarding the reliability of PrPSc detection in appendix
tissue, even in the terminal stages of vCJD disease. In one study only one out of four
appendices obtained at necroscopy from pathologically confirmed cases of vCJD was
positive for PrPSc (186). Probably the most interesting finding from the retrospective,
large-scale appendix review was that in both cases where PRNP codon 129 genotype
was analysed the individual was valine homozygous (VV), providing the first
indication that the VV subgroup are susceptible to vCJD infection.
1.10.4 Codon 129 genotype and variant CJD
The influence of codon 129 genotype on CJD susceptibility, incubation period and
disease expression has already been mentioned in this introduction. All vCJD patients
to date have been homozygous for methionine (MM) at codon 129. However, vCJD
has been transmitted to a methionine valine (MV) heterozygous individual via blood
transfusion, although at the time of death the patient was not clinically symptomatic.
As mentioned above two presymptomatic valine homozygous (VV) individuals have
been identified with detectable PrPSc in their appendices. There is much speculation
as to whether clinical vCJD can occur in non-MM patients and if so what the clinical
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phenotype will be. A recent paper on kuru highlighted the effect of PRNP 129
genotype on incubation period, with the very late onset cases being MV (42). This is
potentially relevant in vCJD. We may not have observed non-MM vCJD cases
because it is simply too early for them to present. Alternatively they may be truly
resistant to infection, may be infected but never develop the clinical manifestations of
vCJD, or be eluding diagnosis because clinically they differ from the MM patients.
1.10.5 Neuropathology of variant CJD
Neuropathology is required for a definitive diagnosis of vCJD and this usually
involves routine microscopy plus immunocytochemistry for PrPSc using a range of
monoclonal antibodies against PrP epitopes. Interestingly the neuropathological
findings in vCJD are relatively uniform with less diversity than that recognised in
sCJD, although this may simply reflect the fact that all vCJD patients to date have had
the same PRNP genotype (methionine homozygous).
Cerebral atrophy is not generally a feature but long duration cases may have
cerebellar atrophy. As with other prion diseases a characteristic finding is spongiform
change throughout the cerebral cortex, but particularly involving the corpus striatum
in vCJD. However, the extensive confluent spongiosus seen in the cerebral cortex in
sCJD is not encountered. Neuronal loss is variable but often most pronounced in the
cerebellar cortex associated with reactive gliosis. The most striking microscopic
feature is the florid plaque, visible with haematoxlyin and eosin stains (fig 1.9). The
term florid plaque was first used to describe the structures seen after experimental
transmission of Icelandic scrapie to mice (187), and the plaques seen in vCJD appear
similar microscopically. They are complex structures with eosinophilic centres
surrounded by fibrils, with an outermost halo of spongiform change. They are
scattered throughout the brain but are most prominent in the occipital and cerebellar
cortex, basal ganglia and thalamus (188). Florid plaques are easily distinguished from
the amyloid plaques seen in kuru and some cases of sCJD (usually PRNP codon 129
methionine valine heterozygotes), as amyloid plaques have a more restricted




Immunocytochemistry confirms that florid plaques stain strongly for PrP, but PrP is
more widely distributed in perivascular, pericellular and diffuse plaque-like patterns
throughout the brain. Quantitatively PrP accumulation is greatest in the occipital and
cerebellar cortices. Its pattern of distribution varies depending on the anatomical site.
E.g. in the basal ganglia PrP tends to be linear and perineuronal with multiple small
plaques, whereas in the thalamus it is in a more reticular pattern.
Western blot analysis of PrP extracted from vCJD brain confirms that it is different to
PrP isotypes recognised in sCJD. Its distinct profile relates to fragment size following
digestion with proteinase K and to glycosylation (with most of the PrP being
diglycosylated as opposed to non glycosylated or monoglycosylated in sCJD). Some
laboratories have reported different isoform mobility between PrP in vCJD and sCJD,
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classifying the variant isoform as type 4. However, this has not been a consistent
distinction with most laboratories finding mobility indistinguishable from type 2 PrP
in sCJD and therefore the vCJD isotype has been termed type 2B (and this latter
nomenclature will be used throughout this study) (189). The glycotype appears to be
modified by the tissue in which it accumulates, with slight differences noted between
tonsillar and cerebral PrPSc on western blots (200).
An important feature distinguishing vCJD from all other human forms of prion
disease is the identification of PrPSc outwith the central nervous system in lymphoid
tissue. This has not been found using comparable techniques in sCJD. In vCJD PrP
has been detected in follicular dendritic cells within germinal centres of the tonsil (the
basis for the tonsil biopsy diagnostic test), in spleen, appendix and lymph nodes and
possibly in Peyer's patches in the ileum (183, 189). These findings have major
implications for the possibility of secondary transmission of vCJD, either via blood or
surgical instrumentation.
1.10.5 Diagnostic Criteria for vCJD (2)
I A Progressive neuropsychiatric disorder
B Duration > 6 months
C Routine investigations do not suggest an alternative diagnosis
D No history of potential iatrogenic exposure
E No evidence of a familial form of TSE
II A Early psychiatric symptoms a
B Persistent painful sensory symptoms b
C Ataxia
D Myoclonus or chorea or dystonia
E Dementia
III A EEG does not show typical appearance of sCJD c
B Bilateral pulvinar high signal on MRI scan
IV A Positive tonsil biopsy d
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Definite: IA and neuropathological confirmation of vCJD e.
Probable: I and 4/5 of II and IIIA and IIIB
Or
I and IVA
Possible: I and 4/5 of II and IIIA
a Depression, anxiety, apathy, withdrawal, delusions
b This includes both frank pain and / or dysaesthesia
c Generalised triphasic complexes at approximately one per second
d Tonsil biopsy is not recommended routinely, nor in cases with EEG appearances
typical of sporadic CJD, but may be useful in suspect casesin which the clinical
features are compatible
e Spongiform change and extensive PrP deposition with florid plaques, throughout the
cerebrum and cerebellum
1.11 Secondary Transmission of CJD
The emergence of vCJD in 1996 heightened concerns about the possibility of
secondary transmission of CJD. Experience with iatrogenic CJD demonstrated that
sCJD could be transmitted to humans via contamination with brain tissue. However,
there have not been any substantiated reports of blood borne transmission of sCJD
and the weight of epidemiological evidence, including look back and case control
studies, suggests this does not occur. Similarly there is no evidence supporting
vertical transmission of sCJD. The situation is different with vCJD.
The lymphoreticular distribution of vCJD provides theoretical possibilities for blood
borne spread. There is evidence of experimental transmission of BSE in sheep via
intravenous transfusion of whole blood taken from pre-symptomatic sheep. There is
now good evidence for blood borne transmission of vCJD relating to four individuals.
In 1996 a neurologically well 24 year old donated blood. 3.5 years later the donor
succumbed to vCJD. One unit of this donated blood was transfused into a 62 year old
in 1996. 6.5 years later he developed the characteristic clinical phenotype of vCJD
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and this was confirmed pathologically when he died at the age of 69. He was
methionine homozygous at codon 129. At the time the probability of this being a
chance occurrence was estimated at 1 in 30,000 (191).
In the second case a 27 year old donated blood eighteen months before developing
symptoms of vCJD. One unit of this blood was transfused into an individual in 1999
and this recipient remained neurologically well up to her death in 2004 from unrelated
causes. At autopsy the spleen and a cervical lymph node were positive for PrPSc but
the brain and other lymphoid tissue including tonsil was negative. She was found to
be a codon 129 heterozygote (59).
The third individual received a vCJD-implicated blood transfusion in 1997. 8 years
later he developed painful parasthesiae of his lower limbs associated with fatigue,
anxiety and personality change. He gradually deteriorated with development of ataxia
and cognitive impairment, and died 10 months after symptom onset. Prior to his death
MRI brain demonstrated the pulvinar sign and PRNP analysis confirmed he was
methionine homozygous at codon 129 without any mutations. No tonsil biopsy was
performed but autopsy confirmed the diagnosis of vCJD (192, 193). Recently a fourth
case of transfusion - associated vCJD was identified, and again followed a typical
disease course. In this case tonsil biopsy was performed and was positive for PrPSc
(personal communication G Chohan).
To date there is no evidence that vertical transmission of vCJD can occur, based on a
study of nine women who gave birth within one year of developing vCJD symptoms
(194). However, this is limited by the small number of cases and relatively short
period of follow up. BSE has been transmitted from ewe to lamb in an experimental
sheep flock, although it is still not known if this was in utero vertical transmission or
horizontal spread perinatally (195).
These secondary transmission issues have major public health implications, ranging
from blood transfusion services to instrument sterilisation and the safety of bone
grafts. A number of precautionary steps have been taken. Since 1999 all blood
components have been leucodepleted. Fresh frozen plasma is imported from USA for
all recipients born in or after 1996 and USA plasma is used for fractionation. Any
transfusion recipient is banned from donating blood (implemented 2004) and all those
who have received blood from a vCJD donor have been notified.
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There are also concerns that the passage of the prion through one human prior to
transmission could potentially modify the clinicopathological phenotype, making
cases due to secondary transmission harder to detect.
1.12 Treatment of CJD
There is no known cure for CJD and treatment remains extremely limited. There are
major challenges to identifying successful therapy for human prion disease. Most of
the work has been on neuroblastoma cell lines or rodent scrapie models, with the
therapeutic agent being introduced at the same time as prion infection. However, in
real life CJD infectivity will predate treatment, probably by years. There is no pre-
symptomatic diagnostic test so a successful drug needs to halt disease progression and
ideally reverse pre-existing neurological damage. The rapidly progressive nature of
the disease means any agent must act quickly. It also needs to penetrate the blood-
brain barrier or be introduced directly into the cerebrum.
The principal therapeutic target has been conversion of PrPc to PrPSc and subsequent
aggregation of PrPSc (196, 197). Laminin receptor, a cell surface receptor for PrPc and
PrPSc, has been identified (198) and provides an alternative therapeutic option, either
via production of competing antibodies (199) or by inhibition of laminin receptor
production at the mRNA level (200). Numerous antiprion agents have been identified
experimentally, including amphotericin B, congo red, polysulphated polyanionic
substances such as dextran sulphate and pentosan polysulphate, chlorpromazine and
quinacrine (both tricyclic compounds with aliphatic side chains), designer peptides
like beta-sheet breaker and RNA aptamers (197). Unfortunately this has not translated
into great clinical success.
Quinacrine and chlorpromazine impair de novo formation of PrPSc aggregates in cell
and murine models, but are less effective at degrading pre-existing PrPSc fibrils (201,
202). Initially there was cautious optimism about the clinical prospects of quinacrine
and chlorpromazine (203, 204, 205) but results have been disappointing (206, 207).
An ongoing MRC - sponsored trial, PRION-1, is evaluating the efficacy of quinacrine
in the UK CJD population. Results are not yet published but a decision has been made
not to trial quinacrine in the rest ofEurope.
Pentosan polysulphate (PPS) is a large polyglycoside molecule with weak heparin-
like activity. It has been shown to prevent propagation of PrPSc in cell culture (208)
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and prolong TSE incubation period in rodent scrapie models (209). Following
promising preliminary animal studies it has been used experimentally in a number of
individuals with variant, genetic and iatrogenic CJD (210). The numbers are small and
the results to date are mixed. Several patients treated with PPS are still alive,
including the longest surviving case of vCJD, and modest neurological improvement
has been reported (211). However, others have been treated without any noticeable
benefit and died within a few months (212). A major practical drawback is the
requirement for intraventricular access. Further evaluation of PPS in a larger cohort is
essential.
1.12 New developments in TSEs
There have been a number of recent interesting developments in the understanding of
animal TSEs, with potentially important implications with respect to human prion
disease.
The first naturally occurring case of BSE in a goat was confirmed in France in 2005,
suggesting that BSE may have been accidentally transmitted to other ruminant species
(213). Subsequently there has been a possible case of BSE in a UK goat (214).
Previously BSE (and consequently vCJD) was thought to be caused by a single prion
strain, in contrast to scrapie where multiple strains exist. However, there is now
evidence that challenges this. Experimental transmission of BSE to transgenic mice
expressing human PRNP MM has resulted in two distinct molecular phenotypes with
differing PrPSc glycotypes and neuropathological profiles (215, 216). Transmission of
human vCJD to chimeric mice with human and mouse PrP has produced two stable
distinct prion strains (217). This suggests either the existence of two prion strains
within individual cases of BSE and vCJD or potentially generation of a new prion
strain on transmission. More recently two atypical strains of BSE have been identified
with clinical features, PrPSc signatures and neuropathological lesion distribution
distinct from BSE (3, 4, 218). Both of these atypical strains are experimentally
transmissible and the inoculated transgenic mice exhibit strain-specific features
clearly distinguishable from BSE. One of these strains is termed BASE (bovine
amyloidotic spongiform encephalopathy) and is particularly interesting because it
shares striking similarities with human sCJD of the MV2 subbtype, in terms of PrPSc
56
deposition and formation of amyloid plaques. It also has the intriguing ability to
convert into a strain indistinguishable from classical BSE after serial passage through
nontransgenic mice (219).
Other atypical TSEs have been identified in smaller ruminants, including atypical
scrapie in sheep and goats (220).
What are the implications of all these findings to human prion disease? It is postulated
that BASE might be the sporadic form of cattle prion disease, similar to sCJD in
humans. Could sCJD be somehow related to BASE exposure, particularly in view of
the pathological similarities with MV2 sCJD? The apparent conversion of BASE to
BSE implies this could be the origin of BSE. Are these apparently novel atypical
TSEs really new, or are they just being identified for the first time due to
improvements in detection techniques and surveillance programmes?
Many questions remain unanswered but ongoing monitoring of human prion disease
is vital.
1.14 CJD Surveillance
The word surveillance originates from the French and literally means 'to watch from
above'. However, in medical terms it has been variously described as 'the collection,
collation, analysis and dissemination of data' and 'a type of observational study that
involves continuous monitoring of disease occurrence within a population.' In the
context of transmissible spongiform encephalopathies, surveillance has a particularly
important role because of concerns regarding transmission of prion disease, including
animal to human and human to human spread. Thus individual cases may have far
reaching implications for the population as a whole. Following the identification of
BSE in British cattle the Southwood report was commissioned (221). This
recommended that CJD was monitored in the UK population and shortly afterwards
the NCJDSU was set up. CJD surveillance aims to identify all cases, collate
clinicopathological data, monitor the epidemiology of the disease and inform health
professionals, scientists, policy makers and the public of any relevant developments.
The NCJDSU was established in its current form in 1990 but CJD surveillance in the
UK actually dates from 1970 and has occurred in four phases. A retrospective study in
England and Wales covered 1970 - 1980. Between 1980 and 1984 a prospective study
was undertaken in Oxford, again confined to cases in England and Wales. The third
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phase was a retrospective review of all UK cases between 1985 and 1990. Prospective
surveillance was instituted for the UK from 1990 and is currently ongoing. It is
guided by the following eight principles, which are followed in order to optimally
manage CJD in the UK:
• Provide care and support for patients and families
• Offer skilled clinical investigation to enable a reliable diagnosis to be made
• Early recognition of probable and possible cases of sCJD, vCJD, inherited and
iatrogenic human prion disease
• Rapid reporting of such cases to the surveillance system
• Prompt gathering of information from and about patients to allow enhanced
surveillance
• Maintenance of rigorous controls to minimise possible risks of secondary
transmission via medical procedures or other means
• Quality assure existing controls on possible primary sources of transmission
(e.g. the food chain) and keep under review the need for new controls
• Promote high quality research directed at various aspects of human prion
diseases focussed on achieving early diagnosis and eventual effective
treatment for these disorders
Numerous other countries run CJD surveillance programmes and there is a
harmonised system for surveillance of CJD in Europe involving all major member
states. EUROCJD (European and Allied Countries Study Group of CJD) was
established in 1993 under the auspices of the European commission, and initially
involved the national CJD registries of France, Germany, Italy, the Netherlands,
Slovakia, Spain and the UK. It was extended in 1997 to incorporate Australia,
Austria, Canada and Switzerland.
In 1996 the European clinical council recommended that epidemiological surveillance
of CJD should be extended to all member states. Therefore NEUROCJD (the
Extended European Collaborative Study Group of CJD) was established. It involves
the CJD registries of Belgium, Denmark, Finland, Greece, Iceland, Ireland, Israel,
Norway, Portugal and Sweden. Both NEUROCJD and EUROCJD are co-ordinated
through the NCJDSU in Edinburgh.
58
In this study EUROCJD data on sCJD from 1993 to 2004 will be compared with UK
figures for the same time period.
EUROCJD has a number of objectives including:
• Observation of trends in sCJD disease incidence across and within countries
• Assessment of putative risk factors for CJD
• Study of the clinicopathological variants and molecular biology of CJD with
specific reference to genetic factors that influence susceptibility to disease
• Evaluation of diagnostic tests for sCJD.
Accurate data collection is vital if CJD surveillance is to be a reliable means of
identifying novel disease phenotypes and identifying changes in disease incidence,
both within one country and between countries. Virtually all national CJD registries
have demonstrated an increase in sCJD incidence in the first few years after initiating
a surveillance programme, presumably related to improved case ascertainment.
However, the sCJD incidence rate in the UK has now been relatively stable since
1997 and is comparable with other developed countries with similarly established
surveillance programmes (67). 100% case ascertainment is probably not realistic but
current evidence suggests that the vast majority of sCJD cases are being detected in
the UK (see discussion section 4.1).
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Chapter 2. Methods
2.1 The study population
The principal study population was all suspect cases of sporadic CJD referred to the
NCJDSU in 1993, 1994, 2003 and 2004. This included individuals who ultimately
turned out not to have CJD or remained classified as Possible cases or 'Diagnosis
Unclear', as one of the principal aims of the thesis was to identify novel 'atypical'
phenotypes of sCJD. They were selected by year of referral rather than year of death
because some of the non - sCJD cases and the Possible / Unclear diagnosis group
recovered or remained unwell but alive, and it was important not to omit these
individuals. In addition all UK Definite and Probable sCJD cases (as defined by their
final classification by WHO diagnostic criteria) that died between 1st January 1993
and 31st December 2004 inclusive were reviewed. Basic demographic data and
investigation results were extracted on all the study population. A more detailed
review of clinical and pathological features was made on the 1993, 1994, 2003 and
2004 referrals and any patient aged fifty or under at onset and any pathologically
confirmed case with a negative 14-3-3 CSF result.
Exclusion criteria were those referrals to the NCJDSU outwith the above timeframe,
individuals referred and finally classified as having another type of CJD (genetic,
iatrogenic or variant) and patients referred as suspect sCJD that were later identified
as familial cases on the basis of PRNP mutations. One patient with a strong family
history of genetic CJD in whom genetic analysis was not performed was also
excluded. None of the study population was known to have a family history of CJD at
the time of inclusion.
Data collection stopped at the end of July 2005. Therefore any of the study population
that were alive at this stage were included but remain classified as 'alive' for the
purposes of this study. Any additional information received after July 31st 2005 was
not included in the analysis.
The UK data were compared with European sCJD data collected as part of the
ongoing collaborative project, EUROCJD. All Definite and Probable sCJD cases
notified to the relevant national CJD registries as having died between 1993 and 2004
were evaluated and compared with UK cases for the same time period. Annual
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referrals were identified by date of death rather than date of referral because the
EUROCJD database does not have referral dates for all patients.
Various subsets of sCJD patients were assessed in more detail and compared with
appropriately selected 'control' sCJD patients. E.g. Definite sCJD referrals in 1993/4
and 2003/4 who underwent brain biopsy were compared with Definite patients for the
same time period who did not have a biopsy. All young sCJD Cases with onset at age
fifty or less between 1993 and 2004 inclusive were compared with Cases with onset
over age fifty from 1993/4 and 2003/4 (the comparison cohort came from a more
restricted time period because only these cases had sufficient information for a
clinical comparison). All 14-3-3 negative pathologically proven patients from the time
the test was introduced (December 1996) until 2004 were compared with 14-3-3
positive pathologically confirmed patients in 2003/4 (and again the comparison group
were selected to provide sufficient detail to contrast clinical phenotypes).
2.2 The referral process
Referral of suspect sCJD cases to the NCJDSU occurs in one of three ways.
Clinical - passive ascertainment: neurologists, neuropathologists and
neurophysiologists are reminded annually of the need to refer any individuals in
whom sCJD or vCJD is considered a possible diagnosis to the NCJDSU.
Death certificates - passive ascertainment: the Office for National Statistics for
England and Wales and the General Register Offices for Scotland and Northern
Ireland supply all death certificates coded under rubrics A81.0 and F02.1 (10th ICD
revision; and equivalent under the earlier 9th ICD revision).
Other sources - passive ascertainment: psychiatrists, paediatricians, geriatricians,
other health professionals and members of the general public may refer cases to the
NCJDSU. An enhanced surveillance system also exists for the paediatric population
via the PIND study (Progressive Intellectual and Neurological Deterioration), in
conjunction with the British Paediatric Surveillance Unit. This is primarily to avoid
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missing childhood onsets of vCJD but will also apply to the very rare adolescent
onsets of sCJD.
The majority of the study population were referred in one of these three ways with
either a death certificate or pathology report / specimen reaching the NCJDSU, or a
phone call from the clinician discussing and referring their patient. In July 2004, the
Chief Medical Officer announced a new national reporting system centred on the
National CJD Reporting Form (see appendix). This is faxed by the notifying clinician
to the NCJDSU, the National Prion Clinic (NPC) and the local consultant in
communicable diseases. However, very few of the study population were referred in
this manner and all those that were had follow up phone calls prior to a visit to discuss
the suspect case details further. Therefore this minor change in the reporting system
did not impact on data collection.
All suspect sCJD referrals were given a unique NCJDSU number for anonymity and
future identification. Occasionally a clinician informally discusses a doubtful case
with the surveillance team but if this was not felt to reflect a referral and hence no
number was allocated then the individual was not included in this study. Similarly,
increasingly patients are being referred for CSF 14-3-3 analysis but this alone was not
classified as a referral unless further contact was made with the unit.
2.3 Data collection
The NCJDSU archives were reviewed retrospectively for all individuals in the study
population. However, in the majority of suspect cases the information was originally
collected prospectively following referral when the patient was symptomatic but
alive. Wherever possible such a referral prompted a meeting between the NCJDSU
research registrar and the patient and their family, usually in hospital but occasionally
at a nursing home or the individual's own home. This took place with the consent of
the family and referring clinician. During the visit a detailed history was obtained
from the family, a physical examination was performed and investigation results were
reviewed. The examination included a neurological assessment recorded in a
standardized fashion. The individual was classified as Definite, Probable, Possible,
Diagnosis Unclear or Non Case using the current WHO diagnostic criteria as
described in the introduction. (In this study capital letters will be used to denote these
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classifications). All the information was recorded on a 'Patient review and
examination form' with space to freely describe the history plus an additional section
with specific questions regarding clinical features and investigation results. The
questionnaire design and the specific questions were modified in 1997, so there may
have been a slightly different emphasis in 1993/4 referrals compared to 2003/4
referrals (addressed in more detail in the discussion; see appendix for both versions of
questionnaire).
One or two research registrars are employed at any one time at the NCJDSU,
changing on average every two years, and therefore a number of different doctors
visited the suspect cases over the time course of this study. A total of 10 doctors*
were involved in CJD visits for the study population, but the majority of surveillance
in 1993/4 was performed by two registrars (RS, MZ), and by three registrars in 2003/4
(SC, CAH, KM). To try and minimize inter-registrar differences the information was
recorded on the questionnaire in a standardised manner. The history was acquired by
allowing the family to freely describe their relative's illness, followed by a number of
directed questions as to the presence or absence of particular symptoms and their
timing. A new registrar usually accompanied a more experienced registrar on their
first visit in order to learn how the history was taken and recorded, but some
variability in the directed questions is inevitable depending on individual registrars
and also different patients and families.
A research nurse usually accompanied the registrar and also interviewed the family in
order to complete a risk factor and epidemiology questionnaire. This is part of a
separate case-control study. A visit typically concluded with a discussion with the
family regarding the certainty of diagnosis, its implications and prognosis. The family
were offered information leaflets produced by the CJD support network and made
aware of the National CJD Care package if appropriate. The possibility of genetic
CJD was often discussed and genetic analysis offered.
Hospital notes were copied at the time of interview with the next of kin's consent, or
if unavailable were requested by post. If an individual had been in several hospitals
since their disease onset then all sets of notes were requested. General Practitioner
* RK, RS, MZ, GS, MAM, AL, CH, SC, CAH, KM
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notes were not requested until after the suspect case had died. They were not used in
this study as they were frequently unavailable or illegible and often did not provide
any information over and above the hospital notes and data from the visit.
Details on the neurological examination at first presentation were obtained from the
hospital notes. This was defined as the first documented neurological examination and
usually occurred at admission or first clinic visit, but occasionally the GP referral
letter was used if sufficiently detailed.
Where possible investigation results, particularly EEG and MRI, were reviewed at the
time of the visit and either copied then or requested later by letter.
When data such as notes, information on date of death, EEG traces orMRI scans were
missing attempts were made to rectify this via a further letter or phone call to the
hospital or GP. The family were not contacted directly again.
Sometimes a suspect sCJD case was not visited in life, either because the referral was
made when death was imminent and the registrar could not visit in time, or because
the referral was made by death certificate or pathology, or the family were not happy
for a visit to occur. In such cases attempts were made to visit the family at a later date
if the diagnosis of sCJD was Definite or Probable and the local clinician and family
gave their consent. This provided the opportunity to gather a detailed history although
obviously no examination was possible. On these occasions a 'Late referral'
questionnaire was completed (see appendix).
2.4 Definitions
(i) Dates
Information regarding dates of onset, death and timing of investigations was extracted
from the hospital notes and relative interviews. Frequently accurate data were
unavailable and therefore dates were recorded as the 1st of the month for all dates
between the 1st and 10th inclusive, the 15th for all dates between the 11th and 20th, and
30th for all dates between the 21st and 31st. If only the month was given with no other
indications this was recorded as the 15th. This strategy was used for all dates in the
study.
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• Notification date - defined as the date of referral to the NCJDSU, either by
phone call, fax or when a letter was received. However, if the suspect case was
referred after death, by pathology or death certificate, then date of death was
taken as the referral date. This was to minimize artificial clustering due to
death certificate referrals being sent in batches every few months.
• Date of onset - usually decided at the time of the visit by the interviewing
registrar but if no decision was made at this time or new information came to
light then the date was reviewed by the author.
• Disease duration - time interval in months between date of onset and death.
• Time to referral - calculated as the difference between the date of referral and
the date of onset.
• Delay to referral - calculated as the difference between the date of referral and
the date diagnosis of sCJD was first suspected.
(ii) Diagnosis / classification
• Final diagnosis - 'best guess' as judged by the author, not necessarily
pathologically proven but taking into account all available information. If the
final diagnosis was not clear it was discussed with one or both of the two
consultant neurologists in the unit (RGW, RK).
• Final classification - classification according to the appropriate WHO
diagnostic criteria when case closed or based on information available in July
2005 (Rome version for 1993/4 referrals, Rotterdam version for 2003/4
referrals).
• Initial classification - classification at time of NCJDSU visit. If no visit
occurred then classification at time of referral was used.
• Who first suspected sCJD - established by examining the clinical notes to




The presence or absence of a large number of clinical features was recorded for the
1993/4 and 2003/4 referrals and all cases aged fifty or less at onset or those with
negative 14-3-3 results. The symptoms and signs are listed and defined as follows.
Symptoms:
• Symptoms of impaired cognition including memory loss, disorientation and
confusion (abbreviated on graphs to 'forgetful').
• Symptoms suggestive of cerebellar dysfunction. E.g. Unsteady gait,
incoordination , clumsiness (abbreviated on graphs to 'unsteady').
• Visual disturbance - patient or family / friend reporting visual problems,
including blurring, difficulty focussing, symptoms suggesting a field defect
and colour, size or shape distortion. Diplopia as an isolated visual symptom
was excluded as it might reflect brainstem or cerebellar pathology (and in fact
there were no such cases).
• Language disturbance - speech problems including expressive and receptive
dysphasia , excluding dysarthria (abbreviated on graphs to 'speech problems').
• Weakness - symptoms of limb or facial weakness, either of gradual or acute
onset, but excluded non-specific descriptions such as 'generally feels weak all
over' without any lateralising features.
• Sensory symptoms - included numbness, parasthesia, dysaesthesia and limb
pain without any obvious non-neurological explanation such as trauma. When
reviewing data on young onset sCJD sensory symptoms were subdivided into
those that were painful and persistent. Painful sensory disturbance included
dysaesthesia, painful parasthesia or any sensory symptom reported as being
associated with discomfort or pain. Persistent sensory disturbance was harder
to define as dates were rarely available, so any symptom reported on several
occasions or prompting referral to hospital or GP was included, and any
reported on only a single occasion or described as brief / transient were
excluded.
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• Psychiatric symptoms - including psychosis, depression, low mood, anxiety
(judged by the visiting registrar to be abnormal rather than simply a normal
reaction to their illness). A diagnosis of depression / low mood did not need to
be formally confirmed by a psychiatrist.
• Hallucinations / delusions - hallucinations were defined as sensory
experiences occurring without stimulation of the relevant sensory organ, and
included visual and auditory hallucinations. Delusions were defined as false
beliefs, firmly held despite evidence to the contrary. These could be reported
by the patient, friend / family or medical / nursing staff.
• Headache.
• Seizure - history suggesting a seizure, not necessarily witnessed by medical
staff.
• Dizziness - Non-specific dizziness or vertigo but not simply unsteadiness.
• Fatigue / sleep disturbance - included lethargy, fatigue, insomnia and
excessive daytime sleepiness.
• Weight loss - either reported by the patient or family, or documented in the
hospital notes.
• Other - prominent symptoms reported by patient / family / medical staff which
did not fit into any of the above categories. Examples included new onset
deafness, tinnitus, vivid nightmares and difficulty writing with no apparent
cognitive, language or coordination problems.
Signs:
• Dementia - usually on basis of bedside mental state tests in hospital or
neuropsychology testing but if described as confused and unable to cooperate
with formal cognitive assessment then this was also included.
• Cerebellar signs - any of ataxic gait, heel-shin ataxia, finger nose
incoordination or dysdiadochokinesis.
• Pyramidal signs - at least two of increased tone, sustained clonus
hyperreflexia, extensor plantars and pyramidal pattern weakness.
• Signs of parkinsonism- at least two of rigidity, bradykinesia and parkinsonian
type tremor, or described as having parkinsonian features.
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• Lower motor neurone signs - at least two of muscle wasting, absent reflexes
and fasciculation.
• Myoclonus - brief involuntary jerks were included if the description was
consistent with myoclonus.
• Movement disorder other than myoclonus - included chorea, athetosis and
dystonia but excluded tremor alone.
• Primitive reflexes - any of pout, snout, palmomental or grasp reflexes.
• Cortical blindness - if described as blind with no ocular explanation or if, on
examination, patient appeared unable to see and did not blink to confrontation.
• Akinetic mutism - as judged by the visiting registrar or if the notes described
patient as mute and unable to move (without alternative explanation such as
sedation).
• Oculomotor abnormalities - included any opthalmoplegia and abnormal
saccades and pursuit movements but excluded isolated nystagmus.
• Dyspraxia - defined as a disorder of planning and execution of learned tasks
not explained by abnormal tone, power, coordination or sensation.
• Sensory signs - included altered sensation to light touch, pin prick, vibration
or abnormal joint position sense but not a positive Romberg's test alone.
The presence or absence of each symptom was noted at onset and 'ever' (at any stage
during the illness), and similarly each clinical sign was noted at first examination and
at any stage in the disease course. There was also a 'don't know' category for those
instances where information was unavailable.
Clinical presentation at onset:
• Rapidly progressive dementia - presentation with an encephalopathic illness
with dementia and diverse other neurological features, progressing rapidly
over weeks to a few months, with no individual physical or cognitive deficit
being present for greater than two weeks alone.
• Heidenhain's - presentation with impairment of visual acuity and / or field,
progressing into cortical blindness, without any other significant clinical
deficit for the first two weeks of the illness.
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• Pure psychiatric onset - presentation with psychiatric symptoms such as
depression, anxiety, paranoia and delusions, without the presence of other
features for at least four weeks.
• Slowly progressive dementia - presentation with a slowly progressive
dementia, developing over months to years, without any other significant
neurological features in the first six months.
• Pure cerebellar onset - presentation with a progressive cerebellar syndrome
without other significant features, for at least two weeks.
• Extrapyramidal onset - Presentation with an extrapyramidal syndrome
involving parkinsonian features with or without chorea, dystonia or athetosis,
but without other significant features for at least two weeks.
• Stroke like onset - presentation sufficiently abrupt for stroke to be reasonably
considered in the initial stages.
• Sensory onset - presentation with pure sensory symptoms, excluding vague
aches and pains and special sensory symptoms (i.e. visual, olfactory, auditory,
gustatory).
• Other - none of the above presentations applicable.
• Insufficient information.
2.5 Investigations
(i) MRI brain scans
MRI scans were requested on all patients who underwent this type of imaging. The
MRI sequences available depended on the practice of the referring hospital, but
included T1 and T2 sequences in all instances, and PD (proton density), FLAIR (fluid
attenuated inversion recovery) or DWI (diffusion weighted imaging) in some. They
were reviewed by one of two experienced neuroradiologists with an interest in CJD
based at the NCJDSU (DC and DS). The neuroradiologists were aware the patients
had been referred to the NCJDSU but had no other information regarding the type of
CJD suspected or the likelihood of the diagnosis. MRI classification was as follows:
• Positive - defined as high signal in the putamen and caudate (usually bilateral
but asymmetry allowed), with or without cortical hyperintensity.
• Cortical hyperintensity alone.
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• Negative - no caudate / putamen / cortical hyperintensity. Other non - sCJD
changes could be present. E.g. diffuse white matter disease, previous strokes.
• Scan unavailable or too poor quality to review.
(ii) EEGs
EEG tracings were requested and were reviewed by one of two experienced
consultant neurologists based at the NCJDSU (RGW, RK). Similar to the MRI review
process, the neurologists were blinded to any clinical details but were aware that the
patient had been referred to the unit. The EEGs were classified on a five point scale:
typical, highly suggestive, suggestive, non specific, normal (see appendix).
(iii) CSF
Protein and white cell count results from CSF analysis were obtained from the
hospital notes. The 14-3-3 Western blot assays and S100 ELISAs were performed
either at the NCJDSU or The National Hospital for Neurology and Neurosurgery
using standardized methods (93, 165).
(iv) PRNP gene analysis
PRNP gene analysis was done to exclude familial CJD and to check genotype at
codon 129 of the prion gene. This was performed either at the NCJDSU or National
Prion Clinic, by DNA extraction, PCR amplification and gene sequencing using an
automated analyser (220, 221).
(v) Neuropathology
Neuropathology was performed either at the NCJDSU by Professor J. Ironside, or by
a local pathologist with tissue sections sent to the unit for review, or by a
neuropathologist in London without any input from the NCJDSU. A pathology
summary form was reviewed to identify the final pathological diagnosis, PrP type,
codon 129 status if tested and presence or absence of kuru type plaques.
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2.6 Database compilation and statistical analysis
All information was recorded on a database using the SPSS (version 12) package.
Graphs were produced using the power point graphics programme. Statistical analysis
utilised the SPSS programme. Student's t - test or Mann Whitney test were used to
compare continuous variables, with Mann Whitney being selected if the variable was
not normally distributed. The variables included disease duration, onset age, time to
referral and time to investigations between the following cohorts:
• 1993/4 versus 2003/4 referrals
• sCJD Cases versus Non Cases
• sCJD patients aged fifty or less at onset versus those greater than fifty years
• pathologically proven sCJD patients with a negative CSF 14-3-3 result versus
a positive result
Chi square (x2) analysis was used to compare categoric values including clinical
features and investigation results in the same cohorts. The two tailed Fisher's exact
version was used when the number of expected variables per cell was less than five.
Logistic regression was used to assess trends with time.
For the purposes of graphs and statistical analysis clinical features that were recorded
as absent or 'not known' were categorised together.
The diagnostic criteria and the value of specific clinical features were assessed by
calculating sensitivities, specificities and positive and negative predictive values.
Sensitivity was defined as the proportion of individuals with sCJD with a positive
result (where a positive test was either fulfilling the diagnostic criteria or presence of
a clinical feature). Specificity was the proportion of patients without sCJD with a
negative test result. Positive predictive value referred to the proportion of patients
with a positive test result who actually had sCJD. Negative predictive value was




3A. Overview of UK sporadic CJD 1993 - 2004
Suspected sporadic CJD patients that were either referred to the NCJDSU or died
between 1993 and 2004 were evaluated. Fig 3.1 demonstrates the number of referrals
finally classified as Definite, Probable and Possible each year whereas fig 3.2 shows
the number of Definite, Probable and Possible sCJD patients dying each year. The
figures are similar, irrespective of whether individuals were collated by date of
referral or date of death. The overall trend has been an increase in the number of
Definite, Probable and Possible referrals, albeit with an as yet unexplained drop in
2004. Using Poisson regression this annual increase is significant, both for Definite
and Probable cases (average increase 1.05 / yr, p<0.001), and for Definite, Probable
and Possible combined (average annual increase 1.04, p = 0.001). The proportion of
Probable classifications in particular has increased with time, with an increase in 1998
following the introduction of 14-3-3 testing a year earlier, and a marked rise in 2002 -
2004, but with a decline in Definite, neuropathologically confirmed cases in 2003 and





























Definite, Probable and Possible cases of sporadic CJD by
year of death 1993-2004





The mean age of onset of sCJD has remained constant at approx. 65 - 66 years (fig
3.3). Similarly mean age at death has remained stable at approx. 66 - 67 years (fig
3.4). Consistent with these findings median disease duration has not changed
significantly with time and remains at 4 -5 months (fig 3.5).
Fig. 3.3




















Mean age at death of Definite and Probable sporadic CJD by
year of death: 1993-2004
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Fig 3.5
Median duration of illness in sporadic CJD by year of
death: 1993 - 2004
Yr of death
The proportion of sCJD cases undergoing autopsy was reviewed (fig 3.6). The
autopsy rate was relatively stable with a mean of 85% until 2000 but since then has
declined to a minimum rate of 61% in 2003. Whilst the post mortem rate shows
significant heterogeneity from year to year, the data does not convincingly fit a linear
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or curvilinear trend if logistic regression is applied. Thus there is currently insufficient
evidence to support a statistically significant decreasing trend in annual autopsy rates.
Fig 3.6
PM rate in sporadic CJD Cases: 1993 - 2004
100-n
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Yr of death
Referral source was evaluated for sCJD deaths during the period 1993 - 2004. The
number and proportion of cases referred by death certificate was low throughout this
time period at no more than 5 cases / year or usually 5% or less of the total referrals
(the exception being 1993 when death certificate referrals made up 11%).
Neuropathology referrals were also infrequent with a trend towards fewer pathology
referrals with time. Before 1998 20 - 27% of cases were notified in this manner
whereas after this date only 10 - 15% were. A minority (7%) of the referrals made by
other sources also occurred after death. However, irrespective of the year the majority
of referrals were made in life (figs 3.7 and 3.8).
When death certificate and pathology referrals are excluded it is apparent that
between 70 and 85% of 'in life' referrals are made by neurologists, and this has
remained relatively constant with time. Physician referrals are the next commonest
comprising 10 - 20% of cases. Psychiatry, neurophysiology / EEG department and




Source of referral in Definite and Probable sporadic CJD
by year of death: 1993-2004
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Fig 3.8
Source of referral in Definite and Probable sporadic CJD
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Fig 3.9
Source of referral in Definite and Probable sporadic CJD
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Fig 3.10
Source of referral in Definite and Probable sporadic CJD
by year of death and % of referrals (excluding pathology and
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The distribution of PRNP codon 129 genotype was analysed over time. The total
number of Definite and Probable sCJD patients increased with time, as did the
number where codon 129 genotype was known. However, a significant proportion
each year did not have genetic analysis performed and this ranged from 20 - 48%
with an average of 35% untested annually, limiting data interpretation. When the
unknown genotype cases are excluded it is apparent that methionine homozygotes
(MM) predominate, but there is a trend towards fewer MM cases with time with
correspondingly more heterozygotes and valine homozygotes. This result did not
reach statistical significance, possibly because of the relatively small numbers (%2 p =
0.07 when the data was analysed for PRNP type in 4 year subgroups). The remaining
20 - 40 % of individuals are fairly equally divided between MV andW genotypes.
PrP isotype distribution with time was also reviewed (concentrating on Definite sCJD
patients only as PrP typing requires neuropathology). PrP type 1 comprised between
one half and two thirds of tested Definite cases each year, without any sustained
changes in time. Initially the remainder of patients were PrP type 2A but in 1996 the
first individuals with mixed PrP types (1 and 2A) were identified in the UK. The
number of mixed isotype cases has increased with time but they remain infrequent (to
date maximum 5 / year).
Fig 3.11
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Fig 3.13
Codon 129 distribution in Definite and Probable sCJD by % and
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*PrP isotype is available for 32% of the UK sporadic cases
Table 3.1 summarises the Parchi subtypes for Definite sCJD cases over three time
periods: 1993-96 prior to and up to the identification of vCJD, 1997 - 2000 when
vCJD emerged and peaked, and 2001-2004 when vCJD numbers began to decline.
The percentages of each subtype are relatively similar for each time interval, with
MM1 being most common, followed by VV2 and MV2. If MM1 and MV1 are
combined as 'typical' sCJD and compared with the other Parchi types ('atypical'
sCJD) for each of the three time periods there is a non significant trend towards more
atypical subtypes with time.
Similar findings are expressed graphically in fig 3.15 looking at the distribution of
Parchi subtypes by year of death. The absolute numbers of the rarer Parchi types are
small so even minor differences each year may impact significantly on annual
percentages. Despite this there is no significant sustained trend with time and it is
apparent that MM1 remains the commonest Parchi subtype each year.
80
Table 3.1 Distribution of codon 129 / PrP type in pathologically confirmed sCJD by
year of death
1993 - 1996 1997 - 2000 2001 -2004
MMI 60% (24) 47.5% (38) 51.7% (46)
MM2 7.5% (3) 8.8% (7) 4.5% (4)
MV1 0% (0) 8.8% (7) 4.5% (4)
MV2 12.5% (5) 10% (8) 14.6% (13)
VV1 2.5% (1) 1.3% (1) 4.5% (4)
VV2 15% (6) 13.8% (11) 12.4% (11)
MM1/2 2.5% (1) 6.3% (5) 1.1% (1)
MV1/2 0% (0) 1.3% (1) 4.5% (4)
VV1/2 0% (0) 2.5% (2) 2.2% (2)
Total tested n = 40 n = 80 n = 89
Not tested 125 153 172
(actual numbers shown in brackets)
Fig 3.15
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Summary of overview of 1993 - 2004 UK sCJD data
• There has been a significant overall increase in sCJD referrals to the NCJDSU
between 1993 and 2004, but with an unexplained decrease in 2004.
• Mean age of sCJD onset, death and median disease duration have all remained
constant with time.
• Each year the majority of Cases are referred prior to death by neurologists.
• Autopsy rates in suspected sCJD have shown a non significant decline with
time.
• MM is the commonest PRNP genotype but has decreased non significantly
with time.
• There has been no significant change in Parchi subtype or PrP isotype with
time, with the exception of the recognition ofmixed PrP types (1 / 2A) within
individuals.
82
3B. Sporadic CJD in 2003-4 compared with 1993-4
3.1 Demographics
3.1.1 Number and classification of referrals
In 1993/4 there were 159 suspected sCJD referrals compared with 196 in 2003/4 a. In
1993/4 49.7% were seen in life, relatives were interviewed in a further 22.6%
following the patient's death and 27.7% were not visited. In 2003/4 64.8% were seen
in life, relatives were interviewed in 11.7% after the patient's death and no interview
was performed in 23.5%.
Their final classifications are detailed in table 3.2. There were 95 classified as Cases
in 1993/4 95 and 129 in 2003/4, where a Case is defined as meeting the WHO criteria
for Definite or Probable sCJD. The percentage of cases compared to total referrals
was similar for each time period (60% and 66%). However, the proportion ofDefinite
and Probable classifications differed with time, with 86% of Cases being
pathologically confirmed in 1993/4 compared to only 59% in 2003/4. This trend away
from neuropathology is also demonstrated to a smaller extent with the Non Cases
(defined as clinically or pathologically not sCJD corresponding to WHO criteria 4.2
and 4.3). 37% of the Non Cases were pathologically confirmed in 1993/4 compared to
29% in 2003/4. A smaller proportion of referrals were classified as Possible sCJD
compared to 1993/4 (3.6% v 11.3%) but this may partly reflect a change in the
classification system due to introduction of 14-3-3 testing (see section 4.3.1).
Irrespective of the time period, only a minority of referrals to NCJDSU were
confidently felt not to have sCJD.
a. In comparison there were 24 other (non sCJD suspect) CJD referrals to the
NCJDSU in 1993/4 (classified by date of onset), including 13 familial / GSS, 9
iatrogenic and 1 variant CJD case and 1 patient initially suspected of vCJD that was
not ultimately a case. In 2003/4 there were 73 other CJD referrals to the NCJDSU in
total, including 22 familial / GSS, 9 iatrogenic and 37 variant CJD cases and 5
patients initially suspected of having vCJD that were ultimately not CJD cases.
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Table 3.2 Final classification of suspected sCJD referrals in 1993/4 and 2003/4 b
Year Final Classification Number of
referrals
% for year
1993/4 Definite CJD 82 51.6%
1993/4 Probable CJD 13 8.2 %
1993/4 Possible CJD 18 11.3 %
1993/4 Unclear diagnosis 8 5.0 %




2003/4 Definite CJD 76 38.8 %
2003/4 Probable CJD 53 27.0 %
2003/4 Possible CJD 7 3.6 %
2003/4 Unclear diagnosis 25 12.8 %




b. Following completion of data collection there have been a small number of
revisions to 2003/4 patient classifications, as discussed in section 4.3.1. Two sCJD
referrals have been reclassified, one from Probable sCJD to Unclear diagnosis, and
the other from Unclear to Probable sCJD. Two suspected sCJD referrals were
received late by death certificate, one subsequently classified as Possible sCJD and
one as a Non Case. Finally one Probable sCJD case is highly likely to be a familial
E200K mutation following the discovery of an estranged sibling with this mutation,
but remains classified as Probable sCJD due to lack of genetic material for testing.
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3.1.2 Gender
A slight excess of referrals were female for all suspected classifications. However,
there was no significant gender difference between Cases and Non Cases, nor any
change in gender distribution related to year of referral.
Table 3.3 Gender of sCJD Cases and Non Cases in 1993/4 and 2003/4
Classification / Year % male : female
Case 1993/4 43 : 57
Possible / Unclear 1993/4 35 : 65
Non Case 1993/4 42 : 58
Case 2003/4 47 : 53
Possible / Unclear 44 : 56
Non Case 2003/4 37 : 63
3.1.3 Mean age of onset
Mean age of onset was 66 years, both for Cases referred in 1993/4 and in 2003/4.
Mean onset age was also 66 years for Non Cases in both time periods (fig 3.16). Age
at onset was normally distributed for Cases and Non Cases and for each time period.
Mean onset age was higher at 72 years for Possible diagnoses in 2003/4 and Unclear
diagnoses in 1993/4 but these were the two smallest groups with only 7 and 8 patients




Mean age at disease onset by classification in 1993/4 and 2003/4
□ 1993/4
□ 2003/4
Case Possible Unclear Non Case
3.1.4 Disease duration
Median disease duration (from onset to death) was calculated for all suspected sCJD
referrals in 1993/4 and 2003/4 (fig 3.17). Data was incomplete in 12 of the 1993/4
referrals and 39 of the 2003/4 referrals, due either to the patient still being alive (23,
all from 2003/4), or because date of onset was not known (5 in 1993/4, 4 in 2003/4) or
lack of information as to whether the patient had died and / or date of death (7 in
1993/4, 12 in 2003/4). For Definite sCJD median disease duration was 4.5 months for
referrals in 1993/4 and 4.9 months for 2003/4 referrals. However, the range was wide
with the longest pathologically confirmed patients in 1993/4 and 2003/4 surviving for
54 and 62 months respectively and the shortest for 1.5 and 1 month only. Non Cases
had significantly longer illnesses than Cases (median 21.5 months for Non Cases
versus 4.4 months for Cases, p < 0.001 Mann-Whitney test).
When median duration was compared between 1993/4 and 2003/4 referrals the only
significant difference was for Non Cases, with longer duration in 1993/4 than in
2003/4 (36.5 months versus 8.5 months, p = 0.007). The average disease duration for
all other classifications was similar between the two time periods.
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Fig 3.17
Median disease duration by CJD classification for all suspect sCJD
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Summary of demographic findings in sCJD referrals in 1993/4 and 2003/4
• There were 196 suspected sCJD referrals to the NCJDSU in 2003/4 compared to
159 in 1993/4, but a higher proportion were pathologically confirmed or excluded
in 1993/4.
• Approximately 60% of all suspected sCJD referrals in 1993/4 and 2003/4 were
confirmed as sCJD Cases based on WHO diagnostic criteria (Definite and
Probable)
• Approximately 20% of all suspected sCJD referrals were ultimately classified as
having alternative diagnoses, with the figure being slightly higher in 1993/4 than
in 2003/4
• Mean age of onset was stable at 66 years for Cases and Non Cases in 1993/4 and
2003/4
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• Median disease duration was stable at 4 - 5 months for Cases in 1993/4 and
2003/4 but significantly longer in Non Cases, particularly in 1993/4 referrals
• There was no significant gender difference with time or classification
3.2 Referral process in 1993/4 and 2003/4
3.2.1 Referral Source
Referral source in 1993/4 and 2003/4
Source of referral was identified for all suspected sCJD patients in 1993/4 (n = 159)
and 2003/4 (n= 196) and are summarised in figs 3.18 and 3.19. The majority of
referrals were seen by neurology at some stage during their illness (83% in 1993/4
and 91% in 2003/4). The commonest referral source, irrespective of time period, was
neurology or neurophysiology. This accounted for 56.6% of referrals in 1993/4 and
66.3% in 2003/4. There were fewer referrals by physicians and geriatricians in 1993/4
compared to a decade later (8.8% v 17.9%). The proportion of referrals made by
psychiatry was small but remained fairly constant (5% and 6%). The most obvious
difference with time was the dramatic reduction in referrals made by neuropathology
and death certificate. In 1993/4 17.0% of suspect cases were notified to the NCJDSU
by neuropathology and 9.4% by death certificate. This contrasts with 10 years later
when only 5.6% were neuropathology referrals and just 0.5% were via death
certificate (a single patient). In total in 1993/4 32% were notified after death whereas
in 2003/4 this figure was 9.2%. This difference was significant (p< 0.0001 Mann
Whitney) and cannot be accounted for by delays in receiving neuropathology and
death certificate referrals at the time data collection stopped (see discussion 4.3.1).
A total of twelve referrals were made by 'other' sources, i.e. not neurologists,
physicians, geriatricians, psychiatrists, neuropathologists or by death certificate.
These comprised four referrals by microbiologists / virologists, two by EEG
technicians, two by relatives and one each by a general practitioner, neurosurgeon,




















Referral source for all patients in 2003/2004
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Referral source comparing Cases with Non Cases
Neurology / neurophysiology was the commonest referral source, both for Cases and
Non Cases, at 64% and 51% respectively (figs 3.20 and 3.21). The most striking
difference in referral patterns between Cases and Non Cases related to psychiatrists,
with only 3% of Cases being referred by psychiatry compared to 12% of Non Cases.
This was statistically significant (p = 0.03 yj). A higher proportion ofNon Cases than
Cases were referred by death certificate (with the death certificate diagnosis
subsequently being reviewed once hospital notes were available and / or the registrar
had visited relatives and corroborated the history) although this was not significant.
As expected, more Cases were referred by neuropathology. A minority of Non Cases
(n = 3) were referred to the NCJDSU by neuropathologists as suspected sCJD but on
further pathological review they did not have sCJD and were reclassified. Their final
diagnoses were Alzheimer's disease, cerebrovascular disease and dementia with no
cause identified on post mortem (but no pathological features of sCJD).
Overall there was a significant difference in the distribution of referral sources for
Cases compared to Non Cases (p < 0.001 xl.
Fig 3.20









Referral source for sCJD Cases and Non Cases in 1993/4 and 2003/4
□ Case 93/4
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3.2.2 Who first suspected sCJD?
The data for who first suspected the diagnosis of sCJD is similar but not identical to
data for source of referral and is summarised in fig. 3.22. The diagnosis was most
commonly first suspected by a neurologist / neurophysiologist, in 67.1% of referrals
in 1993/4 and 70.4% in 2003/4. These figures are slightly higher than neurology
referral figures suggesting that sometimes the neurologist makes the diagnosis but
does not refer. In 1993/4 many more sCJD referrals were made by pathology than
were first suspected by them (24 versus 6) implying that some patients diagnosed in
life were not being notified until autopsy. This was less prominent in 2003/4 referrals.
Only a minority of Cases (6 in 1993/4, 3 in 2003/4) were first suspected by pathology;
usually the diagnosis was suspected in life.
There was generally little difference as to who first suspected the diagnosis in 1993/4
compared with 2003/4.
There was insufficient information from the notes to determine who had first
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3.2.3 Time to suspect sCJD
The median time to suspect the diagnosis of sCJD in Cases was short at less than 3
months. Interestingly in 1993/4 the time was similar whether the final classification
was sCJD Case, Possible sCJD or Unclear diagnosis, whereas in 2003/4 the times
became progressively longer with increasing diagnostic uncertainty as reflected by the
WHO criteria (i.e. Case < Possible < Unclear).
Time to suspect sCJD was significantly shorter for Non Cases in 2003/4 than in
1993/4. In 1993/4 individuals with a history extending back for up to seventeen years
were being referred as suspected sCJD whereas the longest history for a Non Case in
2003/4 was less than four years and most were less than two years, possibly reflecting
increasing understanding of the typical sCJD disease course.
Figs 3.23 and 3.24 graphically summarise the time to suspect sCJD for Cases and Non
Cases in each time period. The majority of Cases were suspected of having sCJD
within 8 months of illness onset, and most within 4 months. In contrast, although
92
sCJD was suggested (incorrectly) in some Non Cases within a few months of disease
onset it was frequently not considered until much later, particularly in the case of
1993/4 referrals.
Table 3.4 Median time to suspect sCJD diagnosis in months (and range).
Classification 1993/4 2003/4 Significant diff.
between 1993/4
and 2003/4?
Case 2.5 mo (0.5 - 22.9) 2.8 mo (0.5-61.9) NS
Possible sCJD 2.6 mo (1.4- 11.5) 4.5 mo (1.0-7.0) NS
Unclear 2.6 mo (1.5-26.9) 5.0 mo (0.5-137.8) NS
Non Case 9.5 mo (0.1 - 124.7) 3.5 mo (0.1-39) p = 0.04
Fig 3.23
Time to suspect sCJD diagnosis for Cases and Non Cases in
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Fig 3.24
Time to suspect sCJD for Cases and Non Cases in 1993/4 and
2003/4 (expressed as %)
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3.2.3 Time to referral
Median time to referral to NCJDSU for all suspected sCJD patients in 1993/4 was 4.0
months (interquartile range 2.4 - 8.7 mo) and in 2003/4 it was similar at 3.6 months
(interquartile range 2.0 - 7.0 mo). However, if subdivided for sCJD classification it is
apparent that time to referral for Non Cases was significantly shorter in 2003/4 than in
1993/4 (p = 0.006 Mann Whitney). There were no other significant differences
comparing the two time periods.
Time to referral was significantly longer for Non Cases than Cases (p = 0.001 Mann
Whitney). In 8 patients time to referral was not calculated because onset date was
missing.
The median delay between suspecting the diagnosis of sCJD and referring to the
NCJDSU was one month or less with no consistent differences between the two time
periods or with different classifications. Median delay was used rather than mean as
the values were not normally distributed. However, the range is also included to
illustrate that although the median time delay was extremely short there was a
minority of cases where referral was delayed by many months.
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Summary of findings about the NCJDSU referral process in 1993/4 and 2003/4
• Sporadic CJD was suspected and the patient subsequently referred to the NCJDSU
by a neurologist in the majority of instances in 1993/4 and 2003/4.
• In 2003/4 significantly more referrals were made when the patient was alive and
correspondingly fewer referrals were made by neuropathologists or death
certificate compared to 1993/4.
• A significantly higher proportion of Non Cases were referred by psychiatrists
compared with Cases.
• In sCJD Cases median time to suspect diagnosis of was less than 3 months and
median time to referral was less than 4 months in 1993/4 and 2003/4. The
diagnosis of sCJD was suspected later and referral was delayed in Non Cases in
1993/4 whereas it was similar to Cases in 2003/4.
• Overall Cases were referred to the NCJDSU significantly earlier than Non Cases.
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3.3 Clinical Phenotype: comparing suspected sCJD referrals in 1993/4 and
2003/4
The clinical phenotype in suspected sCJD referrals in 2003/4 was compared with
referrals a decade earlier looking for any differences or evidence to support the
emergence of a novel phenotype. Clinical features were divided into symptoms at
onset, symptoms present at any stage in the illness, neurological signs at onset and at
any stage. 1993/4 and 2003/4 referrals were compared, analysing Definite sCJD,
Probable sCJD and Possible / Unclear diagnosis classifications separately.
3.3.1 Clinical presentation at onset
All suspected sCJD referrals were categorised by their mode of clinical presentation
using the following categories: rapidly progressive dementia, slowly progressive
dementia, Heidenhain's, pure psychiatric onset, pure cerebellar onset, extrapyramidal
onset, stroke - like onset, sensory onset, other and incomplete data (see methods for
precise definitions). The results for Cases and Possible / Unclear diagnosis
classification are summarised in figs 3.25 and 3.26. There were no differences in
clinical presentation of Cases in 1993/4 compared with 2003/4. Rapidly progressive
dementia was overwhelmingly the most common presentation category (65% and
68% in 1993/4 and 2003/4 respectively), followed by pure cerebellar onset (12% and
8%). All other categories represented less than 10% of Cases. In particular only a
single Case in 1993/4 and two Cases in 2003/4 had a pure psychiatric onset, and there
were no sensory onsets in 1993/4 and two a decade later.
In the Possible / Unclear classification the numbers were small (26 in 1993/4, 32 in
2003/4) but again rapidly progressive dementia was most common followed by pure
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3.3.2 Clinical symptoms at onset
The frequency of the following onset symptoms were analysed: symptoms of
impaired cognition ('forgetful'), symptoms suggesting cerebellar dysfunction
('unsteady'), focal weakness, visual disturbance, hallucinations, language disturbance
('speech'), headache, symptoms suggestive of a seizure, dizziness, disturbed sleep /
fatigue, weight loss and sensory symptoms.
Symptoms of cognitive impairment were the commonest presenting feature
irrespective of year group or final classification, being present at onset in 39 - 59%.
Interestingly forgetfulness was at least as frequent in the Possible / Unclear diagnosis
group as Definite and Probable classifications. Other common early symptoms
included unsteadiness, fatigue / altered sleep pattern and visual disturbance. Rare
onset features (present in less than 10%) were sensory disturbance, focal weakness,
seizure activity and hallucinations. Figs 3.27, 3.28 and 3.29 graphically demonstrate
the frequency of each onset symptom in Definite, Probable and Possible / Unclear
diagnosis categories respectively.There were no significant differences between
clinical symptoms at onset in 1993/4 and 2003/4 referrals of Definite and Probable
cases. The only difference related to the possible sCJD / Unclear diagnosis group
where dizziness was more commonly reported in 1993/4 (p = 0.04 y? Fishers exact).
Fig 3.27
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3.3.3 Clinical symptoms present at any stage
Clinical symptoms present at any stage of the illness were evaluated and are expressed
graphically in figs 3.30, 3.31 and 3.32.
Forgetfulness / confusion was almost universal in all three classification groups, being
confirmed in 92 - 100%. The second commonest symptom was unsteadiness, a feature
of 89 - 98% of Definite and Probable cases and 65 - 85% of the Possible / Unclear
diagnosis category. Speech and visual disturbances were also seen in the majority of
patients but were less prevalent in the Possible / Unclear group.
Hallucinations were reported in half of 2003/4 referrals (for each of the three
classification groups) but were less frequent in 1993/4, being recorded in
approximately one third of referrals, although the difference with time was only
significant for Possible / Unclear diagnosis patients. Psychiatric symptoms other than
hallucinations were also relatively common and were present in around one third of
patients, irrespective of year or final classification.
Sensory symptoms were less frequent and were identified in less than 20% of patients.
Overall 1993/4 and 2003/4 referrals were generally similar with respect to
symptomatology at any stage in the illness. In 1993/4 weight loss (Definite and
Probable sCJD), fatigue / sleep disturbance (Definites) and focal weakness (Possible /
Unclear diagnosis) were all recorded more frequently. In 2003/4 the only symptoms
which were more prevalent than a decade earlier were sensory symptoms (Definite
and Probable sCJD) and hallucinations (Possible / Unclear diagnosis). Other
psychiatric symptoms had not increased in frequency. None of the observed
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Clinical symptoms at any stage in Possible sCJD / Unclear
diagnosis in 1993/4 and 2003/4
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3.3.4 Signs present at first examination
Neurological signs present at the first documented examination were reviewed and the
findings compared between 1993/4 and 2003/4. Dementia was the commonest finding
but was by no means universal at this stage, being present in 50 - 65% of patients
(with the exception of 1993/4 Probable sCJD patients where 92% had dementia, albeit
with small numbers). Cerebellar signs were present in approximately half of patients
at first assessment. Myoclonus was relatively infrequent at this stage being apparent in
only 10 - 20%. Akinetic mutism was never present at first examination and cortical
blindness, primitive reflexes, parkinsonism, movement disorders other than
myoclonus and sensory signs were all rare at this stage (seen in less than 10%).
Overall there were no significant differences between signs at first examination in
1993/4 and 2003/4. Interpretation of these results is limited by the timing of the
examination and also who performed it and how thorough it was. The vast majority of
the examinations were performed by hospital neurologists or other physicians, either
in the outpatient clinic or on admission to the ward. The experience level of the doctor
ranged from junior house officer to consultant, and a small number were neurological
assessments documented by the referring GP. There was considerable variation in
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timing of the first examination, ranging from within a week of disease onset to the
terminal stages. However, examination timings for the different classifications in
either 1993/4 or 2003/4 were actually relatively similar with a median of 1.5 - 3.5
months or 42 - 52% through the illness as a whole (table 3.6).



































































3.3.5 Signs present at any stage of the illness
Figs 3.33, 3.34 and 3.35 summarise the examination findings in Definite, Probable
and Possible / Unclear diagnosis referrals in 1993/4 compared to 2003/4.
Dementia was the commonest clinical sign in all three classification groups in 1993/4
and 2003/4. It was identified on examination in 93 - 100% of patients. In the small
minority where cognitive impairment was not confirmed this was due to difficulty
with examination (e.g. patient mute by first assessment) or limited information rather
than definite absence of dementia.
The second commonest sign in suspected sCJD was myoclonus (seen in 78 - 98%).
Approximately two thirds of individuals had cerebellar signs on examination,
although this value was slightly lower in the Possible / Unclear diagnosis group (at 47
- 61%). Around half of all patients had pyramidal signs and primitive reflexes at some
stage throughout their illness. Parkinsonism, movement disorders other than
myoclonus and sensory signs were all infrequent but well recognised findings.
However, definite lower motor neurone abnormalities (as opposed to isolated mild
wasting consistent with disuse) were rarely recognised (< 5%) and may have been
coincidental rather than a feature of sCJD per se.
Akinetic mutism and cortical blindness were of particular interest as they were
significantly less frequent in 2003/4 compared to a decade earlier. Approximately two
thirds of Definite and Probable cases in 1993/4 were defined as akinetic and mute at
some stage, compared to only one third in 2003/4. The same trend was apparent for
Possible / Unclear diagnosis patients although the proportions were smaller (39% v
9%). Similarly cortical blindness was commoner in 1993/4 than 2003/4 with 24% of
Definites, 54% of Probables and 12% of Possible / Unclear diagnosis patients being
affected in 1993/4 compared to 9%, 23% and 0% respectively in 2003/4.
Variant CJD is associated with chorea and dystonia more frequently than sCJD but the
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Fig 3.35
Clinical signs at any stage in Possible sCJD / Unclear
diagnosis in 1993/4 and 2003/4
3.3.6 Summary of statistically significant differences in clinical phenotype
between 1993/4 and 2003/4
Generally the clinical phenotypes seen in the two populations (1993/4 and 2003/4
referrals) were similar and table 3.7 summarises the statistically significant
differences. Results in bold highlight features that were more common in 2003/4
compared to 1993/4.
Table 3.7 Summary of statistically significant differences in clinical phenotype
Between 1993/4 and 2003/4
Clinical feature Classification Significance (%2)
Akinetic mutism Definite p< 0.001
Akinetic mutism Probable p = 0.01
Akinetic mutism Possible / Unclear diag. p = 0.01
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Akinetic mutism Cases p< 0.0001
Cortical blindness Definite p = 0.02
Cortical blindness Probable p = 0.04
Cortical blindness Cases p = 0.02
Weight loss Definite p = 0.01
Weight loss Probable p = 0.04
Weight loss Cases p = 0.001
Sensory symptoms Definite p = 0.02
Sensory symptoms Cases p = 0.003
Fatigue / sleep disturbance Definite p = 0.02
Fatigue / sleep disturbance Cases p = 0.004
Hallucinations Possible / Unclear diag. p = 0.01
Hallucinations Cases p = 0.04
Dyspraxia Definite p = 0.05*
Headache Cases p = 0.01
Dizziness at onset Possible / Unclear diag. p = 0.04
Weakness Possible / Unclear diag. p = 0.02
Suspected seizure Cases p = 0.05**
*p = 0.048 **p = 0.045
Summary of results of clinical phenotype in 1993/4 and 2003/4
• Sporadic CJD Cases presented in a similar manner in 1993/4 and 2003/4.
• Rapidly progressive dementia was overwhelmingly the commonest mode of
presentation and occurred in around two thirds of Cases. Approximately 10%
had a cerebellar syndrome. All other types ofpresentation were rare.
• Cognitive impairment was the commonest single presenting symptom,
irrespective of year or classification.
• There were no significant differences between sCJD onset symptoms in
1993/4 and 2003/4 Cases.
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• Clinical signs at first examination were similar in 1993/4 and 2003/4 but were
heavily influenced by the timing and quality of the examination.
• The commonest symptoms present at any stage of the illness were
forgetfulness, unsteadiness and speech disturbance and were reported in over
80% of sCJD Cases.
• The commonest signs present at any stage of the illness were dementia,
myoclonus and cerebellar signs.
• Akinetic mutism, cortical blindness and weight loss were recorded
significantly more frequently in 1993/4 Cases whereas sensory symptoms
were more frequently reported in 2003/4 Cases.
• There was no difference between the proportion of Cases demonstrating
psychiatric symptoms such as depression and anxiety in 1993/4 and 2003/4,
but hallucinations were more commonly reported in 2003/4.
3.4 Investigation of suspected sCJD in 1993/4 and 2003/4
The standard investigations to support a clinical diagnosis of sCJD include EEG, CSF
examination and neuroimaging, ideally MRI. Fig 3.36 summarises the use of these
diagnostic tools in sCJD Cases referred in 1993/4 and 2003/4. EEG was used in at
least 90% of patients, irrespective of the year. CSF examination was also performed in
the vast majority of patients. The increased use in 2003/4 referrals compared to
1993/4 (88% v 73%) might be explained by the availability of the 14-3-3 protein
assay from 1997. This provides a sensitive and relatively specific diagnostic test for
sCJD whereas previously CSF analysis would primarily be performed to exclude
other pathology such as infection. In 1993/4 there was increased reliance on CT as an
imaging tool and correspondingly lower use of MRI whereas this was reversed in
2003/4. This is likely to reflect the increasing availability ofMRI with time, plus the
increasing awareness of the characteristic MRI changes associated with CJD. No
sCJD patient referred in 1993/4 and only one in 2003/4 definitely did not have
neuroimaging, and in this case it was planned but the individual died before scanning
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was performed. There was insufficient information about imaging in four patients
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3.4.1 Cerebrospinal fluid
CSF protein and white cell count results
CSF examination was performed in 69 / 95 1993/4 Cases (73%) and 113 / 129 2003/4
Cases (88%). CSF protein results were available in all but 2 of the 1993/4 group but
were missing in 23 patients in 2003/4, due either to insufficient details in the hospital
notes or the laboratory refusing to perform the test due to concerns regarding CJD
infectivity. Similarly the white cell count was missing in one instance in 1993/4 and in
10 2003/4 individuals.
Table 3.8 details the CSF protein results. There was no major difference with time.
Approximately two thirds of Cases had a normal result, a third had mildly elevated
protein and just 3% showed marked elevation defined as greater than lg / L. On
reviewing these individuals with protein in excess of lg / L there were no obvious,
consistent unusual features. All five had acellular CSF and four presented with rapidly
progressive dementia and followed a characteristic sCJD course. Only one of these
109
individuals was unusual, with a psychiatric onset followed by an illness lasting twenty
months with an unexplained raised creatinine kinase of 3600 U/L (normal <180 U/L)
in association with a CSF protein of 1.45 g / L.
3.8 Table 3.8 CSF protein levels in sCJD Cases in 1993/4 and 2003/4
CSF protein (g / L) 1993/4 Cases 2003/4 Cases
<0.5 43 (64%) 59 (66%)
0.5-0.99 22 (33%) 28 (31%)
> 1 2 (3%) 3 (3%)
The vast majority of Cases had normal CSF white cell counts (96% in 1993/4, 100%
in 2003/4). In 1993/4 four patients had 5 - 10 x 109 white cells / mm 3. One of these
could be explained by a traumatic tap with over 2000 x 109 red cells / mm 3. The
remaining three had only minimally elevated white cell counts at 5, 6 and 7 x 109
white cells / mm 3 and no alternative causes were identified for these findings. No
Cases had a white cell count greater than 10 x 109 / mm3.
CSF 14-3-3 and S100 results
In 1993/4 14-3-3 and SI00 assays were not available as diagnostic tools for sCJD. 100
Cases in 2003/4 had 14-3-3 results and 92 had SI00 results. The discrepancy of 8 is
explained by CSF samples that were of insufficient volume or frozen too late to
perform SI00 testing or the SI00 result was occasionally unavailable if the test was
performed out with the NCJDSU (at the National Prion Clinic, London). 96% of the
14-3-3 results were positive. However, it must be remembered that to be classified as
a Case a patient must meet either the Definite or Probable criteria and a positive 14-3-
3 result is actually part of the Probable criteria. Considering pathologically proven
patients alone 73% (40/ 55) of the 14-3-3 assays were positive.
SI00 was normal (< 0.38) in 5% (5 / 92) of Cases, moderately elevated (between 0.39
and 0.99) in 38% (35 / 92) and markedly elevated (> 1) in 57% (52 / 92). None of the
4 patients with negative 14-3-3 results had normal SI00s. Their SI00 levels ranged
between 0.75 and 2.0 with one unknown result.
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14-3-3 negative pathologically confirmed sCJD patients
The 14-3-3 negative pathologically confirmed sCJD patients are an interesting
population and to investigate them further the NCJDSU database was used to identify
all such cases from the introduction of 14-3-3 testing in December 1996 up until
December 2004. 26 individuals were identified but no clinical information was
available on one, who was therefore excluded from further analysis. Two patients had
repeat CSF testing with a subsequent positive 14-3-3 result but were still included. In
the same time period 166 Definite sCJD patients had positive 14-3-3 assays giving a
sensitivity of 87% in this population.
14-3-3 negative patients were then compared with 14-3-3 positive, pathologically
confirmed sCJD cases from 2003/4 (n = 64) with respect to clinical phenotype and
PRNP codon 129 / PrP isotype. Mean disease duration was significantly longer and
mean age at referral lower in the 14-3-3 negative group compared to the 14-3-3
positive cohort although the age difference did not reach statistical significance (table
3.9).
Table 3.9 Mean age at referral and mean disease duration in 14-3-3 negative and
positive sCJD
-ve 14-3-3 sCJD +ve 14-3-3 sCJD Signif.
Mean age at referral / yrs 59.8 (SD 12.5) 64.9 (SD 9.2) p = 0.12
Mean disease duration /
months
15.4 (SD 8.9) 6.7 (SD 7.3) pO.0001
The clinical phenotype also appeared slightly different in 14-3-3 negative patients.
Clinical onset more frequently included symptoms of cerebellar dysfunction in 14-3-3
negative sCJD than in 14-3-3 positive sCJD and visual disturbance was never seen as
a presenting feature in 14-3-3 negative patients (p = 0.01 y2 Fishers exact test) (Fig
3.37). When clinical features were reviewed throughout the course of the illness
visual disturbance and myoclonus were significantly rarer at any stage in the disease
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□ 14-3-3 positive sCJD □ 14-3-3 negative sCJD
Fig 3.38
Comparison of clinical features in 14-3-3 negative
and positive sporadic CJD
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Only 4/25 (16%) of the 14-3-3 negative cases had an EEG typical for sCJD with
periodic triphasic complexes. 7/22 (32%) had a characteristic sCJD MRI with basal
ganglia high signal. Almost half (12 patients) had negative results for all 3 of EEG,
MRI and 14-3-3.
In the 14-3-3 negative sCJD population PrP isotype / codon 129 genotype differed
significantly from sCJD patients with positive 14-3-3 (p < 0.001 %2) (fig 24). MM1,
which is associated with a typical sCJD presentation, was significantly less common
in 14-3-3 negative patients (p = 0.03 x2).
Pathology was as expected for codon 129 / prion protein type with at least 9 of the
cases having predominantly subcortical rather than cortical pathology.
Fig 3.39
Codon 129-PrP subtype distribution in 14-3-3 negative sCJD
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The timing of the CSF testing was calculated to assess if this was different between
14-3-3 negative and positive patients. In the 14-3-3 negative population the median
time to take CSF was 6.0 months (range 2-36 months) and the mean proportion
through the illness was 59% (SD 20.7). This compares with 14-3-3 positive patients
where median time to take CSF was shorter at 3.0 months (range 0.5 - 41 months) but
mean proportion through the illness was similar at 66% (SD 21.1), reflecting the
longer disease duration in the 14-3-3 negative group.
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3.4.2 MRI
In 1993/4 44 of the 95 Cases had MRI brain imaging (46%) compared to 111 / 129
(86%) in 2003/4. In one case in 1993/4 and five cases in 2003/4 the MRI was either
not interpretable (due to poor quality scanning or excessive movement artefact) or the
result was unknown. These scans were therefore excluded from further analysis.
Only 2 of the 1993/4 scans were available for review by the NCJDSU radiographers.
Both were reported as having caudate / putamen hyperintensity and were therefore
classified as positive scans. Two other 1993/4 MRIs were described as having basal
ganglia high signal according to the local radiologists but were not available for
review. Therefore 9% (4 / 44) of the scans were considered positive. 37/44 scans were
reported as normal locally and were not reviewed, two had alternative abnormalities
unrelated to sCJD (established and multiple infarcts compatible with underlying
cerebrovascular disease in both cases) and one scan was not interpretable due to
movement artefact. None of the scans were reported as having cortical hyperintensity.
In 2003/4 more MRI scans were both performed and reviewed by the NCJDSU. 34
scans were confirmed as positive on review. A further 14 were unconfirmed positive
results resulting in a total positivity rate of 45% (n = 48). In addition cortical
hyperintensity alone was noted on review of six scans and reported on another. In
isolation cortical hyperintensity does not permit classification as a positive MRI. 20
scans were normal on review and 30 were normal by report. One MRI showed non
CJD pathology, namely T2 high signal in the pons raising the possibility of central
pontine myelinolysis but there was no history of hyponatremia and on balance it was
felt to reflect ischaemic change. No scans showed the pulvinar sign that is
characteristic of vCJD. There were significantly more MRIs with the characteristic
changes of sCJD in 2003/4 compared to 1993/4 (p < 0.001 Mann Whitney test). Figs
3.40 and 3.41 summarises these MRI result
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MRI results were also collated for the Possible and Unclear diagnosis classifications
for each time period. In 1993/4 only 5/26 (19%) patients had an MRI and all were
reported as normal although none were available for review. In 2003/4 a higher
proportion had MRI performed (24 / 32, 75%) and 8 were positive (6 confirmed, 2 by
report only) giving a positivity rate of 33% in this subgroup. Of these 8 individuals 3
were Possible sCJD and 5 Unclear diagnosis. The 5 Unclear diagnosis patients either
had a disease duration greater than two years or insufficient clinical features to fulfil
sCJD diagnostic criteria, but all had a characteristic EEG or positive 14-3-3 in
addition to the typical MRI appearances. In all eight individuals the 'best guess'
diagnosis was felt to be sCJD. 15 scans were normal (4 confirmed, 11 by report) and 1
scan showed alternative pathology with bilateral temporal lobe atrophy and
hyperintensity felt to be radiologically suggestive of either mitochondrial disease or
chronic herpes simplex encephalitis. However, clinically no diagnosis has been made
and the individual remains classified Unclear diagnosis as sCJD remains a possibility.
The timing of the MRI may potentially influence the result and therefore time to MRI
was compared in Cases with a positive or negative MRI result. Timing was assessed
in two ways; as the number of months between disease onset and MRI, and secondly
MRI timing as a percentage of the total illness duration. The former measure was not
normally distributed so medians were used whereas the percentages were normally
distributed and therefore means were compared. Table 3.10 summarises the results.
The MRI was performed significantly earlier in the Cases with a negative scan.
However, when MRI timing was considered proportionate to the illness duration there
was no significant difference between those with a positive and negative scan result.
Table 3.10 Timing ofMRI in sCJD
Positive MRI Negative MRI Significance
Median time to 3.5 months 2.5 months P = 0.01 (Mann
performing MRI Whitney test)
MRI timing as 65% 60% NS
mean percentage (t test)
through illness
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The relationship between basal ganglia high signal on MRI and PRNP codon 129
genotype and PrP isotype was also explored. When only the scans reviewed in the
NCJDSU were considered 86% ofVV cases had basal ganglia hyperintensity on MRI
compared to 57% of MV patients and 54% of MM cases (fig 3.42). If unconfirmed
scan reports were also included the proportion of positive scans decreased for all
genotypes but the trend persisted (basal ganglia hyperintensity VV 57%, MV 37%,
MM 31%). Despite this MM was the most common genotype in cases with a positive
MRI, reflecting the predominance of MM in sCJD generally. If sCJD cases were
stratified by MRI findings (using confirmed MRI results only) there was a higher
frequency of valine homozygosity in the subgroup with MRI high signal (41% v
13%), whereas the reverse was true with methionine homozygosity (45% v 69%) and,
to a lesser extent, heterozygotes (14% v 19%) (fig 3.43). These results were not
statistically significant (x2 p = 0.47 analysing confirmed MRI scans only or p = 0.08
analysing all MRIs)
Fig 3.42
MRI and codon 129 genotype
MM MV W
Codon 129 genotype
15 MRI negative for sCJD*
□ MRI basal ganglia
hyperintensity
(confirmed at NCJDSU)
* MRI negative = no basal ganglia hyperintensity
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Fig 3.43
MRI basal ganglia high signal andcodon 129 genotype




There were only a small number of cases where PrP type was known and MRI
imaging had been reviewed at the NCJDSU. Of these 36.4% (4/11) of PrP 1 cases had
characteristic caudate / putamen changes on MRI compared to 77.8% (7/9) of PrP 2
cases. If unconfirmed scans were included 38.5% (5/18) were positive in PrP 1 cases
versus 50% (9/18) in PrP 2 patients. This was not statistically significant (x2 p = 0.06
using confirmed MRIs or p = 0.13 using all MRIs).
Table 3.11 summarises the MRI findings in the different Parchi subtypes.
Unfortunately the numbers are too small for any meaningful interpretation but MRI
proved a useful diagnostic tool in three out four of the VV2 patients where images
were reviewed and two out of three MV2 cases.
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Table 3.11 MRI results by Parchi subtype
Parchi subtype MM1 MM2 MV1 MV2 VV1 VV2
No. of cases with confirmed 4 1 0 2 0 3
basal ganglia hyperintensity (5) (1) (0) (2) (0) (5)
on MRI
(unconfirmed MRI results)
No. of cases with confirmed 6 0 0 1 0 1
absence of basal ganglia (11) (0) (1) (4) (0) (4)
hyperintensity
(unconfirmed MRI results)
MRI and extrapyramidal features
A positive association between extrapyramidal features and basal ganglia
hyperintensity on MRI has been postulated in sCJD. However, in this study there was
no such positive correlation. 13.5% of sCJD Cases with caudate / putamen high signal
on MRI had extrapyramidal signs, compared to 13.3% of Cases with a negative MRI
(not significant).
3.4.3 EEG
The vast majority of sCJD Cases were investigated with EEG. In 1993/4 89.5% of the
Cases (85 / 95) had EEGs. In 2003/4 the percentage was marginally higher at 94.6%
(122 / 129). The mean number of EEGs per individual Case was similar at 1.65 in
1993/4 and 1.56 in 2003/4 with a range of 0 - 5 EEGs for both time periods. However,
fewer EEGs were available for review at the NCJDSU in 1993/4 Cases compared to
2003/4 Cases (52 versus 104).
Timing of the EEG was similar in 1993/4 and 2003/4 with median time to EEG of 2.7
months (range 0.6 - 18.9) and 2.6 months (range 0.5 - 41.3) respectively. EEG date
was missing in one Case in 1993/4 and three in 2003/4 so these were excluded from
the analysis. When time to EEG was expressed as a proportion of the total illness
duration the median values were similar in 1993/4 and 2003/4 at 77.1% (range 6.6 -
100%) and 72.0% (range 13.7 - 100%).
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Overall just over half of 1993/4 Cases and one third of 2003/4 Cases had EEGs that
were characteristic of sCJD and were sufficient to classify the individual as a Probable
Case if clinical features allowed (fig 3.44). This difference between the time periods
was significant (p = 0.02 Mann Whitney). If the percentage of characteristic EEGs is
calculated based only on the traces that were reviewed in the NCJDSU the difference
is even more marked with 73.1% of reviewed EEGs being classifiable in 1993/4
compared to 38.5% in 2003/4. Generally EEGs were only classified as characteristic
if they were reviewed by one of two individuals in the NCJDSU (RGW, RK).
However, there were six exceptions, all in 1993/4, whereby EEGs were examined by
the visiting registrar or NCJDSU consultant and termed characteristic but were then
missing by the time this study was performed so could not be reviewed and
reclassified.
Figs 3.45 and 3.46 summarises the breakdown of EEG classifications for each time
period. 27% (n = 23) of EEGs in 1993/4 were entirely typical for sCJD compared to
17% (n = 21) in 2003/4 whereas the proportion of highly suggestive traces was similar
at 20% and 17% respectively (n = 17 and 20). 38% of EEGs were unavailable for
review in 1993/4 compared to 13% in 2003/4.
Fig 3.44
Proportion of characteristic EEGs in Cases in 1993/4 and 2003/4
Cases 1993/4 Cases 2003/4
n = 85 n = 120
■ EEG not typical / highly
suggestive









□ No trace, report suggestive






■ No trace, report suggestive














The EEG findings were also analysed for suspect sCJD referrals that were ultimately
classified as only Possible sCJD or Unclear diagnosis (figs 3.47 and 3.48).
Unfortunately the numbers were small and over half of the traces were unavailable for
review (58% in 1993/4, 51% in 2003/4). In both 1993/4 and 2003/4 referrals 14%
were considered characteristic of sCJD. In 1993/4 all 14% were classified as highly
suggestive (n = 3) whereas in 2003/4 7% (n = 2) were highly suggestive and 7% (n =
2) typical.
Figs 3.47 and 3.48








□No trace, report suggestive
■ No trace, report non-specific





EEG and codon 129 genotype
The relationship between PRNP codon 129 genotype and the EEG was explored (fig
3.49). When 1993/4 and 2003/4 referrals were analysed together MM genotype was
significantly more common amongst patients with an EEG characteristic for sCJD (p
< 0.001 %2). This statement remains valid if 1993/4 and 2003/4 referrals are analysed
separately (p < 0.001 Fisher's exact x2 for 1993/4 and for 2003/4).
93.5% (n = 58) of Cases with typical / highly suggestive EEGs were methionine
homozygous and only 3.2% (n = 2) were valine homozygous and 3.2% (n = 2)
methionine valine heterozygous. In contrast in those Cases where there was no
characteristic EEG (either because no EEG was available or because it was reviewed
and felt to be non specific or suggestive at best) PRNP genotype was more evenly
distributed (MM 36.9%, n = 31; MV 23.8%, n = 20; W 39.8%, n = 33). This
difference was slightly more pronounced if only EEGs that were reviewed in the
NCJDSU and deemed not characteristic were included although the numbers were
smaller (MM 33.3%, n = 15; MV 28.9%, n = 13; W 37.85%, n = 17).
Fig 3.49
Relationship between characteristic sCJD EEG anclodon 129
genotype
□ Characteristic sCJD EEG
■ No characteristic sCJD EEG
MM MV W
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Assessment of the impact of PrP isotype on the EEG was limited because of small
sample sizes. Despite this there appears to be an excess of PrP type 1 in Cases with
typical / highly suggestive EEGs and this was statistically significant (p = 0.001
Fisher's exact x2)- Table 3.12 summarises the findings when 1993/4 and 2003/4 Cases
are combined.
Table 3.12 EEG results by PrP isotype




1 11 (100%) 17(45.9%)
2A 0 (0%) 20 (54.1%)
EEGs in Non Cases
Three individuals were referred as suspected sCJD and had characteristic EEG
appearances but ultimately proved pathologically to have alternative diagnoses. Two
fulfilled criteria for Probable sCJD in life, whereas in the third case the dementia was
considered slowly progressive and therefore unlikely to be due to sCJD. Interestingly
one of these patients was referred on the basis of clinical features prior to the EEG
being performed. They are of particular clinical interest and are described in more
detail below:
(i) In 2003/4 a previously well female presented at the age of eighty with mild
unsteadiness of gait. This remained relatively static for eighteen months until subtle
cognitive impairment was noted and the patient began falling. There onwards the
illness progressed relentlessly with increasing memory problems, poor balance and
urinary urgency and frequency.
CT brain imaging at eighteen months revealed ventriculomegaly, initially attributed to
cerebrovascular related atrophy. At three years a lumbar puncture was done with
normal opening pressure and marked improvement in mobility and cognition,
supporting the clinical impression of normal pressure hydrocephalus. This was
followed by lumbar drainage with a good but transient response lasting two weeks.
Ventriculostomy was then performed but was complicated by sepsis and
hyponatremia and the patient never recovered to her immediate pre-operative level of
function, despite a further attempt at ventriculoperitoneal shunting.
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She continued to deteriorate and when reviewed by the NCJDSU registrar 39 months
into her illness she was bed bound with confused speech, spontaneous multifocal
myoclonus, generally brisk reflexes and a positive pout. She died 2 months later.
5 months prior to death an EEG showed periodic complexes, 14-3-3 CSF protein was
positive and MRI showed small vessel ischaemic changes only. Post mortem
demonstrated marked enlargement of the third and lateral ventricles and minimal
cerebrovascular disease and occasional Alzheimer type neurofibrillary tangles (both
felt unlikely to be of clinical significance). The appearances were felt to be consistent
with normal pressure hydrocephalus. There was no pathological evidence of a
spongiform encephalopathy.
(ii) In 1993/4 a seventy year old lady presented with dementia progressed rapidly over
nine months with the emergence of pyramidal and extrapyramidal features, akinetic
mutism but no myoclonus. During this period she also underwent cataract surgery.
She died with a total disease duration of ten months.
EEG just prior to death showed periodic complexes at a frequency of 1 - 2 Hertz, and
was reported by the local neurophysiologist and the NCJDSU as being highly
suggestive of sCJD (fig 3.50). MRI showed only generalised cerebral atrophy.
Pathology demonstrated Lewy bodies within the cortex, thalamus and brainstem
consistent with diffuse dementia with Lewy bodies. There was no evidence of
spongiform encephalopathy.
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(iii) The third individual, also female, developed mild memory problems aged 56
resulting in early retirement from her job as a secretary. She was treated for
depression without any benefit. The cognitive problems progressed slowly over
several years with the eventual development of dysphasia, startle myoclonus,
infrequent generalized seizures and visual hallucinations. Examination confirmed
myoclonus, global dementia, pyramidal signs and primitive reflexes. She died aged
65, 9 years after the onset ofher cognitive impairment.
CT brain imaging demonstrated mild generalised atrophy with disproportionate left
temporal lobe atrophy and marked periventricular white matter changes. SPECT scan
showed severe perfusion deficits throughout the cortex but was not typical of any
particular dementia. CSF and bloods were normal. Three EEGs performed in the last
year of the illness were felt to be typical for sCJD, both by the reporting
neurophysiologist and the NCJDSU (fig 3.51). Prion gene analysis showed that she
was homozygous for methionine at codon 129 and no mutations were present.
At autopsy there was no evidence of CJD. However, there were widespread senile
plaques and neurofibrillary tangles consistent with Alzheimer's disease (CERAD
definite) plus moderate arteriosclerosis.
Fig 3.51
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Interestingly two of these unusual cases underwent surgery during their final illnesses
(one neurosurgical, one opthalmic). Therefore the EEG findings taken in conjunction
with the clinical features stimulated major public health concerns regarding the
possibility of CJD and subsequent transmission. In fact in both cases the instruments
were quarantined until the autopsy results were available.
A further nine Non Cases had EEGs which were reviewed in the NCJDSU and
designated 'suggestive' of sCJD although not sufficient to use in classification. The
final diagnoses in these patients is summarised in table 3.13.
Table 3.13: Diagnoses in Non Cases with EEG appearances characteristic or
suggestive of sCJD




Alzheimer's disease Pathological 1993/4 Typical
Dementia with Lewy
Bodies
Pathological 1993/4 Highly suggestive
Normal pressure
hydrocephalus




Alzheimer's disease Clinical 1993/4 Suggestive







Viral encephalitis Pathological 2003/4 Suggestive




No diagnosis but clinically
not compatible with sCJD
Clinical 2003/4 Suggestive
127
Six Non Cases had EEG traces that were reported by the local neurophysiologist as
suggesting sCJD but were unavailable for review. Interestingly one of these patients
presented with rapidly progressive dementia and EEG was reported locally as
characteristic of sCJD with periodic complexes at 1-2 second intervals on a slow
background. However, CJD was then discounted because she made a dramatic
spontaneous recovery although no alternative diagnosis was ever made.
3.4.4 Brain biopsy
Brain biopsy is not part of the routine work up of a suspected sCJD patient. It was
done infrequently in both referral periods with five patients in 1993/4 and five patients
in 2003/4 undergoing brain biopsy (representing 5.3% and 3.9% of Cases
respectively). All ten individuals had brain biopsy results supporting a diagnosis of
sCJD although in one case this was felt to be inconclusive. Half ultimately proceeded
to autopsy with the diagnosis being confirmed in all patients. No brain biopsies were
performed on referrals that subsequently turned out not to have sCJD (although this
partly reflects the study design as a suspected sCJD patient with a subsequent brain
biopsy proven alternative diagnosis will obviously not be referred to the NCJDSU at
this stage). Interestingly eight of the ten brain biopsies were performed in a single
centre (including all five 2003/4 patients), raising the possibility that different
hospitals have different practices and thresholds for performing biopsies. It is
important to note that brain biopsy is a rare investigation for sCJD and the figures
have not increased since the emergence of vCJD.
This cohort of sCJD patients that underwent brain biopsy were studied in more detail
to determine if they differed from usual sCJD cases, or if the biopsy could have been
avoided on the grounds of a secure diagnosis based on clinical features and other, less
invasive investigations (table 3.14). The five cases from 1993/4 and the five from
2003/4 were combined for these analyses and compared with the total pathologically
proven sCJD cohort (1993/4 and 2003/4 excluding the brain biopsy cases).
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Table 3.14 Comparison of demographics, clinical features and investigation results in






biopsy (n = 148)
Significance
Age (years) 54.3 (SD 15.8) 67.3 (SD 9.8) p = 0.005
Mean duration
(months)














Insufficient data 5.4% (8)







EEG Typical 10% (1)
Not typical 90% (9)
Typical 37.4% (49)
Not typical 62.6% (82)
(Not done / known 17)
NS
MRI brain Caudate / putamen




Caudate / putamen high
signal 30.3% (27)
















* RPD = rapidly progressive dementia ** SPD = slowly progressive dementia
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It is difficult to draw firm conclusions due to the small number of patients who
underwent brain biopsy but in general they appear to be significantly younger than
non brain biopsy sCJD patients (p = 0.005 Mann Whitney), with a significantly longer
mean illness duration (p = 0.003 Mann Whitney). The clinical presentation in 70% of
the brain biopsy patients was fairly typical for sCJD with either rapidly progressive
dementia or cerebellar onset. However, the three other onsets were more unusual with
one individual presenting with abdominal pain and weight loss raising the possibility
of a neoplastic or paraneoplastic disorder, one presenting with chorea and one with
personality change and irritability. Codon 129 genotype was only known in eight of
the brain biopsy patients and the results were not typical of codon 129 distribution in
sCJD generally. Only 25% of the biopsy cases were methionine homozygous whereas
64% of the other pathologically proven cases were methionine homozygous. In
contrast MV and W genotypes appeared more frequently than one would expect
although the numbers are small. These differences in PRNP codon 129 distribution
between biopsy and non-biopsy patients were not quite significant, probably reflecting
the small numbers (p = 0.07 % ).
Half of the biopsy cohort had an MRI scan which supported the diagnosis of sCJD
(compared to one third of non biopsy cases). All the positive MRIs were performed
prior to the biopsy so one can question whether brain biopsy was still required.
Similarly CSF 14-3-3 protein was positive in the majority of the brain biopsy patients
who had this investigation, whereas EEG only provided positive support for the
diagnosis of sCJD in one individual (and in this case the EEG was performed prior to
biopsy). There were no statistically significant differences between brain biopsy and
non biopsy sCJD patients with respect to EEG, 14-33 and MRI results.
Without pathology four of the brain biopsy cases fulfilled criteria for Probable sCJD,
four would have been classified as Possible sCJD and two were Unclear diagnosis, in
both instances due to their prolonged disease duration of over two years. sCJD was
suspected clinically in all ten cases before the brain biopsy was done.
3.4.5 Pathology and codon 129 genotype
PRNP 129 genotype distribution was compared between 1993/4 and 2003/4 sCJD
referrals. The findings are summarised in figs 3.52, 3.53, 3.54 and 3.55 looking at
Definite and Probable patients separately and either including or excluding those
where genotype was unknown. In both time periods the genotype was not available in
a significant proportion of sCJD patients, either because the relatives did not consent
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to genetic testing or because the individual was referred after life and genotyping was
not possible on the available autopsy tissue. When these 'unknown' results were
excluded there was no statistically significant difference between codon 129
genotypes with time, either in pathologically proven sCJD (p = 0.84 x2), Probable
sCJD (p = 0.5 Fisher's exact x2) or in Definite and Probable Cases combined (p = 0.49
X2). However, there was a non significant trend for a higher proportion of VV
genotypes in 2003/4 compared to 1993/4, with correspondingly fewer MM genotypes
in 2003/4 (Definite sCJD 20.8% W in 1993/4 v 29.4% W in 2003/4, Probable sCJD
19.3%W in 1993/4 v 27.0% VV in 2003/4).
Fig 3.52
Codon 129 genotype in pathologically proven sCJD in 1993/4
and 2003/4
1993/4 2003/4
n = 82 n = 76
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Fig 3.53
Codon 129 distribution in pathologically proven sCJD in 1993/4
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Codon 129 distribution in Probable sCJD patients in 1993/4 and




The possible impact of PRNP genotype on sCJD duration and age of onset was
explored. Onset age was similar, irrespective of codon 129 type (no significant
differences with Mann Whitney tests comparing MM with MY, MM with VV and
MV with VV). Disease duration was significantly longer in MV compared to MM
cases (p < 0.001 Mann Whitney) and W compared to MM cases (p < 0.001 Mann
Whitney). The proportion of each genotype undergoing autopsy was also reviewed
but there were no significant differences (p = 0.87 %2). Table 3.15 summarises the
findings.
Table 3.15 sCJD onset age, duration and PM rate by PRNP type






MM 67.4 3.0 75.3
MV 64.6 8.6 77.3
VV 65.0 5.5 71.4
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PrP isotype was rarely known for 1993/4 referrals as isotyping was not routinely
carried out at this time. Therefore only two such individuals have PrP results, one
being PrP type 1 and the other type 2A. In contrast PrP type was analysed in 67% of
2003/4 Definite sCJD patients and table 3.16 summarises the findings. Because of the
disparity in numbers it is not possible to make comparisons between the two time
periods. A single case was found to have both PrP 1 and PrP 2A. No individual was
positive for PrP 2B, the isotype characteristic of vCJD.





PrP 1 1 30 (58.8%)
PrP 2A 1 20 (39.2%)
PrP 1 + 2A 0 1 (2.0%)
Not known 80 25
No sCJD referrals in either time period had the florid plaques characteristic of vCJD.
However, a minority of pathologically proven cases had kuru type amyloid plaques on
histopathology. These were significantly more common in 2003/4 than in 1993/4
referrals (n = 11, 14.5% in 2003/4 compared to n = 3, 3.7% in 1993/4; p = 0.02 Mann
Whitney). Kuru plaques are typically associated with the MV2 Parchi subtype and 7
of the 14 patients with kuru plaques had full PRNP / PrP isotype analysis. 6 of the 7
were MV2 with 1 individual being MM1, and the neuropathologist commented that
this Parchi subtype was unusual given the pathological appearances. Unfortunately it
is not possible to compare the proportion ofMV2 sCJD patients for each time period
due to the lack of PrP testing in 1993/4. However, the proportion of Definite cases
heterozygous for methionine valine was similar for both time periods (15% in 1993/4
and 16% in 2003/4 of those tested).
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Summary of results regarding sCJD investigations in 1993/4 and 2003/4
• Sporadic CJD is associated with a normal CSF white cell count.
• In pathologically proven sCJD CSF 14-3-3 analysis had a sensitivity of 73%.
• 14-3-3 negative sCJD patients are uncommon and clinically and pathologically
atypical, probably in keeping with the underlying codon 129 / prion protein type.
• A negative CSF 14-3-3 result does not exclude the diagnosis of sCJD, particularly
in young patients with unusual clinical presentations and prolonged disease
course.
• 45% of 2003/4 sCJD Cases undergoing MRI were recognised to have basal
ganglia hyperintensity compared to only 9% in 1993/4.
Typical sCJD appearances of basal ganglia high signal on MRI were more
frequently recognised in PRNP codon 129 valine homozygotes and in association
with PrP 2A isotype but these findings were not statistically significant.
There were significantly fewer EEGs characteristic of sCJD in 2003/4 Cases
compared to 1993/4 Cases.
Typical EEGs were associated with methionine homozygosity at PRNP codon 129
and with PrP 1 isotype.
Three pathologically proven Non Cases had EEG appearances that were
characteristic of sCJD, implying that such periodic sharp wave complexes are not
specific to sCJD.
Brain biopsy was rarely performed in the work-up for sCJD and biopsy Cases
tended to be younger and with longer disease duration than Cases without cerebral
biopsy.
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• There was no significant difference in PRNP codon 129 distribution between
sCJD Cases in 1993/4 and 2003/4 although there was a trend towards more valine
homozygotes and fewer methionine homozygotes in 2003/4.
• PRNP MM Cases had significantly shorter disease durations than either MV or
VV sCJD cases.
• Kuru plaques were rare but significantly more common in 2003/4 referrals than in
1993/4, and were usually associated with the MV2 Parchi subtype. No individual
had florid plaques on neuropathological examination.
3.5 The differential diagnosis of sCJD
Fig 3.56 summarises the number of Non Cases that were referred to the NCJDSU as
suspected sCJD each year between 1993 and 2004. The number of Non Cases
increased gradually between 1993 and 2000 but there was a marked drop in 2002
which has persisted. The proportion of pathologically confirmed Non Cases was
between 40% and 57% between 1994 and 1999 but more recently it has decreased
with a low of 28% in 2004.
Fig 3.56
Number of Non Cases referred annually between 1993 and 2004
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Non Cases referred in 1993, 1994, 2003 and 2004 were analysed in more depth. There
were 38 Non Cases in 1993/4, of which 14 (37%) had pathologically proven
alternative diagnoses and 24 (63%) were clinical diagnoses. In 2003/4 there were 35
Non Cases, 10 of which were pathologically confirmed (29%) and 25 clinical
diagnoses (71%).
3.5.1 Diagnosis in pathologically proven Non Cases
Table 3.17 summarises the final pathological diagnoses in suspected sCJD referrals in
1993/4 and 2003/4 that were ultimately Non Cases. Other forms of CJD (genetic,
iatrogenic, variant) were excluded. There was a wide range of alternative diagnoses,
all but one of which were primary neurological disorders (the exception being
generalised sepsis and renal failure). The commonest pathologically proven
alternative was Alzheimer's disease seen in 8 / 24 patients (33%). Dementia with
Lewy bodies accounted for 3 / 24 (13 %), as did encephalitis of unknown cause. Two
individuals had dual pathology with both Alzheimer's disease and Lewy body
dementia pathologically.
There were two malignancy - associated cases, one with cerebral and meningeal
metastases from a presumed small cell lung primary, and one with cerebral non
Hodgkins lymphoma. There were no definite paraneoplastic cases. Interestingly the
precise cause of death in three individuals remained unclear despite post mortem; one
being reported as subacute encephalitis, one as cerebellar encephalitis and one as
chronic limbic encephalitis, all of unknown aetiology. In all three instances the
pathologist commented that the appearances would be consistent with a
paraneoplastic process although there was no positive evidence to support this such as
identification of a tumour or positive paraneoplastic antibodies in blood or tissue.
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Table 3.17 Final diagnosis after autopsy in Non Cases referred in 1993/4 and 2003/4
Final diagnosis after autopsy Frequency
Alzheimer's disease 8*
Dementia with Lewy Bodies (DLB)** 3*
Encephalopathy / encephalitis cause unknown 3
Cerebrovascular disease 2
Parkinson's disease with dementia (PDD)** 2
Malignancy associated 2
Dementia - type unknown 2
Normal pressure hydrocephalus 1
Multifocal calcifying leucoencephalopathy 1
Viral encephalitis 1
Sepsis / Acute renal failure 1
Total no. of pathological Non Cases 24
* 2 patients had dual pathology with both Alzheimer's disease and Lewy body
dementia on autopsy
** DLB defined as dementia within a year of onset of Parkinsonism , whereas PDD
defined as cognitive problems coming on more than a year after Parkinsonian features
3.5.2 Diagnosis in clinical Non Cases
Table 3.18 summarises the diagnoses in those patients who were felt not to have CJD
but where the alternative diagnosis was made on clinical rather than pathological
grounds. Again Alzheimer's disease was the commonest diagnosis (20%, 10 / 49) and
a further five had dementia which was not classifiable clinically.
Two patients were diagnosed with CNS vasculitis; one had a positive vasculitic blood
screen and the second responded to steroids but deteriorated and died some six
months later with a death certificate diagnosis of CNS vasculitis. The single
malignancy associated case had positive anti - Yo antibodies suggesting
paraneoplastic aetiology. Two patients were ultimately diagnosed with motor neurone
disease (MND). One presented with fasiculations and had a family history of MND
but sCJD was suggested as a diagnosis because of mild cognitive impairment,
cerebellar signs and a positive 14-3-3 CSF protein although the subsequent disease
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course favoured MND. In the second individual a clinical diagnosis of MND was
supported by evidence of anterior horn cell dysfunction on EMG, but he was initially
referred as a possible sCJD case due to associated mild cognitive impairment and a
history suggestive of complex partial seizures. Five patients had no diagnosis or
improvement but their clinical course was felt incompatible with sCJD.
There is likely to be some overlap between the diagnoses. E.g. Four patients improved
without a clinical diagnosis (two spontaneously and two with steroids) and some of
these may have had vasculitis or encephalitis.
Table 3.18 Final clinical diagnosis in Non Cases referred in 1993/4 and 2003/4
Final clinical diagnosis Frequency
Alzheimer's disease 10
Dementia - type unknown (not CJD) 5
No diagnosis but clinically not CJD 5
Dementia with Lewy Bodies (DLB) 4
Cerebrovascular disease 3
Parkinson's disease with dementia (PDD) 3
Epilepsy 3
Motor neurone disease +/- frontotemporal dementia 2
CNS vasculitis 2
Improved with steroids without diagnosis 2
Improved spontaneously without diagnosis 2
Malignancy associated 1
Hypoxic encephalopathy 1
Normal pressure hydrocephalus 1
Central pontine myelinolysis 1
Viral encephalitis 1
Encephalopathy / encephalitis - cause unknown 1
Acute confusion with shingles 1
Learning disabilities 1
Total no. of clinical Non Cases 49
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3.5.3 Why was sCJD suspected in Non Cases?
8 of the 73 Non Cases fulfilled the WHO criteria for Probable sCJD based on clinical
features and either a characteristic EEG or positive 14-3-3 result. Seven were 2003/4
referrals and one was referred in 1993/4 prior to the introduction of 14-3-3. Their final
diagnoses and the reasons they were classified as Probable are summarised in table
3.19. A further 20 Non Cases could have been classified as Possible sCJD based on
clinical features alone. Therefore 45 Non Cases fulfilled neither the Probable or
Possible sCJD diagnostic criteria, yet were still referred to the NCJDSU as suspected
sCJD, presumably based on the clinical suspicion of the referring consultant in most
instances.
Table 3.19 Final diagnosis in Non Cases that fulfilled Probable sCJD criteria




Alzheimer's disease Pathological + ve 14-3-3











Clinical + ve 14-3-3
CNS vasculitis Clinical + ve 14-3-3
Central pontine
myelinolysis
Clinical + ve 14-3-3
No diagnosis but not
sCJD**
Clinical + ve 14-3-3
* 1993/4 Non Case
** No clinical diagnosis reached but still alive at 2 years and felt not to be CJD at
final review by National Prion Clinic.
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3.5.4 The clinical phenotype of Non Cases
Figs 3.57, 3.58 and 3.59 summarise the symptoms and signs in Non Cases compared
to sCJD Cases. There were numerous significant differences between Cases and Non
Cases with respect to onset symptoms and symptoms and signs present at any stage
during the illness (table 3.20). As one might predict almost all the clinical features
were recorded more frequently in sCJD Cases rather than Non Cases. The exceptions
were extrapyramidal signs, symptoms suggesting a seizure at any stage and
interestingly sensory symptoms at onset, all of which were noted more frequently in
Non Cases. One needs to interpret this data with caution as there tended to be less
clinical information available on Non Cases, which may have biased the results.
These analyses regarded absence of a symptom / sign and insufficient information as a
single category, but even if the analyses were recalculated using only definite
presence or absence of a clinical feature then the significant results were not markedly
different.
Fig 3.57





Clinical symptoms at any stage in Non Cases compared to sCJD
Cases
Fig 3.59
Clinical signs at any stage in Non Cases compared to sCJD Cases
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Table 3.20 Statistically significant differences in clinical features between Cases and
Non Cases
Clinical feature Significance (x2)
Symptoms at onset Visual disturbance p< 0.001
Sleep disturbance p = 0.009
Sensory symptoms* p = 0.01
Symptoms at any stage Unsteadiness p< 0.001
Visual disturbance p< 0.001
Sleep disturbance p< 0.001
Hallucinations p< 0.001
Speech disturbance p< 0.001
Dizziness p = 0.002
Weight loss p = 0.04
Seizure* p = 0.005
Signs at any stage Cerebellar p< 0.001
Myoclonus p< 0.001
Cortical blindness p< 0.001
Akinetic mutism p< 0.001
Oculomotor p< 0.001
Primitive reflexes p< 0.001
Pyramidal p = 0.001
Movement disorder p = 0.003
Parkinsonism * p = 0.01
* more common in Non Cases than Cases
3.5.5 Diagnosis in Possible sCJD / 'Unclear diagnosis' classifications
Amongst 1993/4 referrals there were 18 individuals finally classified as Possible sCJD
and in 2003/4 there were 7 Possible sCJD referrals. In 1993/4 they were of a similar
onset age to the sCJD Cases (mean 65 years) whereas in 2003/4 they were a little
older (mean 73 years). Median disease duration was similar to Definite and Probable
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sCJD Cases (4.5 months in 1993/4 and 7.5 months in 2003/4). The majority were
referred whilst alive (12 in 1993/4, 5 in 2003/4) and a neurologist reviewed all but one
patient. The NCJDSU visited the patient and / or family in 10 of the 18 1993/4
patients and 5 of the 7 2003/4 referrals. None of the 1993/4 Possibles had the
characteristic MRI changes associated with sCJD, although only 5 had an MR!
performed and none of these were reviewed at the NCJDSU. In contrast in 2003/4
Possibles 3 underwent MRI scanning and all 3 had basal ganglia hyperintensity (2
confirmed by NCJDSU, 1 by report). Obviously no individual classified as Possible
sCJD had either a brain biopsy or post mortem to our knowledge. PRNP type was
known in only 10 of the 25 Possibles and of these 4 were methionine homozygous, 2
valine homozygous and 4 were heterozygotes. Sporadic CJD was considered the most
likely diagnosis for all the individuals ultimately classified as Possible sCJD, but there
are a number ofprovisos to this statement that are addressed in the discussion (section
4.6).
In the 'Unclear diagnosis' group there was a range of 'best guess' diagnoses but in a
substantial minority it was not possible to provide any diagnosis (27%). One third (11
/ 33) were felt to represent sCJD cases that simply failed to meet the diagnostic
criteria. In a further five (15 %) sCJD remained a distinct possibility. The remaining
referrals (52%) were suspected not to have sCJD and the provisional diagnoses
included Alzheimer's disease (1), dementia with Lewy bodies (3), cerebrovascular
disease (4) and paraneoplastic syndromes (2). However, the clinical picture was not
sufficient to confidently exclude sCJD and hence they remain classified in the 4.1s
'Unclear diagnosis' category rather than 4.2 'Clinically not sCJD' category.
Investigations were of some diagnostic value in this Unclear diagnosis group who
failed to fulfil sCJD criteria clinically. Twenty five 4.1s patients were referred in
2003/4 and of these ten had a positive 14-3-3 result, three had a typical EEG and five
had an MRI showing basal ganglia hyperintensity (confirmed by NCJDSU in 4/5
instances). All these Unclear diagnosis patients with a typical EEG and / or positive
MRI had a 'best guess' diagnosis of sCJD. Seven of the 4.1s patients with a positive
14-3-3 were ultimately thought to have sCJD, with the remaining three having 'best
guess' diagnoses of Alzheimer's disease, dementia with Lewy bodies and no diagnosis
but unlikely sCJD.
None of the eight Unclear diagnosis patients referred in 1993/4 had supportive EEG
or MRI results (and 14-3-3 was not available at this time).
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Summary of differential diagnosis of sCJD results
• The differential diagnosis of sCJD is wide and includes isolated cases of
numerous neurological conditions.
• Alzheimer's disease was the commonest pathologically confirmed alternative to
sCJD, followed by dementia with Lewy bodies / Parkinson's disease with
dementia.
• Alzheimer's disease was the commonest clinically identified alternative to sCJD.
• No diagnosis was made in a significant proportion of patients, sometimes despite
autopsy.
• A minority of non CJD patients fulfilWHO diagnostic criteria for sCJD, usually
on the basis of a positive 14-3-3 result in conjunction with clinical features.
• Sensory symptoms at onset, symptoms suggesting a seizure and signs of
parkinsonism were more common in Non Cases than in sCJD Cases.
3.6 The diagnostic criteria
The current WHO diagnostic criteria date from January 1998 (Rotterdam) when the
previous Rome criteria from 1993 were revised with the addition of CSF 14-3-3
analysis. A positive 14-3-3 result now permits a clinically Possible patient to be
reclassified as Probable (as does a typical EEG). To review the sensitivity, specificity
and predictive value of the criteria they were retrospectively applied to all
pathologically confirmed sCJD cases in 2003/4 and all Non Cases (clinically or
pathologically defined) in the same time period (table 3.21). There was insufficient
data to classify one Non Case which was excluded from the analysis.
The same process was applied with 1993/4 referrals of pathologically proven cases
and clinical and pathological Non Cases in order to validate the previous diagnostic
criteria for comparison (table 3.22). Three cases and two Non Cases were excluded
due to insufficient information.
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Table 3.21 sCJD Cases and Non Cases fulfilling diagnostic criteria for Probable and
Possible sCJD in 2003/4
2003/4 referrals Pathologically confirmed
sCJD
Non Cases
No. meeting probable criteria 55 7
No. meeting possible criteria 12 11
No. not meeting criteria 9 16
Total 76 34
Table 3.22 sCJD Cases and Non Cases fulfilling diagnostic criteria for Probable and
Possible sCJD in 1993/4
1993/4 referrals Pathologically confirmed
sCJD
Non Cases
No. meeting probable criteria 33 1
No. meeting possible criteria 41 9
No. not meeting criteria 5 26
Total 79 36
3.6.1 Sensitivity, specificity and predictive value of diagnostic criteria
Sensitivity, specificity, positive predictive value and negative predictive value were
calculated for Probable classification in 2003/4 using the current Rotterdam criteria
(1998) and similarly for Probable classification in 1993/4 where classification was
based on the Rome criteria (1993). Findings are summarised in table 3.23.
146





criteria (Rome 1993, pre
14-3-3)
Sensitivity 72.4 % 41.8%
Specificity 79.4% 97.2 %
Positive predictive value 88.7 % 97.1 %
Negative predictive value 56.3 % 43.2 %
The inclusion of the 14-3-3 result in the newer criteria has resulted in improved
sensitivity at the expense of lower specificity and lower positive predictive value.
Therefore more sCJD patients will fulfil the criteria for a Probable case but equally a
larger number of non CJD patients are also likely to be classified as Probable. Today
the probability of a suspected case that meets the Probable criteria actually being a
case of sCJD is just under 90%, whereas using the old criteria the probability was
over 97%. The negative predictive value remains relatively low at 56%; consequently
even if a patient is not classified as a Probable there is still a significant chance they
have sCJD.
3.6.2 Effect of includingMRI in the diagnostic criteria
At present MRI findings are not included in the diagnostic classification system for
sCJD (although they are part of the vCJD criteria). However, basal ganglia
hyperintensity is well recognised as a characteristic MRI appearance in sCJD, with
cortical hyperintensity being recognised less frequently, and there has been
considerable debate as to whether MRI results should be incorporated in the same way
as a positive 14-3-3 result was. i.e. A 'positive' MRI permitting a Possible case to
become Probable with 'positive' being defined as caudate / putamen hyperintensity.
Therefore, the current criteria were also reviewed with the addition ofMRI to assess
the impact on diagnosis.
In 2003/4 twenty individuals with pathologically proven sCJD had MRI basal ganglia
hyperintensity confirmed by the NCJDSU. A further seven had basal ganglia
hyperintensity reported locally but scans were unavailable for confirmation. However,
of these twenty seven patients twenty three already fulfilled Probable criteria in life,
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based on their clinical phenotype and positive 14-3-3 protein or typical EEG. The
remaining four patients previously only met Possible criteria so would be upgraded to
Probable by the introduction ofMRI. This would increase the sensitivity only slightly
to 77.6 % (compared to 72.4 % without use of MRI). Three Non Cases referred in
2003/4 had caudate / putamen high signal on MRI (confirmed by NCJDSU in two of
the three) but their final classification would not change because one was already a
Probable and the other two did not have sufficient clinical features. Therefore test
specificity remains unchanged despite addition ofMRI. The effect ofMRI on positive
predictive value is also minor, with an improvement from 87 % to 89 %.
If a 'positive' MRI is more loosely defined including cortical hyperintensity as well as
caudate and putamen changes then this would still have a relatively minor impact. In
2003/4 four pathologically proven sCID cases had cortical hyperintensity alone on
MRI but one already fulfilled Probable criteria and one did not have sufficient clinical
features to be classified as Possible or Probable, so final classification would only be
affected in two cases. No Non Cases had cortical hyperintensity. Therefore specificity
remains unchanged at 79.4 % but sensitivity increases to 80.3 % and positive
predictive value is essentially unchanged at 89.7 %. Table 3.24 summarises the effect
of incorporating MRI results on the current diagnostic criteria.
MRI results do not have a significant impact on 1993/4 referrals as few scans from
this time had either basal ganglia or cortical hyperintensity. This probably reflects the
smaller number of MRIs performed, the minority reviewed in the NCJDSU and the
lack of general awareness of characteristic sCJD appearances on MRI as opposed to
any real change in MRI appearances in sCJD over a decade.
Table 3.24 Sensitivity, specificity and predictive value of sCJD diagnostic criteria












+ / or cortical
hyperintensity
Sensitivity 72.4% 77.6% 80.3%
Specificity 79.4% 79.4% 79.4%
+ve predictive value 88.7% 89.4% 89.7%
-ve predictive value 56.3% 61.4% 64.3%
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3.6.3 Sensitivity, specificity and predictive value of individual clinical features
The clinical features incorporated in the diagnostic criteria were also analysed
individually for pathologically proven cases in 1993/4 and 2003/4 and for Non Cases
for each referral period (table 3.25).
Unsurprisingly dementia was almost universal in both Definite sCJD patients and Non
Cases for both time periods (and no individual was actually documented not to have
dementia, simply that information confirming cognitive problems was lacking in a
minority of referrals). Myoclonus was the second most sensitive clinical sign for
Definite cases, being present in 85 - 90%. Cerebellar and visual problems were next
most common being present in approx. 65% of sCJD patients, followed by pyramidal
signs with a sensitivity of around 55%. Paarkinsonism was rarer being present in less
than a quarter of definite cases. The only feature which showed a significantly
different sensitivity in cases between 1993/4 and 2003/4 was akinetic mutism, being
much less frequently reported in 2003/4 (36% versus 70%).
After dementia, myoclonus was the most prevalent clinical feature in Non Cases but
was less common than in cases. Visual symptoms, cerebellar and pyramidal signs and
akinetic mutism were all less prevalent in Non Cases compared to Definite cases. In
contrast parkinsonism was more common in Non Cases than cases in 1993/4 and
similar in 2003/4.
Table 3.25 Prevalence of individual clinical features in Definite sCJD and Non Cases
Definite Case Definite Case Non Case Non Case
1993/4 2003/4 1993/4 2003/4
Dementia 95% 97% 94% 94%
Myoclonus 85% 88% 50% 60%
Cerebellar signs 62% 68% 18% 49%
Visual problems 61% 66% 8% 14%
Pyramidal signs 56% 52% 34% 37%
Parkinsonism 22% 17% 37% 20%
Akinetic mute 70% 36% 18% 9%
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As the values from 1993/4 and 2003/4 were generally similar the data were combined
to calculate sensitivity, specificity, positive and negative predictive values for each
clinical feature used in the diagnostic criteria. They are summarised in table 3.26.
Table 3.26 Sensitivity, specificity and predictive value of individual clinical features
in sCJD






Dementia 96% 10% 69% 40%
Myoclonus 87% 45% 77% 61%
Cerebellar signs 65% 67% 81% 47%
Visual problems 63% 89% 93% 53%
Pyramidal signs 54% 64% 77% 39%
Parkinsonism 20% 71% 60% 29%
Akinetic Mutism 53% 86% 89% 46%
Dementia was the most sensitive sign for sCJD but had extremely low specificity at
10%, reflecting the fact that almost all referred Definite Cases and Non Cases had
dementia. Therefore it was not a valuable discriminating sign in the context of
suspected sCJD referrals. The most specific clinical feature was visual disturbance
(89%) whereas myoclonus had a low specificity at 45% despite high sensitivity. This
low specificity might be explained by the observation that myoclonus is a well known
and characteristic feature of sCJD and its very presence can trigger CJD to be
considered, sometimes even if the rest of the clinical picture is atypical.
Positive predictive value was highest for visual problems and akinetic mutism at
approx. 90% and was greater than 75% for every feature except dementia and
parkinsonism. Negative predictive values were consistently low implying that the
absence of any one clinical feature does not reliably predict against the diagnosis of
sCJD.
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Summary of results on sCJD diagnostic criteria
• Current sCJD diagnostic criteria have a sensitivity of 72%, specificity of 79% and
positive predictive value of 89%.
• Incorporation of CSF 14-3-3 into the diagnostic criteria has significantly improved
sensitivity at the expense of a reduction in specificity and positive predictive
value.
• Incorporating MRI into the diagnostic criteria would improve sensitivity and
positive predictive value only slightly without any major impact on specificity
(based on available data).
• In the context of the NCJDSU, dementia and myoclonus were highly sensitive but
poorly specific features, whereas visual problems and akinetic mutism were more
useful at discriminating sCJD from non CJD disease.
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3C. Young sCJD patients
3.7 Demographics
Variant CJD tends to affect young adults whereas sCJD is extremely rare in the under
thirties and uncommon under the age of fifty (fig 3.60). Therefore young sCJD
patients are of great interest, particularly comparing cases before and after the onset of
vCJD to see if there has been any change in their clinical phenotype. The number of
young sCJD referrals (definite and probable) annually between 1993 and 2004 is
shown in fig 3.61, where 'young' is defined as onset at or below the age of fifty.
Fig 3.60
Number of Sporadic and Variant CJD cases by 10 year age
group: 1993-2004
□ sCJD H vCJD
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Fig 3.61






































All sCJD cases aged fifty or under at onsets that were referred between 1993 and 2004
were reviewed. They were compared with a group of older sCJD patients, comprising
Probable and Definite cases aged over fifty at onset referred in 1993/4 and 2003/4 (n
= 210). There were 54 young patients, 46 (85%) of whom were ultimately classified
as Definite and 8 (15%) remained Probable. The NCJDSU visited 40 (74%) cases
while they were alive and the relatives were interviewed after death in a further 10
cases (19%). Only 4 patients (7%) had no visit at all.
Sporadic CJD was suspected in life in all but one instance. However, the possibility of
vCJD was raised in many patients and was actually suspected by the visiting
NCJDSU registrar in seven patients. Table 3.27 summarises the classifications made
at the time of NCJDSU visit, or at referral if no visit occurred. The bold type denotes
those where vCJD was considered to be the possible diagnosis. None of the young
cases fulfilled the diagnostic criteria for probable variant CJD at any stage as no one
had either a positive tonsil biopsy or the pulvinar sign on MRI. However, 19 (35%)
met the criteria for Possible variant CJD based on their clinical features and illness
duration greater than 6 months.
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Table 3.27 Classification of young and older onset sCJD at time ofNCDSU visit
Classification at visit No. of young sCJD Cases
(%)
No. of older sCJD Cases
(%)
Definite sCJD 14 (26%) 42 (20%)
Probable sCJD 11 (20%) 89 (42%)
Probable sCJD / Possible
vCJD
1 (2%) 0 (0%)
Possible sCJD 13 (24%) 60 (29%)
Possible sCJD / vCJD 3 (6%) 0 (0%)
Unclear diagnosis ?sCJD 9 (17%) 18 (9%)
Unclear diagnosis ?sCJD
/ ?vCJD
2 (4%) 0 (0%)
Unclear diagnosis ?vCJD 1 (2%) 0 (0%)
Clinically not CJD 0 (0%) 1 (0.5%)
Total 54 210
In the majority of young sporadics the diagnosis was first suspected by a neurologist,
similar to sCJD patients as a whole. Likewise referral was most frequently by
neurology (table 3.28). 'Other' included one case where the diagnosis was first
suspected by neuropsychology and another first suspected by a consultant in learning
disabilities. One referral was made by a nurse.








Death Certificate n/a 1
Other 2 1
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Psychiatry only first suspected sCJD in one individual and did not refer any of the
young cases. However, 44% (24) of the young sCJD patients were seen by
psychiatrists at some point in their illness, most frequently in the early stages prior to
diagnosing CJD because of concerns regarding depression and anxiety.
Mean and median disease durations were significantly longer in the younger patients
using the Mann Whitney test (as duration was not normally distributed) (table 3.29).
Table 3.29 Disease duration in young compared to older onset sCJD
Young sCJD sCJD onset > 50 yrs Significance 1
Mean disease
duration
14.7 months 6.4 months p< 0.001
Median disease 1
duration I
10.5 months 4.0 months p< 0.001
3.8 Clinical features in young sporadic CJD patients
Fig 3.62 shows the clinical presentation of all the young sCJD patients compared to
clinical presentation of the control group of older sCJD patients. The commonest
clinical presentation in both young and older sCJD patients was with rapidly
progressive dementia. The young cohort more frequently had a psychiatric or sensory
onset (5.6% each) but this was still rare and not significantly different to the older
sCJD cases. Presentation with 'other' symptoms not meeting any of the defined
categories was also commoner in the young cohort. This included three patients with
personality change (without clear cognitive impairment, one associated with painful
cramps, two associated with fatigue), two presenting with reduced exercise tolerance
and fatigue, two patients with visual disturbance (insufficient to meet a diagnosis of
Heidenhain presentation) and one each of onset with headache, chorea and fatigue,
progressive left sided weakness and numbness and episodic dysphasia and altered




Clinical presentation in young patients with sCJD compared to
patients >50 years at onset
80
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□ Young sCJD
■ sCJD>50
(RPD = rapidly progressive dementia, SPD = slowly progressive dementia, EP =
extrapyramidal)
Fig 3.63 summarises the clinical features that were present at any stage of illness in
the young sCJD cohort compared to sCJD cases with onset age greater than 50 years.
Generally the two groups were clinically similar with dementia and myoclonus being
almost universally present irrespective of age. Sensory and psychiatric features were
of particular interest as these are more characteristic and common in vCJD than sCJD.
In vCJD sensory symptoms need to be persistent and painful in order to fulfil the
criteria. The only significant difference between the young and older sporadic cohorts
related to sensory symptoms, which were more frequently reported in the young cases
(35% v 11%, p < 0.0001 x2)- These sensory symptoms were persistent and painful*
in 19% (10 cases). Psychiatric features (depression, anxiety, psychosis) were present
in slightly more young sCJD patients than older ones (44% v 33%) but this was not
significant.
*Using the same definitions as vCJD criteria, i.e. frank pain and / or dysaesthesia.
'Persistent' is not clearly defined in the vCJD diagnostic criteria so this study used
sensory symptoms reported on two or more separate occasions, or described as
longstanding, persistent or present over weeks to months
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Fig 3.63
Clinical features present at any stage in young sCJD compared
with sCJD cases aged > 50 yrs at onset
120
* Movt. disorder = movement disorder other than myoclonus
3.9 Investigations in young sporadic CJD patients
The young sCJD patients were investigated in a similar manner to older sCJD cases
but, as might be anticipated, they were more thoroughly investigated. 98% had one or
more EEG (compared to 92% of sCJD cases aged greater than fifty years at onset
from 1993/4 and 2003/4 referrals), 91% had CSF analysis (compared to 81% of older
Cases) and 87% had an MRI (compared to 69% of older Cases). The investigation
results in young sporadic patients compared to older cases are summarised in table
3.30. Statistically significant results are in bold type. EEG was less likely to be typical
in young sporadics compared to the older control group (p < 0.001 i2). CSF 14-3-3
result was more frequently negative in the young sCJD cohort compared to the older
patients (p = 0.005 x2)- 1° young sporadics fewer MRIs demonstrated caudate and
putamen high signal and a slightly higher proportion had cortical hyperintensity than
in the older onset cases but these findings did not reach statistical significance.
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Table 3.30 Comparison of investigation results in sCJD with onset less or greater than
50 years
Investigation Young sCJD Older sCJD control group
EEG Typical 20% (n = 10) Typical 39% (n = 78)
CSF 14-3-3 +ve 70% (n = 21) 14-3-3 +ve 98% (n = 92)
S100 < 0.38 8% (n = 2) S100 < 0.38 5% (n = 4)
0.38 - 1.0 36% (n = 9) 0.38- 1.0 37% (n = 32)
> 1.0 56% (n= 14) > 1.0 58% (n = 50)
wcc < 5 100% (n = 49) wcc < 5x109 98% (n= 173)
5- 10 x10s 2% (n = 4)
protein < 0.5 77% (n = 36) protein < 0.5 63% (n = 92)
(g/L) 0.5 - 1.0 21% (n = 10) (g/L) 0.5-1.0 33% (n = 48)
> 1.0 2%(n= 1) > 1.0 3% (n = 5)
MRI Caudate / putamen hyperintensity Caudate / putamen hyperintensity
22% (n = 10)* 36 % (n = 49 )**
Cortical hyperintensity alone Cortical hyperintensity alone
9% (n = 4) 4% (n = 5)
* 7 confirmed at NCJDSU ** 34 confirmed at NCJDSU
A limitation of evaluating investigation results in Probable and Definite patients
combined is that classification as Probable relies on either a positive EEG or 14-3-3.
However, if the Probable young sCJD patients were excluded the results were not
markedly different. 16% (7) of the Definite cases had a positive EEG and 73% (16)
had a positive 14-3-3.
13% (7 / 54) of the young patients had a brain biopsy compared to 4% (8 / 210) of
older sCJD patients. 11% (6 / 54) of the young sporadics underwent tonsil biopsy and
all were negative. Of these 6 only 2 met the clinical criteria for Possible vCJD. None
of the older sCJD cohort was known to have had a tonsil biopsy. 76% of the young
sporadic cases had an autopsy compared with 55% of the older sCJD cases.
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Codon 129 genotype was determined in 80% of the young sCJD patients. Of those
tested just over half were methionine homozygous and one third were valine
homozygous. This compares with older sCJD patients where 61% of those tested were
methionine homozygous and 23% were valine homozygous, but no results were
available in a higher proportion of the older cohort limiting comparisons (fig 3.64).
The differences in codon 129 distribution in young and older sCJD cases were not
significant, either when codon 129 type was analysed as a whole (p = 0.47 x2) °r
when individual genotypes (MM, MV and VV) were compared (y2 p = 0.82, 0.82 and
0.23 respectively).
PrP type was only available in 13 of the young cases and approximately halfwere PrP
type 1 and halfPrP type 2A (n = 6 and 7 respectively). Kuru plaques were present in 4
young cases, absent in 38 and in 12 either no post mortem was performed or there was
insufficient information to determine if plaques were present.
Fig 3.64
Codon 129 genotypes in young sCJD patients and sCJD patients
greater than 50 yrs at onset
Young sCJD sCJD>50 yrs at onset
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Summary of findings in young onset sCJD
• Sporadic CJD presenting at or below age fifty ('young sporadic') is rare but well
recognised
• Young sporadic patients had a more prolonged disease course than older sCJD
patients
• Clinical features did not significantly differ between young and older sCJD
patients, with the exception of sensory symptoms, which were more frequently
reported in young cases.
• Rapidly progressive dementia was the commonest presentation, irrespective of
age.
• EEG was less often characteristic and CSF 14-3-3 less frequently positive in
young sporadic patients.
• Young sporadic cases were more likely to undergo invasive investigation with
brain and tonsil biopsies.
• Variant CJD was frequently suspected in young onset sporadic CJD patients,
possibly by virtue of their age and disease duration.
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3D. Sporadic CJD in the UK compared with EuroCJD nations
UK data was compared with results from the EuroCJD database for 1993 to 2004.
French data was evaluated separately as France has had significantly more cases of
vCJD than any country other than the UK, suggesting a higher level of exposure to
BSE than the rest of mainland Europe. 'Other countries' includes Austria, Australia,
Canada, Germany, Italy, Netherlands, Slovakia, Spain and Switzerland for the
purposes of this analysis.
Mean age of onset of sCJD was similar in UK, France and 'other' countries (fig 3.65).
Mean onset age was 65.9 years in the UK and 'other', and slightly (but not
significantly) higher in France at 67.2 years. Similarly age at death was essentially the
same in UK, France and 'other' sCJD cases (mean 66.6, 68.2 and 66.8 years in UK,
France and 'other' respectively. Fig 3.66). Median disease duration remained stable at
4 to 6 months, irrespective of country of origin (fig 3.67).
Fig 3.65
Mean age at onset of Definite and Probable sCJD
shown by year of death 1993-2004
Year of Death
—♦—UK -•-France Other Countries
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Fig 3.67
Median duration of illness of Definite and Probable sCJD
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Codon 129 distribution was compared in UK, France and 'other' sCJD populations.
Overall France had a slightly higher proportion of cases where genotyping had been
performed (76%) compared to the UK (66%) or other EuroCJD countries (63%).
There were no significant differences between the three geographical areas when the
period 1993 to 2004 was assessed as a whole (figs 3.68 and 3.69). Considering sCJD
cases where the PRNP genotype was known, the majority were methionine
homozygous (61 - 67%), with the remaining 33 - 39% being divided fairly equally
between methionine valine heterozygotes and valine homozygotes, irrespective of
country of origin (fig 3.68).
When codon 129 distribution was examined by individual year the results were
slightly different. The majority of cases were still methionine homozygous (MM), but
in the UK and France there was a trend towards a smaller proportion of MM
individuals with time (figs 3.70 and 3.71). Using logistic regression this was
statistically significant (p = 0.004 for UK, p = 0.001 for France). However, the pattern
of declining MM frequency was different in the two countries. In France the
percentage of methionine homozygotes was stable between 1993 and 1998 and then
dropped to a relatively stable, lower level between 1999 and 2004. In contrast in the
UK there was a more general decrease in MM frequency which was most marked in
2003 and 2004. No significant decline in the proportion of methionine homozygous
sCJD was observed in the other EuroCJD nations (fig 3.72).
When the same data was examined as actual numbers rather than percentages
additional information becomes available (figs 3.73, 3.74 and 3.75). In France the
number of Cases undergoing genotyping increased steadily year on year with the
exception of 2004, but the actual number of MM patients was relatively static each
year whereas numbers ofMV and VV Cases increased. In contrast, in other EuroCJD
countries the absolute number genotyped gradually increased with time up until 2003,
but the numbers of MM, MV and VV all increased resulting in the percentages
remaining fairly constant. In the UK the figures were more variable between years
with less distinct patterns. However, overall they resemble the French findings, with a
trend towards more Cases being genotyped, more MV andW patients and relatively
stable numbers ofMM sCJD Cases with time.
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Fig 3.68
Codon 129 distribution in sCJD Cases over
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Fig 3.69
Codon 129 distribution over the period 1993-2004: all sCJD cases
MM MV W Result Not
Available
■ UK £1 France 0 Other Countries




Codon 129 distribution in sCJD cases in UK (where codon
129 result is available1) over the period 1993-2004
Year of Death
□ MM E MV □ VV
'codon 129 result is available for 76% of the French sporadic cases.
Fig 3.71
Codon 129 distribution in sCJD cases in France (where codon
129 result is available1) over the period 1993-2004
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Yearof Death
□ MM 0 MV □ VV
'codon 129 result is available for 76% of the French sporadic cases.
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Fig 3.72
Codon 129 distribution in sCJD Cases in'other countries'(where
























1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Yearof Death
□ MM HMV □W
'codon 129 is available for 63% of sCJD cases.
2Other countries = Australia, Austria, Canada, Germany, Italy, Netherlands, Slovakia, Spain,
Switzerland
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Codon 129 distribution in other EuroCJD countries by year and
number of sCJD Cases
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Yr
PrP isotype was compared between the UK, France and 'other countries' between
1993 and 2004. However, conclusions are limited by the fact that PrP type was known
in less than a third of sCJD cases in each geographical data set. Generally PrP type 1
predominated, particularly in 'other countries', with a smaller proportion being PrP
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type 2A and a minority having a mixture of type 1 and 2A (figs 3.76, 3.77 and
No cases were identified as having PrP type 2B, which is associated with vCJD.




PrP isotype in sCJD Cases in the UK1 by year of death
n-9 n-9 n-9 n-13 n-15 n-22 n-24 n-2I n-18 n-24 n-31 n-16
Year of Death
□ Type 1 ■ Type 2A B Type 1/2
*PrP isotype is available for 32% of the UK sporadic cases
Fig 3.77
PrP isotype in sCJD Cases in France1 by year of death
Year ofDeath
□ Type 1 ■ Type 2A 0 Type 1/2
♦PrP isotype is available for 29% of the French sporadic cases
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Fig 3.78
PrP isotype in sCJD Cases in 'other countries'1 by year of death
n«=12 n-18 n-18 n-40 n-61 n-62 n-79 n-70 n-96 n-114 n-98 n-94
Year ofDeath
□ Type 1 1 Type 2A E3 Type 1/2
*PrP isotype is available for 25% of the sporadic cases in the other countries
(Australia, Austria, Canada, Germany, Italy, Netherlands, Slovakia, Spain, Switzerland
Full Parchi subtype was only available for small percentage of sCJD cases (32% from
UK, n = 209; 24% from France, n = 234; 21% from 'other', n = 661), and hence the
absolute numbers of each subtype were relatively small. The UK Parchi type
distribution was not significantly different from either France or 'other countries' (y2
p = 0.2). In each data set MM1 was most common, followed by W2 and MV2, with
the remainder of the subtypes generally comprising 5% or fewer of the cases (fig
3.79). A higher proportion of French patients were MM 1/2 than elsewhere, probably
reflecting the slightly higher incidence ofmixed PrP isotypes in France.
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Fig 3.79
Sporadic CJD by Parchi subtype:
1993-2004
n
J fTTL, f fTl, I f=WL^
MM 1 MM2 MV1 MV2 VV1 VV2 MM1/2 MV1/2 VV1/2
Parchisubtype
□ UK S3 France ffl Other Countries*
*Other countries = Australia, Austria, Canada, Germany, Italy, Netherlands, Slovakia.
Spain, Switzerland
Summary of comparison between UK, France and 'other' EuroCJD data
between 1993 and 2004
• Overall the sCJD data obtained from the UK, France and 'other' EuroCJD
nations were similar.
• There were no significant differences in age of onset, disease duration, PrP
type or Parchi subtype distribution between the three geographical areas.
• In the UK and France the proportion of codon 129 methionine homozygotes
decreased with time. This was not seen in 'other' EuroCJD countries.
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Chapter 4: Discussion and Conclusions
A. Discussion
4.1 The study population
The principal study group comprised patients referred to the NCJDSU in 1993, 1994,
2003 and 2004. The latter two years were chosen because data collection began in
2005 and these were the most recent completed years. 1993 and 1994 were selected to
represent suspect sCJD referrals prior to identification of vCJD, plus they provided a
study period spanning a decade of CJD surveillance. The UK population was
probably exposed to BSE from as early as 1980 (224) but it was not possible to use
referrals from this time as UK - wide prospective surveillance was only commenced
in 1990. Prior to 1990 surveillance was either retrospective or confined to England
and Wales so meaningful comparisons with current data would be limited. The
earliest years of UK - wide prospective surveillance were not chosen simply because
it takes time for a surveillance programme to become established and by selecting the
very early years one might miss many suspected cases due to doctors' lack of
awareness of the NCJDSU. Two year time periods pre and post vCJD were used
rather than a single year in order to increase the amount of available data.
A more restricted data set was collected on all sCJD Cases dying between 1993 and
2004 inclusively, in order to assess trends over this period. Ideally a full data set
would have been collected for each year but this was not possible due to time
constraints. The restricted UK data from 1993 to 2004 was compared with
corresponding figures from the EUROCJD database for the same time period. The
aim was to identify any trends confined to the UK, or possibly the UK and France,
that might be attributable to BSE exposure. EUROCJD Cases are collated by date of
death rather than referral date, so date of death was also used for UK Cases between
1993 and 2004 inclusively in order to facilitate direct comparison of data. However,
date of referral was used for the principal study group (1993/4 and 2003/4) because
individuals that ultimately were felt not to have sCJD (Non Cases) were included and
might have otherwise been missed because they recovered or had extremely
prolonged illnesses. Similarly a key aim of the study was to identify changes in sCJD
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characteristics with time, particularly those that might relate to BSE, so it was
sensible to use date of referral rather than death in case disease duration has become
more prolonged with time akin to vCJD.
Data collection based on referrals to the NCJDSU may potentially bias towards
patients suspected and referred by neurologists as opposed to other clinicians, because
only neurologists receive letters reminding them of the existence of the unit.
Therefore it is possible that cases not referred to neurology are being missed,
potentially including older individuals who may be more likely to see geriatricians,
and individuals with a psychiatric onset who are managed by psychiatrists. However,
it is unlikely that significant numbers are being overlooked. A systematic study
reviewed autopsies on 308 patients with dementia in a geriatric hospital and 137
elderly patients with dementia in a psychiatric institution and only one case of sCJD
was confirmed (225). In another study one physician visited all Parisian nursing
homes searching for previously unidentified cases of sCJD and found none (226).The
characteristic rapidity of the disease course in sCJD and the evolving neurological
picture means that most affected individuals will be brought to the attention of a
neurologist at some stage, even if the onset is not clearly neurological. This
assumption is supported by the fact that a neurologist saw over 90% of all suspect
sCJD referrals in this study. A review of French CJD patients between 1968 and 1977
found that all were reviewed by a neurologist, although admittedly this might be a
self-fulfilling prophecy as other cases might be missed (227).
There are also a number of safety nets to reduce the chances of missed referrals. Any
patient who has a death certificate diagnosis of 'CJD' or 'dementia in CJD' (ICD 10
codes A81.0 and F02.1) will be automatically notified to the NCJDSU, the notes
obtained and the case classified according to the diagnostic criteria. Even if the
diagnosis is not suspected in life UK neuropathologists are aware of the need to notify
cases they identify at autopsy. Neuropathology remains an important component of
cases ascertainment, particularly in atypical presentations. Obviously if the diagnosis
of prion disease was never suspected in life and no post mortem was performed then
such individuals would not be identified in this study, but this is unavoidable and
likely to be a rare scenario. (The overall post mortem rate in CJD suspects in the UK
is approximately 70%).
Use of the NCJDSU database implies that the only Non Cases included are those
where there was a reasonably high suspicion of sCJD. There are likely to be many
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more patients where sCJD was briefly considered but excluded on clinical or
investigation grounds prior to a referral being made. However, this in itself is not a
significant flaw of the study as the Non Cases clinicians are particularly interested in
are those where there is real diagnostic confusion rather than more straightforward
cases where an alternative diagnosis is readily apparent.
For the purposes of this study Cases were defined as individuals fulfilling WHO
criteria for Definite or Probable sCJD (see appendix for definitions). Cases were then
scrutinised both as one group and separately as Definites and Probables. This was to
minimise potential bias from concentrating on either Definite or Probable patients in
isolation. For example, Definite sCJD patients may differ from sCJD as a whole
because younger individuals and those with less typical disease courses may be more
likely to undergo autopsy and hence be classified as Definite. Conversely relying on
Probable patients may bias towards those with characteristic clinical features. There is
the additional problem that the WHO definitions of Probable and Possible sCJD are
based on various clinical features and investigation results. Therefore it is difficult to
study frequency of these same features in these classifications, as it becomes a self-
fulfilling prophecy. In order to assess validity of the diagnostic criteria Definite sCJD
patients must be used as neuropathology remains the gold standard in diagnostic
terms. However, it is not sensible to rely on Definite, pathologically proven sCJD
cases when a new BSE phenotype is being sought, because if this phenotype is
associated with novel pathology then this might exclude the very individuals that the
study is aiming to identify.
As a result of these potential problems this study evaluates Definite, Probable,
Possible, Unclear and Non Cases either separately or in combination depending on the
question being addressed.
Genetic analysis to exclude familial prion disease was only performed in around half
(52%) of all suspect sCJD referrals in this study and in 65% of Cases. Therefore it is
possible that a small number of genetic CJD patients have been included accidentally.
Pathological appearances and family history can also provide clues to genetic CJD but
neither is completely reliable. One case had pathological appearances suggesting
familial rather than sporadic CJD but underwent formal genetic analysis of the prion
protein gene on two occasions with no mutations identified. A further case was
initially felt to have a pattern of PrP staining reminiscent of an insertional mutation
but on review was deemed pathologically more consistent with atypical sCJD. No
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genetic analysis was performed but the patient had no family history of CJD or other
dementia and died at the age of 88.
At the time of referral no individuals included in this study were known to have a
family history of CJD but at a later date one individual was identified as having an
estranged sister who had died of pathologically confirmed fCJD with the E200K
mutation. Unfortunately no genetic material was available on the study case so she
remains classified as sCJD, but in all likelihood she too was a familial E200K case.
Interestingly her brain pathology was entirely consistent with sCJD as is often the
case with E200K mutations, illustrating the point that pathological appearances do not
reliably discriminate between sporadic and genetic prion disease. Thus it is probable
that one familial CJD patient has been included in this study but it is unlikely that
many other genetic cases have been included. Therefore this is not likely to
significantly impact on the conclusions.
4.2 Limitations related to data collection and documentation
There are numerous potential pitfalls inherent in any surveillance system that relies on
collecting data provided by a third party, in this case usually the next of kin. Whilst
various strategies were applied to try and minimise these problems they were not
altogether avoidable.
4.2.1 Quality of data
First and foremost the quality of the data varies widely between individual cases. This
is influenced by a number of factors including the degree of closeness of the next of
kin and their ability to recall and recount a clear history in an often emotionally
charged interview. Usually the NCJDSU registrar interviewed a partner or adult
offspring who was frequently, but not invariably, in close contact with the patient.
Occasionally the relative was more distant and could provide a less detailed history,
particularly if they lived many miles away and relied on telephone calls to keep in
touch. Given the nature of sCJD it was rarely possible to elicit any reliable story from
the patient directly. Obviously less information was available on the minority of
Cases that were never visited but this should not alter the conclusions when
comparing Cases in 1993/4 and 2003/4 as similar numbers were not visited (6.1%, n =
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6, and 5.4%, n = 7 respectively). It is more relevant when comparing Cases and Non
Cases as significantly fewer Non Cases were visited by the NCJDSU registrar (94%
of Cases visited versus only 34% ofNon Cases).
To try and reduce these problems hospital notes were used as a source of back up
information but again the information available was of variable quality. This was
influenced by the thoroughness of the doctor admitting the patient, the degree of
speech and cognitive problems at admission and the standard of documentation
generally. It was not possible to eliminate these variables. Some patients were initially
admitted to a district general hospital before being transferred to a tertiary centre, and
occasionally the initial set of hospital notes were incomplete or unavailable, despite
being requested by letter.
4.2.2 Modifications to the questionnaire
The NCJDSU registrar uses a questionnaire during the interview to provide a partially
standardised approach. However, the bulk of the information still comes from a
general, unstructured conversation with the family and is recorded as free text.
Specific questions are posed in the questionnaire and should therefore be addressed in
all cases. These questions have been modified with time, due to the questionnaire
being altered in 1997 to a more detailed format. For instance the original
questionnaire set up in 1990 asked specifically about weight loss, depression, odd
behaviour and sleep disturbance. The revised questionnaire introduced in 1997 omits
weight loss and sleep disturbance but includes extra questions on symptoms including
visual disturbance, speech disturbance, hallucinations and dizziness. The 1997
questionnaire also has a section on physical signs where the registrar documents
presence / absence / unsure for each sign. In contrast the earlier questionnaire was less
structured with a free space for examination on admission and progression of signs
(see appendix for copies of questionnaires). Therefore, it is likely that certain clinical
features are documented with greater or lesser accuracy at different times, reflecting
changes in the interview process rather than any real differences in the underlying
disease. However, this is unlikely to be a problem with the most characteristic clinical
features of sCJD (such as dementia and myoclonus) as these will be inquired about
and documented in the vast majority of cases, irrespective of the questionnaire.
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4.2.3 Inter - registrar variability in data collection
Different NCJDSU registrars have slightly different approaches to the interview. The
sCJD referrals used in this study have relied on the work of ten doctors, but
predominantly five registrars who covered 1993/4 and 2003/4. There is some 'on the
job' training such that a new registrar accompanies an established registrar on a visit
to watch an interview and to standardise techniques and data collection where
possible. However, it is inevitable that each registrar will work slightly differently and
interpret information in subtly different ways. To a degree this is minimised by the
consultant input, which has remained relatively stable since the NCJDSU was
established, with one consultant being present since 1990 (RGW), and the other since
1997 (RK).
4.2.4 Dates
It was frequently difficult to precisely date the onset of various sCJD symptoms and
the illness itself. This was due both to the lack of definite history from relatives plus
the inherent difficulty in dating onset of an illness beginning with subtle features such
as altered personality and mild forgetfulness. In most instances I accepted the decision
of the registrar who visited the patient, only altering their estimates of dates if further
information was available at a later time which clearly contradicted their opinion. An
approximate system was used to record dates (to the nearest 1st, 15th or 30th of the
month) as anything more precise was judged unreliable.
4.2.5 Clinical features
Whilst some symptoms and signs were relatively clear cut (e.g. headache, myoclonus)
others were more subjective. Precise definitions were employed to minimise this
subjectivity; for instance to be classified as having pyramidal signs a patient required
at least two of increased tone (and / or clonus), hyperreflexia, extensor plantar (s) and
pyramidal pattern weakness. However, some signs were less easy to define and
required the examining doctor to make a judgement (e.g. akinetic mutism, cortical
blindness). It is possible that different registrars have been more or less stringent
when assessing these features, thus introducing potential bias.
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4.2.6 Absence of a clinical feature versus insufficient information
An additional problem is that lack of documentation of a sign does not necessarily
equate to absence of that sign. It may be that the registrar omitted to record a positive
finding, particularly with 1993/4 referrals when the questionnaire was less structured.
Thus more signs may have been erroneously analysed as being absent in 1993/4.
Similarly suspect sCJD patients that were never visited by the NCJDSU may be more
likely to have negative results, and this is particularly relevant because 66% of Non
Cases were not visited, compared to only 6% of Cases.
Timing of the visit also influences this. For instance patients seen only in the earlier
stages of disease are less likely to demonstrate late signs such as akinetic mutism. The
amount of extra information obtained after the visit is usually minimal, especially if a
diagnosis has been made. Conversely suspected sCJD cases seen in the late stages
may not demonstrate certain signs due to the limitations of the examination; e.g.
cerebellar signs. It is plausible that patients with a more rapidly progressive disease
course and those that are referred late are therefore getting a skewed assessment.
Ideally the hospital notes provide extra information about signs in the earlier stages of
the illness but this is not infallible.
For the purposes of analysis absence of a sign, insufficient information and 'unsure'
were all treated as a single category. However, one has to remain aware of the
limitations of this strategy.
4.3 Overview of 1993 to 2004 and demographic data in 1993/4 and 2003/4
4.3.1 Incidence
The annual number of referrals to the NCJDSU has gradually increased between 1993
and 2004, with the exception of a dip in 2004. This pattern might reflect a true
increase in disease incidence or simply improved case ascertainment. The latter
explanation appears more likely for a number of reasons.
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Fig 4.1













Note: The horizontal lines indicate the number of deaths approximately equivalent to crude
mortality rates of 0.5 and 1 per million per year.
With time the NCJDSU has become established and clinicians are more aware of its
existence and the need to refer suspected CJD cases. The number of reported deaths
from sCJD has actually been increasing in the UK since surveillance began in 1970
(fig 4.1). Other countries' CJD surveillance programs have experienced similar
increases in referral rates over the early years as they become established (69, 228,
229). The emergence of vCJD in 1996 may have also contributed to the apparent rise
in incidence in the UK as it prompted a letter to all clinical neurologists, further
increasing the profile of the surveillance unit. In addition vCJD was hitting the
headlines in the media, increasing public awareness of prion disease in general. It is
worth noting that the biggest increase in referrals occurred in 1997, just after vCJD
was identified.
Investigations and diagnostic tests for sCJD have also improved with time, in
particular the introduction of CSF 14-3-3 testing and increased sensitivity and
availability of MRI. All these factors help explain an increase in sCJD case
ascertainment with time.
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Alternatively the increase in the figures may represent a real rise in disease incidence,
either of sCJD itself or a new, possibly BSE - related illness, that is being
misdiagnosed as sCJD. However, there is little evidence to support this. Other western
countries with surveillance systems have observed similar increases in sCJD case load
despite a low frequency of BSE in the cattle population (228, 230). This would be
against a BSE associated condition, where one might predict a more isolated increase
in the UK. Underlying this is the problem that the aetiology of sCJD remains obscure.
Therefore it is possible that sCJD incidence is truly increasing throughout Europe due
to some, as yet, unidentified factors. One analysis has shown that the time dependant
increase in sCJD in the UK since 1970 would fit equally well with two statistical
models; either improved case reporting with time or an increase in an (unidentified)
cohort factor over time (131).
When the 1993/4 and 2003/4 figures are analysed in more depth it is apparent that
much of the increase is due to a rise in Probable classifications (from 13 to 53). This
is likely to partly reflect the introduction of 14-3-3 testing in December 1996,
resulting in Possible classifications being reclassified as Probables. However, this
does not fully explain the increase as the number of Possibles has only dropped
slightly (from 18 to 7).
The number ofNon Cases has not changed significantly with time.
The slight dip in figures for 2004 is harder to explain but there are a number of
possible interpretations. It may just be a one-off blip of no particular significance, but
the NCJDSU figures for 2005 also show slightly fewer referrals than in 2002 and
2003, as do those from 2006 although these may still be incomplete. Alternatively it
could be the start of a downward trend in referral figures. This might be due to
worsening case ascertainment, possibly reflecting waning public and medical interest
in CJD now the threat of a 'vCJD epidemic' seems remote, or a real reduction in sCJD
numbers for some unknown reason. Certainly the practice of the NCJDSU has not
significantly changed to explain any reduction. It is also unlikely to be an artefact of
the study design because figures are based on annual referrals and deaths and data
were collected up until the end of July 2005. For cases not referred in life date of
death was used as referral date. By July 2005 all death certificate referrals coded for
CJD in 2004 should have been received and all autopsy results from deaths until the
end of 2004 would be expected to be available. However, reviewing the NCJDSU
database up until May 2006 has revealed two further patients referred by death
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certificate in 2003/4 as suspect sCJD. They were not included in the study database as
the certificates were delayed and there was no information on these individuals at the
time data collection stopped. Subsequently one has been provisionally classified as
Possible sCJD and the other as a Non Case, but the information remains limited and
neither family was visited. No new sCJD Cases referred in 2003/4 have been
identified. As of January 2006 two individuals in the study database have been
reclassified due to extra information becoming available. One patient was reclassified
as Unclear diagnosis from Probable sCJD (based on clinical features and a positive
14-3-3 result), because disease duration exceeded two years. Another was changed
from Unclear diagnosis to Probable because a characteristic EEG developed. Neither
of these alterations significantly change the findings of this study.
Other countries with sCJD surveillance systems have occasionally reported years with
reduced numbers of cases but there has not been a sustained decrease in any country
(69).
The general overview data from 1993 to 2004 inclusively were identified by date of
death whereas the more detailed data from 1993/4 and 2003/4 were collated by date of
referral and the rationale for this was explained in section 4.1 of the discussion.
However, it is worth noting that these differences in data collection did not
significantly impact on the final results, trends and conclusions, as demonstrated in
figs 3.1 and 3.2 of the results section looking at disease incidence by year of referral
and by year of death. Given the short mean duration of sCJD of well under one year
one would not anticipate any major differences with these minor alterations in data
collection.
4.3.2 Gender
A slight excess of referrals and sCJD Cases were female, but this did not change
significantly between 1993/4 and 2003/4. The gender differences were small and not
significant. Similar minor differences have been reported in other studies e.g.
Australia CJD surveillance 1970 - 2003 (52.4% female, 47.6% male), England and
Wales 1970-79 (230, 74). There is no known scientific explanation as to why more
females than males might contract sCJD and generally it is not considered to be a
condition influenced by gender. In the USA the mortality rate from sCJD was slightly
increased in women but this gender difference disappeared once death rates were
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corrected for age, implying the increased female incidence related to their increased
longevity (232). Female sex has been reported as a good prognostic factor and
predictor of relatively prolonged survival in sCJD (72) but this should not
significantly influence the study results as they refer to incidence rather than
prevalence.
4.3.3 Age at onset and death and disease duration
The mean age at onset of sCJD has remained stable in the UK at 65 - 66 years without
any significant change between 1993 and 2004. This finding is similar to the
experience of other countries' surveillance programmes (233, 234, 235). If a novel
BSE related disease was occurring and being misdiagnosed as sCJD one might expect
the average onset age to decrease, as we know that vCJD tends to affect younger
individuals with a mean age of 28 years (150, 158). However, there is no evidence for
this. Similarly vCJD is associated with a longer median disease duration of 14 months
(158, 161) but there is no suggestion that median disease duration is increasing in
sCJD with time. It has remained constant at 4 to 5 months. Mean age at death from
sCJD is also steady at approximately 66 years, reflecting the unchanging age at onset
and illness duration.
There are differences between 1993/4 and 2003/4 referrals with respect to disease
duration in Non Cases. In 1993/4 suspect sCJD referrals that were ultimately
classified as Non Cases had significantly longer illness duration than equivalent Non
Cases in 2003/4. The most likely explanation for this is improved awareness of the
typical sCJD phenotype and therefore more informed referrals in 2003/4. If the
disease duration for Non Cases is compared to Cases (for 1993/4 and 2003/4
combined) then overall Non Cases had a longer illness. This probably relates to the
underlying diagnoses in the Non Cases. The commonest diagnoses in Non Cases are
Alzheimer's disease and Dementia with Lewy Bodies and both of these are typically
slower illnesses than sCJD.
Interestingly mean onset age was identical for Cases and Non Cases in 1993/4 and
2003/4 being 66 years in all categories. Possible referrals in 2003/4 and 'Unclear
diagnosis' referrals in 1993/4 appeared to be slightly older with a mean of 72 years.
However, these results were not statistically significant and were not sustained (in that
Possible referrals in 1993/4 and 'Unclear diagnosis' patients in 2003/4 were not
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associated with older age at onset). They are likely to simply reflect the small number
of referrals in these categories with inevitable susceptibility to skewing of the mean
by one or two outliers.
4.3.4 Post mortem rates
The annual post mortem rate for sCJD Cases was steady at approximately 85% until
2001 and since then there has been a decline to a low of 61% in 2003. However, this
downward trend is not currently statistically significant. It reflects a more general
trend of decreasing autopsy rates for all causes of death in the UK which has been
variably attributed to declining clinical interest in autopsies, greater confidence in the
diagnosis in life due to improved investigations, and recent organ retention 'scandals'
(236). However, the sCJD post mortem rate is still significantly higher than most
terminal illnesses including cancer and most types of dementia and this raises a
potential problem. Whilst the majority of suspect sCJD cases still undergo autopsy
this is not the case for many other neurodegenerative diseases. Conceivably sCJD
might be missed if it was masquerading as a typical presentation of Alzheimer's
disease for example. This is unlikely but cannot be fully excluded.
Diminishing post mortem rates in sCJD are not unique to the UK. One study based in
New York state found that neurologists rarely or never used autopsy to confirm
suspected CJD, due to a combination of family reluctance, infection control concerns
and inadequate facilities (237).
The UK sCJD post mortem rate peaked at 95% in 1997 and it is possible this relates
to the emergence of vCJD because the need for a definitive diagnosis was heightened
at this time.
There are concerns that a CJD surveillance system concerned with identifying cases
of vCJD may bias towards the identification of atypical presentations of sCJD,
particularly young onset cases with prolonged illness courses. We know that such
individuals are less likely to have the PRNP MM genotype. Interestingly this study
did not detect any significant differences in the post mortem rate for the three
different genotypes (results section 3.4.5). Similarly when UK data for sCJD autopsy
rates by genotype are reviewed for all years between 1993 and 2006 there is no









The majority of sCJD Cases referred to the UK NCJDSU between 1993 and 2004
were referred in life, predominantly by neurologists. Overall the proportion referred
after death has diminished with time and this is largely attributable to a decrease in
neuropathology referrals. Only a small number of Definite or Probable sCJD patients
were referred by death certificate in any one year between 1993 and 2004 (fig 4.3).




Number of sCJD Cases referred annually by death certificate: 1993-
2004
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
If all suspected sCJD patients in 1993/4 and 2003/4 are compared the percentage
referred by neuropathology and death certificate has fallen, with a corresponding
increase in the proportion of neurology and physician referrals. This can be partially
explained by the general decline in autopsy rates as discussed above. Alternatively it
may reflect increasing clinician awareness of either the sCJD phenotype or the
existence of the surveillance unit, such that more diagnoses are being suspected and
referred promptly in life. One concern was that death certificate referrals from 2003/4
were artificially low due to the timing of data collection, and that death certificate
cases were being missed. However, this is unlikely to be the case as discussed in
section 4.3.1.
The proportion of psychiatry referrals amongst Cases has not increased with time,
despite increased awareness of CJD amongst the psychiatric community because of
the prominent psychiatric features of vCJD. This is reassuring as it suggests that large
numbers of sCJD patients are not presenting with psychiatric symptoms - obviously a
potential concern if one is postulating that a novel BSE phenotype is being
misdiagnosed as sCJD.
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When referral sources of Cases and Non Cases were compared there were two main
findings. Significantly more Non Cases than Cases were being referred by psychiatry.
This might be because Non Cases have a more psychiatric presentation than Cases.
Against this, when clinical phenotypes of Cases and Non Cases were compared the
latter did not have more psychiatric symptoms (see results section 3.3.3). It could
reflect the fact that old age psychiatrists follow up more elderly patients with
dementia than neurologists and other physicians, and hence are exposed to more
atypical cases of Alzheimer's disease and Lewy body dementia (the most frequent
final diagnoses in Non Cases (69). Alternatively psychiatrists as a group might be less
accurate at diagnosing sCJD than neurologists.
Disproportionately more Non Cases than Cases were referred by death certificate.
This is probably due to the well recognised inaccuracy of death certificate diagnoses,
that can often be attributed to the fact the forms are left to busy, inexperienced junior
doctors who may have only just met the patient before they died (238). Also referrals
made in life are inevitably more critically evaluated by the CJD registrar who takes
the phone call, and if they feel the history is incompatible with prion disease they
might simply offer advice rather than including them as a suspect case. Such
safeguards are obviously not possible with death certificate referrals, which are
simply sent to the NCJDSU at a later date.
4.3.6 Suspecting the diagnosis of sCJD
As might be anticipated the people first suspecting the diagnosis of sCJD are similar
to those making the referral. A slightly higher proportion of Cases were suspected by
neurology than were referred, implying that sometimes a neurologist makes the
diagnosis but fails to alert the surveillance unit. Possible explanations include the
neurologist deferring this task to other clinicians, being unsure about the diagnosis so
opting to watch and wait, or simply not referring in life because they forget or prefer
not to involve other units. However, against the first theory there is no excess of
physician / geriatrician referral over physician / geriatrician suspected diagnosis.
More Cases were referred by neuropathology than were initially suspected by
pathology, supporting the idea that some of the neurologist - diagnosed sCJD patients
were not being referred in life. However, this discrepancy was less marked in 2003/4
than in 1993/4, consistent with increased awareness of the NCJDSU.
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4.3.7 Time to suspect sCJD and refer
The diagnosis of sCJD was suspected quickly in the majority of sCJD Cases, with a
median of 2.5 - 3 months. This is consistent with the typical aggressive disease
course. However, the range was wide and one notable Case in 2004 was only
suspected after 5 years of illness, although this was very much the exception. Despite
a detailed review of this individual's history and neuropathology no additional
neurological diagnosis was made and she appears to have had a very slowly
progressive form of sCJD with a correspondingly delayed diagnosis. In contrast in
some instances sCJD was diagnosed after only two weeks of symptoms.
The diagnosis was suspected after similar lengths of time for Cases and Non Cases in
2003/4. However, in 1993/4 Non Cases had been unwell for considerably longer than
Cases by the time sCJD was raised as a possibility. This was the only significant
difference between 1993/4 and 2003/4 referrals. One interpretation is that in 1993/4
clinicians were less aware of the typical disease course of sCJD and hence were
referring patients with quite prolonged illnesses, whereas this had improved by
2003/4.
The data for time to referral mirrors that for time to suspect sCJD, with only brief
delays (less than a month) between suspecting sCJD and contacting the NCJDSU in
most instances.
4.4 Clinical phenotype in 1993/4 and 2003/4
Overall the clinical phenotype was remarkably similar in Definite, Probable and
Possible / Unclear sCJD referrals in 2003/4 compared with a decade earlier. The
commonest mode of presentation was rapidly progressive dementia, comprising
around two thirds of Cases. Similarly the commonest single presenting symptom was
confusion / forgetfulness and if the entire illness was reviewed forgetfulness and
dementia were essentially universal. A small number of Definite or Probable Cases
were never documented to be demented but this probably reflects insufficient notes /
documentation as no individual was recorded as definitely not having cognitive
impairment. Unsteadiness and speech disturbance were also extremely common
symptoms and were present at some stage in over 80% of Cases, irrespective of year
of referral. The most common signs apart from dementia were myoclonus and
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cerebellar signs. These findings concur with the body of literature on the
characteristic clinical features of sCJD (74, 227, 239).
Despite the similarities between 1993/4 and 2003/4 referrals some statistically
significant differences were noted. However, many can be explained by changes in
the questionnaire, differing registrar practice or the effect of applying multiple tests of
significance and using p = 0.05, such that one in twenty tests would be expected to be
positive just by chance. The Bonferroni correction factor can be used to take account
ofmultiple statistical tests on a single data set but it was not appropriate to apply it in
this study because different outcomes were being analysed (i.e. different clinical
features), and it is possible that these outcomes were not entirely independent of each
other. E.g. There might be correlation between presence of hallucinations and other
psychiatric symptoms. Even when multiple tests are performed highly significant
results (e.g. p < 0.001) are likely to remain significant despite applying correction
factors. For example in this study akinetic mutism would remain significantly more
common in 1993/4 than 2003/4 whilst any apparent difference in dyspraxia incidence
between 1993/4 and 2003/4 might be eliminated because the p value was only 0.048.
Differences that are present in all three sCJD classification groups (Definite, Probable
and Possible / Unclear) are more likely to be real than those just detected in one
category. E.g. akinetic mutism and cortical blindness.
Weight loss was more frequently recognised in 1993/4 than in 2003/4 but this is
probably an artefact of the questionnaire, as the 1993/4 format asked specifically
about weight loss whilst this was omitted in the later version. Conversely sensory
symptoms were more prevalent in 2003/4 Cases and again this can be explained by
changes in the questionnaire. In 2003/4 there were specific questions on sensory
symptoms and signs whereas in 1993/4 only sensory abnormalities found on
examination were detailed. Alternatively this could be interpreted as weak evidence
supporting emergence of a BSE phenotype given that sensory features are prominent
in vCJD. However, it is more likely that clinicians and particularly CJD registrars in
the post vCJD era are more likely to ask about sensory disturbance in all suspected
CJD patients. This phenomenon may also explain why hallucinations appear more
common in 2003/4 Cases, although depression and anxiety, the other psychiatric
features most frequently associated with vCJD (160) have not increased which is
reassuring. Also in 2003/4 there was a question on presence or absence of
hallucinations whilst a decade earlier hallucinations were not specifically mentioned.
187
Akinetic mutism and cortical blindness appear to be significantly more common in
1993/4 in Definite and Probable sCJD patients, and also in Possible / Unclear
diagnoses in the case of akinetic mutism. Initially this is difficult to explain as the
current questionnaire used in 2003/4 still includes specific questions as to the
presence or absence of these signs. One possibility is that these are usually late
clinical signs and the 2003/4 patients were being assessed by the CJD registrar earlier
in their disease course, but the data on timing of visits does not support this. Both
akinetic mutism and cortical blindness can be difficult signs to confirm in a sick
patient and are open to clinical interpretation. Therefore the finding might reflect
different registrar practice with time, such that the registrars in 1993/4 used less
stringent criteria to diagnose akinetic mutism and cortical blindness, or were better at
detecting these signs. This is difficult to retrospectively prove or disprove.
Alternatively there may have been a real change in the disease phenotype and sCJD
patients in 2003/4 are less likely to become akinetic, mute and blind. If this is true the
reason is unclear, although interestingly cortical blindness and akinetic mutism are
thought to develop later and possibly be less common in vCJD (162). In addition
cortical blindness is more common in sCJD cases homozygous for methionine at
codon 129(82), and although there was no statistically significant difference in PRNP
type between 1993/4 and 2003/4 there was a trend away from methionine
homozygotes in 2003/4.
4.5 Investigations
Investigation of suspected sCJD has evolved over the past decade. In 1993/4 the most
popular form of brain imaging was CT and less than 50% of Cases underwent MRI.
This trend was reversed by 2003/4, presumably reflecting both increased availability
of MRI and improved understanding of the utility of MRI in sCJD. CSF 14-3-3
analysis was introduced in December 1996 and this probably explains the increased
use of lumbar puncture, from 73% in 1993/4 to 88% in 2003/4. One might have
anticipated a reduction in EEG testing, because more patients are being classified as
Probable sCJD on the basis of the 14-3-3 result and clinical features. However, this
has not been the case and EEG use has remained extremely high at around 90%
without any significant decrease in the mean number of EEGs performed per case.
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4.5.1 CSF
(i) CSF white cell count
The CSF white cell count was normal in the vast majority of sCJD Cases in 1993/4
and 2003/4. In those where the white cell count was elevated it was only minimally
raised with no individual having greater than 10 x 109 / mm3 white cells in their CSF.
This contrasts with Non Cases for the same time period where 13% (4/31) had CSF
white counts above 10 x 109 / mm3. One can conclude that significant CSF
leucocytosis is atypical for sCJD and should prompt the diagnosis to be reassessed. A
recent publication from a multinational study on CSF in CJD has confirmed this
finding, with only 3 of 298 sCJD patients having a CSF white cell count greater than
5 x 109 / mm3 (90)
(ii) CSF protein
CSF protein was normal or mildly elevated in the majority of sCJD Cases with no
significant differences between 1993/4 and 2003/4 referrals. Only five individuals had
CSF protein values greater than lg / L and in other respects they appeared fairly
typical Cases with acellular CSF and characteristic sCJD clinical features, except one
individual with a more prolonged illness lasting 20 months. Unfortunately PRNP
genotype at codon 129 was only tested in two of the five patients (one MM, one MV),
so it is difficult to make any assessment of genotype effect. The range of CSF protein
levels in this study is similar to previous findings in sCJD in the UK (74). It confirms
the clinical impression that CSF protein is often modestly raised in sCJD but is rarely
very high, and is not a particularly useful or specific investigation in this context.
(iii) CSF 14-3-3
CSF 14-3-3 protein has been widely reported as a sensitive and relatively specific
marker for sCJD, when interpreted in an appropriate clinical context (97, 240, 241,
242). This study found 14-3-3 had a sensitivity of 73% which is rather lower than the
values quoted in the literature. Previously most studies reported sensitivities of 90 -
97% (95, 96, 97) but a recent large multinational review also reported a lower
sensitivity at 85%, admittedly still significantly higher than the result in this study.
(104). Sanchez-Juan et al questioned if their lower than expected sensitivity reflected
their rigid strategy in defining a positive 14-3-3 result, or was related to the large
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number of patients tested (104). The lower sensitivity in my study is most likely to
relate to patient selection. Only pathologically proven sCJD patients could be
considered in the calculation and they may be more likely to be clinically atypical,
prompting the need for pathological confirmation. The literature suggests that sCJD
Cases with less classical histories are less likely to have positive 14-3-3 result (121).
There is also evidence that the sensitivity of 14-3-3 diminishes with prolonged disease
duration (240) but pathologically proven and unproven Cases had similar durations in
this study. A limitation of 14-3-3 is the qualitative, subjective nature of the assay,
which relies on visual interpretation of the western blot. It is possible that the
individual (AG) interpreting the vast majority of UK 14-3-3 results uses particularly
stringent criteria but this same individual has participated in previous studies with
higher 14-3-3 sensitivities (243). There have not been recent changes in experimental
technique that might explain a drop in sensitivity. Bias is always a potential problem
with subjective tests but in most cases 14-3-3 was interpreted with minimal
knowledge of clinical details.
Despite these caveats 14-3-3 remains an extremely useful disease marker and was
more sensitive than EEG or MRI in this study.
All 14-3-3 negative, pathologically confirmed sCJD patients referred in the UK
between December 1996 (introduction of 14-3-3 testing) and December 2004 were
reviewed and produced some interesting findings. They were compared with 14-3-3
positive Definite sCJD patients from 2003/4 only because comparable clinical data
was available on this cohort. However, this should not alter the conclusions
significantly as there is little evidence to support major differences between referrals
confined to 2003/4 and 1996 - 2004. It is apparent that 14-3-3 negative sCJD is
uncommon and appears to be associated with atypical clinical and pathological
features. 14-3-3 negative sCJD patients tend to have significantly prolonged disease
duration with a mean of 15 months, and a non significant trend to young age of onset.
They are less likely to demonstrate myoclonus or visual disturbance. These unusual
features are probably in keeping with the underlying codon 129 genotype / PrP
isotype. MM1, which is associated with a typical sCJD presentation, was rare in 14-3-
3 negative patients whereas MM2 and MV2 were over - represented. Overall the
PRNP codon 129 distribution was significantly different in 14-3-3 negative sCJD
Cases compared to positive Cases. The German TSE reference centre have recently
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published their results of molecular subtype-specific diagnosis of CJD and they also
identified lower 14-3-3 sensitivity in certain subgroups such as MV2 (69).
Other investigations may also be unhelpful in 14-3-3 negative sCJD, with only a
minority having characteristic EEG changes and just a third having a supportive MRI
in this study. Again this might reflect PRNP genotype / PrP isotype. However MRI
has been reported to be a useful diagnostic tool irrespective of genotype, but
particularly in this clinically difficult MV2 sCJD (143, 244), so it was disappointing
that more MRI scans were not positive. The cause is unclear and may be a real finding
or relate to reliance on T1 and T2 MRI sequences, particularly in the early years, as
these are now recognised to be less sensitive than FLAIR or Diffusion Weighted
imaging (see section 4.5.2) (108, 112).
One conclusion from the data is that a negative 14-3-3 does not exclude sCJD, and
unfortunately the assay appears more sensitive in typical sCJD patients where there is
less pre- test diagnostic uncertainty. It is a less helpful investigation in the atypical
cases where you really need it.
Previously Castellani et al have reported that the sensitivity of 14-3-3 analysis varies
with sCJD subtype and they identified PrP2 as the main factor reducing sensitivity
(140). Zerr et al also identified PrP type 2, and particularly MV2 cases, as less likely
to have a positive 14-3-3 result (119,141). This study provides some support for this
finding although the small numbers limit the strength of the results. The rarity of
sCJD itself, and particularly 14-3-3 negative sCJD, means limited data are almost
inevitable as illustrated here, despite using all known UK cases. Ongoing European
collaboration on CSF markers in CJD is addressing this problem.
The observation that 2 of the 25 negative 14-3-3 patients subsequently had a positive
result raises the question that a negative result might relate to testing too early.
Repeated CSF analysis has been reported to increase the diagnostic sensitivity of 14-
3-3, particularly in methionine valine heterozygotes (104, 245). However, there is also
evidence that testing after prolonged disease duration is more associated with a
negative 14-3-3 result, and 14-3-3 concentrations are lowest at both disease onset and
the end stage (240). Also in this study the median time to perform the assay was
longer in the 14-3-3 negative group than the positive group, and a similar proportion
through the illness as a whole. Of note the 14-3-3 assay has only been validated up to
2 years after disease onset so one needs to be cautious in interpreting results outwith
this timeframe.
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A crucial and incompletely understood issue is why CSF 14-3-3 is positive in sCJD at
all, and hence negative in a minority. There are two principal theories; one relating to
dynamics of neuronal damage, one relating to localisation of the sCJD pathology.
Previously cortical disruption was believed to be more strongly associated with 14-3-
3 than subcortical basal ganglia and thalamic pathology (119). However, a recent
study identified a negative correlation between positive 14-3-3 and extensive cortical
spongiform change, and between positive 14-3-3 and severe neuronal loss in the
thalamus suggesting a more complex relationship between CSF protein levels and the
location of brain pathology (246). Presumably 14-3-3 protein leaks into the CSF as
neurones are damaged so an assay performed once there is established, extensive
damage may be too late to detect significantly elevated protein levels (93, 101, 246).
The analysis in this thesis is potentially consistent with both theories on positive CSF
14-3-3, as the longer disease duration of negative 14-3-3 patients may imply slower
neuronal damage and a high proportion of these patients had predominantly
subcortical pathology consistent with underlying codon 129 / PrP type.
(iv) CSF SI00
In this study CSF SI00 was abnormally high in 95% of Cases (all from 2003/4 as not
available in 1993/4) but it ranged from normal to grossly elevated. Therefore an
isolated SI00 result in suspected sCJD is not particularly useful although, as a group,
sCJD patients have elevated levels (247). The main value of performing SI00 assays
is to aid interpretation of the 14-3-3 test (A Green personal communication). Usually
in sCJD both these CSF markers are abnormal but if either one is strongly abnormal
and the other normal this raises a question about the diagnosis. It may reflect a
problem with one or other assay, or indicate a diagnosis other than sCJD. Elevated
SI00 with normal 14-3-3 is rarely seen in sCJD and is more likely to reflect an
alternative cause of dementia such as Alzheimer's disease or be associated with
malignancy or cerebrovascular disease. (248, 249, A Green personal communication).
4.5.2 MRI
Many more 2003/4 Cases had MRI appearances supporting a diagnosis of sCJD than
in 1993/4 (45% v 9%). The most likely explanation is that awareness of the
significance of these subtle MRI signal changes had increased by 2003/4 so they were
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being reported more frequently. The NCJDSU was aware of the value of MRI in
1993/4 but, despite invariably requesting imaging, only 2 scans were received in the
unit for review. Both were classified as positive on the basis of caudate / putamen
high signal whereas only a further 2 of the other 44 MRIs performed were thought to
be positive by the reporting radiologist. This suggests bias was introduced when the
referring clinicians selected scans for review. The experience from both variant and
sporadic CJD is that the characteristic MRI changes were under-reported in the early
days, and detection improved with neuroradiology review in a specialist centre (250,
170). One study estimated 80% of sCJD MRI changes were overlooked by the initial
radiologist reviewing the images (107). Therefore the small numbers of suspect sCJD
MRIs reviewed in the NCJDSU in 1993/4 may well have contributed to the apparent
low rate of typical changes. The quality of MRI scanners has improved over the last
decade and this may also have been influential, together with refinement of scanning
techniques and increased use of diffusion weighted imaging (DWI) and FLAIR
sequences which are most sensitive for sCJD (108, 112, 251, 252). In this study a
pragmatic approach was taken and any available MRI sequence was reviewed and
taken into account when classifying the MRI appearances. Whilst we now believe
DWI is the most sensitive sequence for the radiological diagnosis of sCJD it was not
appropriate to rely on this as often DWI was not performed. T2 -sequences were done
in all cases but if T2 films alone were reviewed then this would underestimate
sensitivity. In the literature some studies have confined analysis to T2 MRI sequences
whereas others have considered FLAIR and DWI too, and this will potentially impact
on reported sensitivity and specificity rates.
Alternatively the disparity between 1993/4 and 2003/4 in this study might reflect a
change in the underlying disease itself. MRI sensitivity for sCJD has been reported at
between 58% and 79% by the German CJD Surveillance group (106, 107, 108).
Somewhat surprisingly their sensitivities have been decreasing with time, in contrast
to the findings of this study. They attribute the decline in sensitivity to performing
more scans in the early stages of illness, less pre-selection of good quality images and
introduction of a policy to review all MRIs (108). The German experience of
declining sensitivity would be against a Europe - wide shift to more sCJD cases with
supportive MRI appearances. Of course the situation may be different in the UK but it
seems unlikely that we are experiencing a UK- limited change in sCJD and MRI
sensitivity, particularly as the MRI sensitivity from this UK based study is still lower
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than the most recent German data. Unfortunately there is no earlier available UK data
on the sensitivity ofMRI in sCJD for comparison (DS, DC personal communication).
One difficulty in exploring the MRI data is the incomplete understanding of the
relationship between the MRI appearances and the clinical and pathological features
of sCJD. It is likely that the high signal on T2 weighted imaging is secondary to
increased free water due to gliosis and / or spongiform change (253). Animal studies
suggest increased T2 signal corresponds with gliosis and reduced attenuation
represents spongiform change (254). However, correlation between the degree of
severity of radiological and neuropathological damage has been poor (255) although
this might partly reflect the inevitable time delays between performing an MRI and
autopsy. One might expect sCJD MRI changes to correlate with extrapyramidal
features given the basal ganglia involvement, but there is not strong evidence
supporting this theory and there have even been reports of a negative association
between extrapyramidal signs and typical MRI appearances (244). This study did not
find a positive association between extrapyramidal signs and caudate / putamen
hyperintensity.
MRI appearances were weakly correlated with PRNP codon 129 although this was not
statistically significant. Cases homozygous for valine at PRNP codon 129 were more
likely to have basal ganglia hyperintensity on MRI than methionine homozygotes or
methionine valine heterozygotes. PrP type also appeared to influence the MRI
although the numbers were small and again the result was not significant. A higher
proportion of PrP 2 cases had caudate / putamen high signal on MRI than PrP 1 cases.
There are a number of studies addressing the relationship between MRI and PRNP or
PrP type (121, 141). However, most papers refer to complete molecular subtypes
(codon 129 type in combination with PrP type) whereas too few cases in the current
study had sufficient data to reliably assess this. Sensitivity ofMRI imaging has been
found to be particularly reliable in the diagnosis ofMV2 patients; a useful finding as
this uncommon subgroup are often clinically atypical and less likely to have other
supportive investigations (119, 143, 243). MRI is also frequently abnormal in valine
homozygotes, with VV2 cases tending to show thalamic hyperintensity whereas VV1
patients are more likely to have cortical or basal ganglia signal changes (144, 256).
The typical sCJD MRI appearance of basal ganglia hyperintensity is seen least
frequently in the classic sCJD subtypes, MM1 and MV1, and in MM2, but cortical
hyperintensity is increasingly recognised in these patients (121, 141, 142). The results
194
of this study partially concur with the literature: as predicted basal ganglia signal
change was most strongly associated with VV cases and observed least frequently in
MM patients. MV1 and MV2 cases were largely evaluated together due to small
numbers and this limits any meaningful conclusions as the reported high sensitivity of
MRI in MV2 is likely to be cancelled out by the reported low sensitivity in MV1.
Isolated cortical hyperintensity was rarely recognised (7% in 2003/4 sCJD cases) yet a
recent paper found cortical signal change was common (141). This may reflect
technical improvement in MRJ with time, and suggests that subtle cortical changes
may be increasingly recognised in the future. Their specificity and significance
remain unknown.
The characteristic MRI appearance of vCJD, the pulvinar sign, was not observed in
any sCJD case in this study. Whilst this remains an effective means of discriminating
between sporadic and variant CJD there have been reports of false positive pulvinar
signs in sCJD suggesting it is not entirely specific (171). Prominent thalamic
hyperintensity has also been noted in sCJD, particularly in the MV2 subtype (143) but
also in VV2 cases (144). However, in most instances it is not classified as the pulvinar
sign because the thalamic signal change is no brighter than that in the head of caudate
and putamen.
4.5.3 EEG
The principal finding when EEGs were compared between 1993/4 and 2003/4 Cases
was that significantly fewer 2003/4 patients had characteristic sCJD EEGs (33%
versus 52%). The obvious assumption is that there is now less reliance on EEG due to
the introduction of CSF 14-3-3, which supports the clinical diagnosis and permits
classification of an individual as a Probable case. To a lesser extent the increased
availability of MRI may have also reduced the need for EEG, particularly as the
significance of basal ganglia hyperintensity is better recognised. However, these
theories do not explain the change in EEG results with time in this study because
interestingly no fewer EEGs were done in 2003/4 than a decade earlier. Therefore an
alternative explanation must be sought.
One possibility is that fewer EEGs were available for review at the NCJDSU in
2003/4, and hence less likely to be classified as characteristic of sCJD. Again this is
disproved because more 2003/4 EEGs were actually reviewed in the unit. The same
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individuals (RGW, RK) reviewed the EEGs blind to clinical details and applied the
same diagnostic criteria so this cannot explain the observed difference. The timing of
the EEG was also similar in 1993/4 and 2003/4.
Could it relate to a change in the underlying disease, possibly influenced by a novel
disease phenotype or changing PRNP genotype distribution? This study has not
demonstrated any significant change in PRNP codon 129 genotype between 1993/4
and 2003/4 (results section 3.4.5) so it seems unlikely to be the full explanation.
However, there has been a non significant trend towards more atypical Parchi
subtypes (non MM1 / MV1) which are less associated with the characteristic periodic
EEG, and correspondingly fewer methionine homozygotes so this may be a factor.
Variant CJD is not generally associated with periodic sharp wave complexes and it is
possible that misdiagnosis of vCJD or a similar BSE related disease could reduce the
frequency of typical sCJD EEGs, but in the absence of other evidence for a novel
phenotype this seems unlikely to be the answer.
The most plausible explanation is that it is an artefact of classification and Case
definition. The percentage of characteristic EEGs was calculated in all sCJD Cases,
namely all patients meeting criteria for Definite or Probable sCJD. In 1993/4 all the
Probable Cases would have typical EEGs, whereas in 2003/4 a significant proportion
would fulfil Probable criteria on the basis of clinical features and a positive 14-3-3
alone. Therefore it is more accurate to assess EEG findings in Definite Cases only.
When this calculation is performed there is no significant difference between 1993/4
and 2003/4, although the trend to fewer characteristic EEGs in 2003/4 persists (38%
in 1993/4 versus 28% in 2003/4; p = 0.18
EEGs were also reviewed in the referrals classified as Possible sCJD or 'Unclear
Diagnosis'. The numbers were extremely small but there was no apparent difference
in the proportion of typical EEGs with time. A significant minority (14%) had EEGs
characteristic for sCJD in both referral periods. They were not classified as Probable
sCJD because of insufficient clinical features, but it is likely that some do represent
sCJD cases, particularly as no alternative diagnoses were made.
The current study has shown an association between the characteristic sCJD EEG and
methionine homozygosity, and also between the characteristic EEG and PrP 1 isotype.
This has previously been reported in the literature. Zerr et al found EEG changes of
periodic sharp and slow waves predominantly with MM1 and MV1 genotypes (119).
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Conversely valine homozygosity has a negative association with a typical EEG (118,
256). The data on MV2 genotype and EEG is mixed, with some reports suggesting
MV2 is not associated with typical EEG changes (143) whereas others report a
positive association (128/
The reason for the links between genotype / PrP isotype and EEG changes is unclear,
not least because the aetiology of the periodic sharp wave complexes themselves is
incompletely understood (257). It is important to point out that the associations are
not absolute, and a number of non-specific EEGs were recorded in MM1 Cases (n =
4). Whether these patients would have ultimately demonstrated periodic sharp wave
complexes is unknown, although it is clear that such changes are by no means
universal in sCJD, even with repeated EEGs performed up to the final stages of
illness. In fact there is evidence that the characteristic EEG is less common in the
preterminal stage of the illness as periodic activity disappears, at least at the level of
scalp electrodes, and diffuse flattening occurs (258, 259, 260). Frontal intermittent
delta wave activity (FIRDA) has also been reported as an early EEG finding in sCJD
but was not observed in this study (260).
Periodic sharp wave complexes are not unique to sCJD. Fortunately the majority of
diseases producing sCJD - like EEGs are clinically distinct from sCJD so should not
cause too much of a diagnostic dilemma (e.g. hepatic encephalopathy, lithium and
baclofen related encephalopathy), although this does stress the importance of
interpreting the EEG in the light of the clinical picture. However, this study identified
3 pathologically proven Non Cases with EEGs that were typical or highly suggestive
for sCJD and potentially compatible clinical histories. Their final diagnoses were
Alzheimer's disease, Lewy body dementia and normal pressure hydrocephalus. These
three conditions have all been reported in association with EEG periodic sharp wave
complexes, albeit rarely (122, 123, 124, 261). The experience of this study confirms
that the characteristic EEG appearances associated with sCJD are not entirely specific
for this disease, even when the EEGs are reviewed blindly by NCJDSU consultants
following stringent criteria (see appendix). The combination of rapidly progressive
dementia and periodic sharp wave complexes can still rarely be due to illness other
than sCJD.
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4.5.4 Brain and tonsil biopsy
A minority of sCJD Cases underwent brain biopsy as part of their investigative work
up. It is difficult to draw firm conclusions on these patients because of small numbers,
but they were generally younger and had more prolonged illnesses than sCJD Cases
who did not get biopsied. These two factors may not be independently significant
because there is a known inverse association between age and disease duration (262).
One might anticipate biopsy cases to be younger as we know young patients are more
thoroughly investigated in many illnesses and are also more likely to have an autopsy
(as reported by the Office of National Statistics for England and Wales). The
unusually long mean disease duration could be explained partly by the correlation
with age, and also because any deviation from the typical sCJD disease course might
prompt more extensive investigation. Similarly this might explain why three of the ten
biopsy patients had odd presenting features (although the remaining seven had fairly
characteristic disease onsets), and the unusual codon 129 genotype distribution of the
ten cases. Methionine homozygotes were underrepresented in the biopsy cohort
compared to sCJD patients not undergoing brain biopsy (25% v 64%), although this
did not reach statistical significance, possibly reflecting the small numbers involved.
Whether the biopsies were necessary or justified remains debatable. Without biopsy 4
of the Cases were classified as Probable sCJD and a further 4 were Possible whereas 2
were 'Unclear diagnosis'. sCJD was suspected in all instances before biopsy. The
decision to perform a biopsy is guided by a risk - benefit analysis, with the potential
risks of the procedure weighed against the chance of altering management. In this
study no major complications were reported from any of the procedures. Obviously
no treatable conditions were identified in the 10 individuals biopsied, but a definitive
diagnosis was made and this in itself can be useful. It provides families with a name
for their relative's condition and can guide clinicians away from repeated
investigations and futile attempts at treatment. The fact that 80% of the biopsy
patients were seen in a single centre implies that different units have different
practises and thresholds at which they believe cerebral biopsy is indicated.
A recent analysis of 90 brain biopsies undertaken for the investigation of dementia
found that 57% were diagnostic but in only 11% was treatment directly modified by
the biopsy findings (263). In all cases the biopsy was requested to exclude potentially
reversible pathology (inflammation, infection) but this was identified in only a
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minority (11%) and the commonest diagnoses were neurodegenerative (including
Alzheimer's disease 18% and CJD 12%). It reported a complication rate of 11%
including intracranial haemorrhage, infection and seizures but no biopsy - related
deaths.
6 of the 54 young onset sCJD Cases studied in this thesis had a tonsil biopsy to help
support or exclude a diagnosis of vCJD. It was negative in all 6 cases, with no
evidence of PrPSc in the lymphoreticular tissue. None of the older onset sCJD patients
referred in 1993/4 and 2003/4 underwent tonsil biopsy. Tonsil biopsy is a valuable
diagnostic tool in suspected vCJD, particularly as tonsillar tissue is more accessible
than brain and therefore the biopsy can usually be performed under local anaesthetic
and it is associated with a lower morbidity than cerebral biopsy. There is evidence
that lymphoid PrPSc is detectable in the pre-symptomatic phase of the disease so tonsil
biopsy could potentially be used to identify asymptomatic vCJD carriers or as an early
disease marker.
However, there are a number of disadvantages associated with tonsil biopsy. It is not
an entirely risk free procedure, particularly in critically ill patients, and significant
haemorrhage can occur. Similar to brain biopsy there are significant public health
implications, and use of disposable instruments is recommended. A positive tonsil
biopsy does not definitively prove a diagnosis of vCJD and the individual remains
classified as Probable (although to date no patient with a positive tonsil result has had
an alternative diagnosis made subsequently). Therefore one can argue tonsil biopsy
adds little in a patient with the characteristic vCJD clinical features and pulvinar sign
on MRI, as they already fulfil Probable criteria. The major disadvantage to tonsil
biopsy compared to brain biopsy is it simply confirms or helps exclude a diagnosis of
vCJD. It has no role in the diagnosis of alternative causes of rapidly progressive
dementia. Therefore in an individual where the differential diagnosis remains wide
and includes both vCJD and sCJD cerebral biopsy may be more helpful.
4.5.5 Pathology and codon 129 genotype
There was no significant difference in PRNP 129 distribution in sCJD Cases in
1993/4 compared to 2003/4. However, there was a trend towards fewer methionine
homozygotes and more valine homozygotes in 2003/4. Given the lack of statistical
significance this may be a chance observation, but it does correspond to the UK and
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French findings of a general decline in MM frequency with time when all years
between 1993 and 2004 are reviewed (see section 3D). Up to date UK figures from
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There are a number of possible explanations. It may reflect a real change in the
disease genotype profile, possibly due to altered prion pathogenesis or host
susceptibility. Alternatively it may relate to case ascertainment. The CJD surveillance
system particularly aims to identify young and atypical presentations of sCJD,
particularly since the advent of vCJD. Young onset sCJD has a higher proportion of
PRNP VV genotype (262). Similarly the classic sCJD phenotype is associated with
Parchi type MM1 and atypical cases are more likely to be non MM (134). MM cases
may also be less likely to undergo genotyping due to lack of time as their disease
tends to be more rapid (section 3.4.5). The introduction of the CSF 14-3-3 test may
have improved detection rates for VV sCJD, because the majority will have a positive
14-3-3 whereas previously they might have been missed when there was more
reliance on EEG (228, 229). All these explanations might bias against identifying and
genotyping MM patients and favour detection ofVV cases.
It was not possible to compare PrP isotypes or full Parchi subtypes in 1993/4 and
2003/4 because only two 1993/4 referrals underwent PrP typing.
When sCJD neuropathology was compared between the two time periods there were
significantly more individuals with kuru type plaques in 2003/4, although they were
still uncommon. As expected from the literature most of these patients were Parchi
subtype MV2 (134). It is not clear why the incidence of kuru plaques has increased,
particularly as the proportion of MV Cases has remained stable. The numbers are
small and therefore susceptible to unexpected results so it would be interesting to see
if this finding is borne out in a larger neuropathological study. There is currently great
interest in amyloid plaques due to the recent identification of an atypical cattle BSE
strain with pathological similarities to MV2 sCJD (4). Therefore any sustained
increase in sCJD patients with kuru plaques might be extremely important.
Reassuringly no case was identified with the florid plaques characteristic of vCJD.
4.6 The differential diagnosis of sCJD
The number ofNon Cases referred to the NCJDSU increased annually between 1993
and 2000 but has since decreased with time. The proportion of Non Cases compared
to total annual referrals is small and is also diminishing with time, particularly since
2001. This suggests that diagnostic accuracy of referrers has improved. Possible
explanations include increased awareness of the characteristic sCJD phenotype and
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better availability and specificity of investigations, both for CJD and the alternative
diagnoses seen in Non Cases. The percentage of pathologically confirmed Non Cases
(as opposed to those defined only on clinical grounds) has also decreased with time.
This probably reflects the general trend away from post mortem.
The differential diagnosis of sCJD is wide and the diagnosis is not always
straightforward in life. In this study the commonest alternative pathological diagnosis
amongst patients referred as suspected sCJD was Alzheimer's disease. Other
pathologically proven alternatives included dementia with Lewy bodies /
Parkinsonism with dementia, cerebrovascular disease (including vascular dementia)
and encephalitis of unknown cause. In the Non Cases identified only on a clinical
basis the commonest diagnosis was again Alzheimer's disease, followed by
unclassified dementia and Lewy body dementia. However, this group is particularly
difficult to study because there is no definitive means of proving the diagnosis, which
depends on clinical judgement. In this study the diagnosis was based on information
from the referring clinician, both at referral and follow-up, and on the opinion of the
visiting registrar. When there was significant clinical doubt it was discussed with one
or both NCJDSU consultant neurologists (RGW, RK) and a consensus was reached.
An alternative diagnosis to sCJD was not always made but the individual was only
classified as a Non Case if the features were felt incompatible with CJD; otherwise
they were classified as 'Unclear diagnosis'. Therefore one study weakness is that a
significant number ofNon Cases have no definite diagnosis other than 'not CJD' (even
including some who had post mortems). This has been a problem in the past when
evaluating the differential diagnosis of sCJD (R.G. Will - personal communication)
and there is no obvious solution, other than to minimise the problem by limiting
analysis to pathologically proven Non Cases. However, this is not a satisfactory
reflection of real life practise and significantly limits the amount of information
available, particularly as fewer autopsies are being performed nowadays.
In this study there were single cases of numerous diagnoses including the expected
such as hypoxic encephalopathy, the rare such as multifocal calcifying
leucoencephalopathy and the surprising such as acute confusion in the context of
shingles. A significant number of the Non Cases recovered, either spontaneously or
with steroids. However, in the pathological Non Cases the autopsy rarely revealed any
potentially reversible diagnoses. One individual had previously unidentified viral
encephalitis that might have been amenable to therapy and three others had
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encephalitis of unknown aetiology. This concurs with the body of literature where the
majority of conditions misdiagnosed as CJD are neurodegenerative and just a small
minority are treatable (including multiple sclerosis and herpes encephalitis) (264).
The literature on the differential diagnosis of sCJD is relatively limited with numerous
isolated case reports but few large studies. The largest reviews support the current
study, identifying rapidly progressive Alzheimer's disease as the condition most
commonly mistaken for sCJD (69, 74, 123, 124, 265). Tschampa et al reviewed
patients with Alzheimer's disease or Lewy body dementia misdiagnosed as sCJD
because of rapidly progressive dementia and focal neurological signs (122). They
concluded that sCJD should be the primary diagnosis in this clinical situation, but
identified long duration as a pointer towards Alzheimer's disease, whereas
extrapyramidal signs and fluctuations favoured dementia with Lewy bodies. A
Belgian study of possible sCJD patients with an alternative final diagnosis had similar
findings, identifying Parkinsonism and fluctuations as markers of Lewy body
dementia, duration greater than a year as a predictor ofAlzheimer's disease and focal
onset and compatible imaging as a pointer towards vascular dementia (124).
However, as the current study shows, these rules are not absolute and long duration
sCJD patients certainly exist, with one proven case surviving 62 months.
Interestingly the German CJD surveillance unit found chronic inflammatory
neurological disease was the commonest alternative in young patients and they
highlighted Hashimoto's encephalopathy in particular (123). No cases of Hashimoto's
encephalopathy were diagnosed in my study, or in the other reviews. One possible
explanation is that many neurologists will check thyroid autoantibodies prior to
referring to the NCJDSU, thus eliminating these patients. Alternatively it might
reflect different interpretation in the UK and Germany of the poorly understood
disease entity that is Hashimoto's encephalopathy (266).
Genetic, iatrogenic and variant CJD are also in the differential diagnosis of sCJD but
were excluded in this study.
Patients ultimately classified as either Possible sCJD or 'Unclear diagnosis' are an
interesting but challenging group. The 'Unclear diagnosis' cohort appear to be a
mixture including patients strongly suspected of having sCJD who do not fulfil
diagnostic criteria despite supportive EEG, MRI or CSF results (often because disease
duration exceeds two years), individuals thought clinically to have an alternative, non
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CJD diagnosis but with insufficient evidence to prove this and lastly patients where
no confident diagnosis has been made at all. Diagnostically the limiting factor is
generally the lack of data to substantiate the clinical impression, whether in terms of
long term follow up or neuropathology.
Individuals classified as Possible sCJD are a little different. The most likely diagnosis
for all the Possible patients referred in 1993/4 and 2003/4 was considered to be sCJD.
However, there are a number of caveats to assuming that all Possibles truly had sCJD.
A 'best guess' diagnosis is, by definition, unproven and can never equate to a proven
neuropathological diagnosis. A number of Non Cases were clinically thought to be
sCJD before autopsy and it is likely that this would also be true for the Possible
cohort. There is classification bias such that two patients may fulfil criteria for
Possible sCJD but one may be designated a Possible by the NCJDSU registrar whilst
the other is reclassified as 'Unclear diagnosis' or a Non Case based on the clinical
suspicion of an alternative diagnosis. Thus the final Possibles are a highly selected
group of patients reflecting the judgement of the NCJDSU. Finally bias may occur
related to information made available to the NCJDSU. An individual may be
classified as Possible sCJD initially but as their illness evolves over months or years
the diagnosis of sCJD may become untenable. However, the local doctor may be less
likely to update the NCJDSU than if the clinical progress favoured CJD, and therefore
this patient would remain classified as Possible sCJD based on the available
information.
4.7 Assessing the diagnostic criteria
From this study current diagnostic criteria for a Probable classification have a
sensitivity of 72%, specificity of 79%, positive predictive value of 89% and negative
predictive value of 56%, using autopsy confirmed sCJD patients as the gold standard.
No other reports assessing these criteria were found in the literature so it is not
possible to compare how they fare in the UK compared to other countries. In
comparison with diagnostic criteria for other neurological conditions they perform
reasonably well. For example the clinical criteria of the Consortium of dementia with
Lewy bodies for probable Lewy body dementia quote a lower sensitivity and positive
predictive value at 61% and 48% respectively, but higher specificity (84%) and
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negative predictive value (90%) (267). One small study validating the NINCDS-
ADRDA clinical criteria for probable Alzheimer's disease found specificity to be
comparable with the current criteria for sCJD (82% v 79%), but the Alzheimer's
disease criteria had a lower positive predictive value (61%) and better negative
predictive value (93%) and sensitivity (80%) (268).
When the current WHO diagnostic criteria for sCJD are compared with those prior to
the introduction of CSF 14-3-3 (Rome 1993) it is apparent that the sensitivity has
increased significantly (42% to 72%), but at the expense of a moderate drop in
specificity (97% to 79%) and a small reduction in the positive predictive value (97%
to 89%). This is probably a reasonable compromise as previously over half the
Definite sCJD patients were classified as Possible or less in life based on this study
data. Brandel et al assessed the same Rome 'Probable' criteria in French patients and
found the sensitivity to be higher than this study at 65%, with similar specificity and
positive predictive values. (269). The reason for the discrepancy between sensitivities
is unclear, but could potentially reflect more EEGs being performed in France and
hence more characteristic EEGs being identified.
The impact of incorporating MRI changes into the diagnostic criteria was also
evaluated. The numbers were relatively small but the addition of MRI did not appear
to make a major difference, irrespective of whether basal ganglia hyperintensity alone
or basal ganglia or cortical hyperintensity were used. Sensitivity and positive
predictive value did increase marginally but specificity was unchanged. This might
reflect the small numbers, particularly of Non Cases with MRI imaging, and it would
be useful to address the utility ofMRI further in a larger study. It would be especially
interesting to look at the false positive rate of the typical MRI changes. In this study
three Non Cases demonstrated basal ganglia high signal although it did not impact on
their classification. However, this may well be a concern if MRI is incorporated in the
future, particularly with increasing use of the more sensitive MRI sequences, DWI
and FLAIR. In particular, the specificity of cortical signal change will need to be
reviewed. The findings in this thesis do not support using MRI in the diagnostic
criteria but this has been recommended by members of the German CJD Surveillance
unit although they did not formally assess the impact of introducing MRI criteria
(108).
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Irrespective of the precise diagnostic criteria used the negative predictive value was
low. This implies that failure to fulfil Probable criteria does not reliably exclude a
diagnosis of sCJD.
There are a number of limitations when validating the diagnostic criteria. The main
problem is the reliance on pathologically confirmed sCJD patients as the gold
standard, because they are a highly selected group and may not be representative of
sCJD in general. As previously discussed some may have a post mortem because they
are clinically atypical, and it is plausible that the more typical patients who already
fulfil Probable classification will be less likely to undergo autopsy as their clinicians
and families already have a relatively secure diagnosis. This will artificially skew the
findings towards lower sensitivity and predictive values. In this study both
pathological and clinical Non Cases were used when evaluating the criteria but one
could argue that this should have been confined to the autopsy proven Non Cases.
However, the numbers would have been too small for any meaningful analysis. Also
individuals were only classified as Non Cases if there was felt to be no possibility of
sCJD, otherwise remaining as 'Unclear diagnosis', so it seemed reasonable to include
all Non Cases in the analysis.
It is important to validate the diagnostic criteria for a number of reasons. It is helpful
for families and health professionals if a label of Probable sCJD can be translated into
everyday language. E.g. Probable sCJD implies that we are around 90% certain that
this is the diagnosis (based on the positive predictive value of 89%). Validation is also
useful on a population basis. A key role of any surveillance centre is to monitor
disease incidence and this is obviously highly dependent on the reliability of the
diagnostic criteria. From time to time criteria will be modified and one needs to
predict the likely effect on diagnostic accuracy to avoid misinterpreting any changes
in incidence. Clearly defined criteria provide consistency so that data from different
countries can be compared. This has been particularly useful with sCJD and the
various European collaborations. Simple, clearly defined diagnostic criteria are also
useful for research purposes, to select and categorise patients entered into trials.
4.8 Utility of individual clinical features in the diagnosis of sCJD
As one might anticipate dementia was almost universal amongst referrals to the
NCJDSU, irrespective of whether the patient ultimately had CJD. Therefore this was
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not a good discriminating feature. Similarly myoclonus was not particularly useful
with high sensitivity of 87% but poor specificity at 45%. This probably reflects the
population studied. Myoclonus is probably the best-recognised sign associated with
sCJD and its very presence may trigger referral to the NCJDSU, so it is not surprising
a significant proportion of Non Cases also had myoclonus. If a less selected
population was studied (e.g. any patient with rapidly progressive dementia) then it
might prove more discriminating.
The most useful clinical feature to differentiate sCJD from non-CJD was visual
disturbance, with a positive predictive value (PPV) of 93%. This is clinically relevant,
particularly as visual symptoms are often an early feature of sCJD. Unfortunately
visual disturbance is an imprecise term but it reflects real life practice, as frequently
sCJD sufferers are unable to precisely define their visual problems. It encompasses
numerous visual symptoms that have been reported in sCJD including micropsia,
macropsia, metamorhopsia, field defects and simple blurred vision (83). Akinetic
mutism was also useful if present (PPV 89%) although sensitivity was low at just
53%. However, its utility in everyday practise might be less than visual disturbance as
it tends to be a feature of late disease. Parkinsonism was generally not a helpful
diagnostic pointer to sCJD (sensitivity 20%, PPV 60%). This might reflect the
significant numbers of Non Cases with Dementia with Lewy bodies or Parkinson's
disease with dementia. Negative predictive values were generally low implying
absence of any single feature does not reliably exclude a diagnosis of sCJD, so it is
important to look at the clinical picture as a whole.
When the Non Cases mistaken for sCJD were evaluated visual disturbance at onset,
cortical blindness and akinetic mutism were all significantly less common than in
sCJD patients, concurring with the above conclusions on the diagnostic utility of these
clinical features. However, numerous other symptoms and signs were also rarer in the
Non Cases (including cerebellar signs, myoclonus and primitive reflexes). Whilst this
may be real one has to be wary of over-interpreting the data on Non Cases. They were
less likely to be visited by the NCJDSU registrar and follow up information was often
scarce, meaning that the quality and quantity of data may not have been comparable
with the sCJD cases. Despite this, three clinical features were more common in the
Non Case population: sensory symptoms at onset, symptoms suggesting a seizure and
parkinsonism. Parkinsonism has already been discussed. Seizures are well recognised
in sCJD but are infrequent and generally a late feature (227, 270, 271). Presentation
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with seizures would be atypical for sCJD (with the possible exception of epilepsy
partialis continua) (272). Non convulsive status is sometimes reported in sCJD on the
basis of the altered mental state and EEG findings, but frequently this is a
misinterpretation of the early periodic sharp wave complexes of sCJD itself (273).
It is not immediately clear why early sensory symptoms were more prominent in Non
Cases than in sCJD. The commonest final diagnoses in Non Cases in this study were
Alzheimer's disease and Parkinson's disease with dementia / Dementia with Lewy
bodies; not conditions characteristically associated with sensory symptoms. sCJD
cases may have been questioned more rigorously about sensory symptoms because of
the association between vCJD and painful sensory disturbance, resulting in better
documentation. However, this should not explain the extra sensory symptoms in Non
Cases as absence of a symptom and insufficient information were analysed together.
4.9 Young onset sCJD
In this study young onset sCJD (defined as onset aged 50 or less) was rare but well
recognised, typically with 5 or fewer Cases per year. The number of young patients
was essentially stable with time, with the exception of an unexplained and non-
sustained rise in 1999 when there were 12 young sporadic Cases. The majority were
aged between 40 and 50 years but extremely young cases were identified, including
one 15 year old and one 25 year old. However, this is well-recognised with seven
cases of adolescent onset sCJD reported in the literature (70, 173, 274, 275, 276, 277).
The concern with such young cases is the potential for diagnostic confusion with
vCJD, which has a mean onset age of 28 years (158).
Unsurprisingly a number of the young sCJD referrals were initially suspected of
having vCJD, not only by the referring team but also by the visiting NCJDSU
registrar. However, when the clinical phenotypes of the young cases were compared
with older sCJD patients they were reassuringly similar. Dementia and myoclonus
were present in the vast majority of young cases and overall clinical presentations
were similar in the two groups. Features that are particularly associated with vCJD,
such as psychiatric symptoms, chorea and dystonia, were not seen significantly more
often than in older patients, with the exception of sensory symptoms. Sensory
disturbance was commoner in young onset sCJD than older onset sCJD (35% v 11%).
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Sensory disturbance in vCJD is typically painful and persistent and this was the case
in 19% of the young sCJD cohort. This is most likely to be an artefact of reporting, as
the visiting CJD registrar is likely to search harder for sensory disturbance in any
young suspected CJD patient in case they have vCJD. Another possible explanation
relates to the longer disease duration in the young cases, meaning they were examined
at a relatively earlier stage of their illness and therefore their ability to report sensory
problems might still be preserved. Thirdly young sporadic patients may have a subtly
different phenotype to older sCJD cases, related to PRNP type or an unidentified
factor. Finally the higher than expected proportion of young cases with sensory
disturbance could represent misdiagnosed vCJD, but against this the clinical features
are otherwise consistent with sCJD.
One notable difference between the two age cohorts was the average disease duration,
which was significantly longer in the young patients and reminiscent of the duration
seen in vCJD. Possible explanations include better premorbid health, more aggressive
supportive care (feeding, antibiotics), genetic background related to PRNP 129 or
misdiagnosis of vCJD as sCJD. This latter possibility is unlikely in view of the typical
sCJD phenotype and pathology. A study has identified early age of onset as a major
factor influencing sCJD survival (72). In comparison older onset cases of vCJD do not
appear to have dramatically more rapid illnesses than young onset patients, with the
eight UK variant cases aged over 50 at onset having a mean duration of 11.6 months
compared to the vCJD average of 14 months. The German CJD Surveillance group
has recently published a review of their young sCJD patients (defined in the same
manner as this study) and they too identified an association between prolonged illness
duration and young age (262). They found this persisted with all three codon 129
genotypes suggesting PRNP type is not the full explanation.
The German study's findings on clinical phenotype were also similar to this study,
except for a preponderance of early psychiatric symptoms in young sCJD not
corroborated by this study. Interestingly they identified 52 young cases between 1993
and 2003 compared to this study's figures of 54 between 1993 and 2004. Given the
smaller UK population this suggests a higher incidence of young onset sCJD in the
UK compared with Germany. The cause for this is unclear. It might simply be a
chance finding given the number of young cases is small. Alternatively it could reflect
better case ascertainment in the UK in light of vCJD concerns, but it seems unlikely
that significant numbers of young onset sCJD cases would be missed in Germany
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given the devastating nature of the condition. Lastly it might reflect a real difference
between the UK and Germany, either BSE related given the higher BSE exposure in
the UK or for another unidentified reason. There is no evidence to support a BSE
related cause and laboratory transmission studies performed in the youngest sCJD
patient in this study did not demonstrate the characteristic lesion profile and
incubation period seen with vCJD. Instead the results were typical of sCJD with
PRNP MV background, and were indistinguishable from transmission studies from
older, pathologically confirmed MV sCJD patients (70).
Potentially as yet unidentified environmental, dietary or genetic factors could
influence the incidence of young onset sCJD, but Germany and the UK have similar
genetic and environmental backgrounds so a chance or surveillance related finding
seems more likely.
Generally investigations were less helpful in establishing a diagnosis of sCJD in the
young compared to the older cohort. Significantly fewer EEGs showed typical
changes, a smaller proportion of 14-3-3 s were positive and there was a trend towards
fewer characteristic MRI appearances in the young cases. No MRJ scans in the young
patients showed the pulvinar sign to suggest vCJD. These results are similar to the
German CJD experience (262). One explanation is again the genetic background of
the young patients. Whilst there were no significant differences in terms of codon 129
genotype in this study there was a trend towards valine homozygosity in the young
cohort (also present in the German study). It is well recognised that periodic sharp
wave complexes are rarely seen with VV homozygotes (120, 121, 141). Alternatively
the reduced sensitivity of investigations might reflect the longer, slower disease
course in young onset sCJD, particularly with 14-3-3 which is postulated to rise due
to rapid neuronal death (93).
Invasive investigations including cerebral and tonsil biopsy were performed more
frequently in young onset sCJD. This is hardly surprising given the lower sensitivity
of the conventional investigations, plus the great pressure to provide a diagnosis in
young patients who are deteriorating quickly. 6 young cases underwent tonsil biopsy
compared with no older sCJD cases. In view of the similar clinical phenotypes of
young and old sCJD patients this suggests tonsil biopsies are sometimes being
recommended on the basis of age and in the absence of other features to suggest
vCJD. Tonsil biopsy carries risks and a negative result in this situation is not
particularly helpful, so this procedure should not be rushed into lightly.
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There is a single case report in the literature of a young onset sCJD patient who
fulfilled the diagnostic criteria for both Probable sCJD and Probable vCJD (173). Her
illness began at the age of 19 with sensory symptoms but otherwise she had a fairly
classical disease course for sCJD, culminating in myoclonus and akinetic mutism.
Similar to the young Cases in this study she had a prolonged disease duration
surviving for almost two years. Brain biopsy and ultimately post mortem confirmed
sCJD of the VV1 type, whilst tonsil biopsy was negative. An unusual finding was that
her MRi reportedly showed the pulvinar sign, suggesting this is not as specific as
previously hoped in the context of prion disease. However, reassuringly no young
cases with a positive pulvinar sign were identified in this study despite 87% of
patients (47/54) undergoing MRI.
A limitation of the young sCJD data is that genetic analysis was not performed in all
instances so it is possible that genetic CJD cases are mistakenly included in the young
sporadic cohort. However, this is unlikely as 80% of patients did undergo genotyping
and the remainder had no significant family history, and frequently genetic cases look
different pathologically, the main exception being E200K mutations which rarely
present in the very young.
4.10 Comparison between sCJD Cases in UK, France and other EuroCJD
countries
Data from UK, France and 'other'* EUROCJD databases was compared searching for
any variation between countries, and particularly any differences in the UK and
possibly France that might be attributed to increased BSE exposure. Overall there
were few significant differences, and therefore no good evidence of a BSE related
effect on sCJD characteristics between countries.
Age at sCJD onset and death was similar in all three geographical areas, as was mean
disease duration. PRNP codon 129 distribution was comparable when the entire
period 1993 - 2004 was reviewed in UK, France and 'other' EUROCJD countries.
*'other' = Australia, Austria, Canada, Germany, Italy, Netherlands, Slovakia, Switzerland, Spain
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However, if codon 129 genotype was analysed by percentage and individual year
there was a significant trend towards fewer methionine homozygous cases with time
in the UK and France, which was not shared in the 'other' countries. There are a
number of possible explanations. It might be a real shift in sCJD genotype
distribution, although limited to the UK and France. This could be due to alterations
in sCJD susceptibility but the geographical variation is not explained, or it potentially
could be a BSE related disease affecting MV and W individuals and being
misdiagnosed as sCJD. However, the rest of this study does not support this, and
certainly the UK Cases have a phenotype consistent with sCJD rather than a novel
illness attributable to BSE. The most plausible explanation for the decrease in MMs in
the UK and France is a shift in the population being genotyped. Previously smaller
numbers of Cases were undergoing PRNP analysis and they were largely typical MM
presentations of sCJD. Recently more MV and VV Cases have been genotyped,
possibly due to improved ascertainment of atypical, non MM patients in the UK and
France with the heightened concerns regarding vCJD in these countries. This theory is
supported by the graphs looking at actual numbers of each codon 129 type annually in
France and the UK, compared to other EUROCJD nations (results section 3D, fig
3.73, 3.74, 3.75).
The racial and genetic backgrounds of the different countries studied here are not
necessarily comparable, and there is evidence supporting a worldwide PRNP 129 west
to east gradient with a higher frequency of methionine homozygotes in the normal
population as you travel eastwards (278, 279, 280). However, this is unlikely to
explain the different patterns in sCJD PRNP 129 distribution between UK / France
and 'other' EUROCJD countries as most European countries have a similar pattern of
codon 129 distribution in the normal population (222, 278, 281). Also one study
found that previously PRNP genotype frequencies in sCJD were not statistically
different across seven European countries (UK, France, Germany, Italy, Netherlands /
Belgium, Slovakia). (281). Individual countries have differing rates ofPRNP analysis
and this may be relevant. E.g. Slovakia has extremely high levels of familial CJD so
any suspected sCJD patient is likely to undergo genetic analysis whereas other
countries are less rigorous (282, 283). In the context of this study UK and 'other'
countries had similar levels of PRNP typing (66% and 63%) whereas France was
higher (76%). This might mean more Cases presenting in an atypical manner are
likely to be genotyped in France.
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Interestingly the trend towards decreased MM frequency with time is not statistically
significant when UK data for referrals in 1993/4 and 2003/4 only were analysed
(results section 4.5.5), presumably reflecting the smaller numbers tested.
PrP isotype and Parchi subtype were also compared between the UK, France and
'other' EUROCJD countries, but unfortunately the relatively small numbers available
limit conclusions. A further concern is that the cases tested were not representative of
all sCJD patients as, by definition, they underwent neuropathological examination and
therefore might be younger or have less characteristic histories or investigation results
than the cases that did not undergo PrP testing. However, against this UK Cases that
were PrP typed did not have significantly different illness durations or ages at death
from those where testing was not performed (data from NCJDSU, table 4.1).
Despite these caveats there does not appear to be any significant difference between
PrP type and Parchi subtype distribution in the UK, France and 'other' EUROCJD





n = 284 (31%)
PrP type not known
n = 639 (69%)
Mean age at death / yrs 67
(range 20 - 87)
67
(range 40 - 95)
Median illness duration /
mo
5
(range 1 - 54)
4
(range 1 - 74)
One concern with respect to UK, French and 'other' EUROCJD results is whether the
data sets are truly comparable. All the countries participating in the EUROCJD
programme collect cases prospectively, use the same sCJD diagnostic criteria and
have categorised cases by year of death. However, there are inevitably disparities
between different countries' surveillance programmes. These include variable access
to neurologists and investigations, differing awareness of the surveillance units with
corresponding dissimilar referral rates, and different autopsy rates. For instance the
post mortem rate in the UK was noticeably higher than France or 'other' EUROCJD
countries, at least until 2001, and this may have influenced patient classification and
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sCJD detection rate (fig 4.6). As mentioned earlier the genetic composition will vary
between countries, both with respect to PRNP and other genes, and this may impact
on sCJD susceptibility and phenotype. Notwithstanding these limitations there is no
evidence of an emergent BSE related phenotype being misdiagnosed as sCJD in the
UK.
Fig 4.6
Percentage of sCJD cases with a neuropathologically confirmed
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B. Conclusions
Sporadic CJD is a rare, universally fatal neurodegenerative disease and a member of
the family of transmissible spongiform encephalopathies. The emergence of BSE in
cattle followed by variant CJD in humans has highlighted concerns that other,
possibly BSE related, forms of human prion disease are being missed. This study
provides a comprehensive review of UK sCJD cases between 1993 and 2004,
concentrating particularly on 1993/4 referrals predating the first recognised vCJD
patient, and 2003/4 referrals after the peak in vCJD incidence. The sCJD clinical
phenotype has remained similar between the two time periods with most differences
being readily explicable by changes in data collection, case ascertainment or
investigation use. There is no convincing evidence supporting a novel BSE related
phenotype. Similarly when young onset sCJD cases are studied their clinical
characteristics are comparable to older onset sCJD patients, with the exception of a
more prolonged disease duration and more frequent sensory disturbance, although this
latter finding is likely to reflect reporting bias. A comparison of sCJD databases in the
UK, France and other European countries does not support any major geographical
differences attributable to BSE exposure. In the UK and France there is a suggestion
that the proportion of sCJD patients with the PRNP MM genotype is diminishing with
time but the most plausible explanation is improved detection and genotyping of
atypical sCJD cases.
This study has validated the WHO sCJD diagnostic criteria in the UK population and
found them to be generally useful with the classification Probable sCJD having a
positive predictive value of 89%. Incorporation of CSF 14-3-3 result has resulted in
improved sensitivity at 72% but at the expense ofmoderate reduction in specificity to
79%. There is currently insufficient evidence to support inclusion of MRI results in
the diagnostic criteria. More research is required to fully evaluate the impact of
including MRI, using larger numbers of sCJD patients and Non Cases and also
studying the sensitivity and specificity of different MRI sequences.
In the UK sCJD population rapidly progressive dementia is the commonest mode of
presentation, and the most frequently reported clinical features are dementia,
myoclonus and cerebellar signs. However, amongst the patients referred to the
NCJDSU the most useful features to discriminate between sCJD and non CJD are
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visual disturbance and akinetic mutism. The differential diagnosis of sCJD is wide
and includes many rarities, but in line with the literature this study identified
Alzheimer's disease as the most common condition mistaken for sCJD. A number of
Non sCJD Cases never get a diagnosis and in a minority this is despite post mortem
neuropathology.
Overall results from this study are reassuring, with no evidence of an emergent BSE
related phenotype being misdiagnosed as sCJD in the UK. However, ongoing
surveillance is vital to promote early and accurate disease recognition and expand our
knowledge of sCJD, its risk factors, relevant investigations and the diseases it can
mimic. The recent developments with experimental atypical BSE strains highlight the
many unanswered questions that still remain in the study of transmissible spongiform
encephalopathies and emphasize the need for disease surveillance.
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Appendix
A. Historical and Current Diagnostic Criteria for sCJD
1. Masters et al 1979
Definite: Neuropathologically confirmed spongiform encephalopathy in a case of progressive






Probable: Neuropathologically unconfirmed but progressive dementia with all 5 of (i) - (v)
Possible: Progressive dementia with either:
Myoclonus and course < 3 years
or
Any least 2 of (i) - (v) plus prominent, early signs of lower motor neurone involvement
(amyotrophic variety)
2. Matthews 1984
Definite: Neuropathologically confirmed spongiform encephalopathy in progressive dementia
with at least 1 of:
Probable: Progressive dementia and at least 2 of:
(i) Myoclonus
(ii) Cortical blindness
(iii) Pyramidal / extrapyramidal / cerebellar signs
(iv) Akinetic mutism
And characteristic EEG




Probable: Rapidly progressive dementia and at least 2 of:
(i) Myoclonus
(ii) Visual or cerebellar problems
(iii) Pyramidal or extrapyramidal features
(iv) Akinetic mutism
And characteristic EEG
Possible: Rapidly progressive dementia and at least 2 of (i) - (iv) and duration < 2 years (without
characteristic EEG or positive 14-3-3)
4. Rotterdam 1998 (current)
Definite: Neuropathological confirmation
Probable: Rapidly progressive dementia and at least 2 of:
(v) Myoclonus
(vi) Visual or cerebellar problems
(vii) Pyramidal or extrapyramidal features
(viii) Akinetic mutism
And characteristic EEG and / or positive 14-3-3 CSF protein
Possible: Rapidly progressive dementia and at least 2 of (i) - (iv) and duration < 2 years (without
characteristic EEG or positive 14-3-3)
ii
B. EEG classification used by the NCJDSU
1. Typical
General deterioration / loss of normal background.
Truly periodic generalised synchronous bi/tri phasic discharges occurring throughout the whole
record or at least one quarter of it, and in relatively long segments (15 seconds minimum)
2. Highly suggestive
General deterioration / loss of normal background.
Intermittent bi / tri phasic discharges similar to those seen in sCJD being truly periodic and
generalised at times
BUT either
a) Occurring in bursts of only relatively short duration (<15 seconds) and occupying less than
a quarter of the record
b) Not being truly generalised and synchronous in all portions of the record where they
occurred
3. Suggestive
General deterioration / loss ofnormal background.
Intermittent bi / tri phasic discharges similar to those seen in sCJD
BUT
a) Occurring in bursts of only relatively short duration (<15 seconds)
And either b) or c) or both
b) Not being truly generalised and synchronous
c) Without true periodicity
4.Non specific
Non specific deterioration in normal background activity





Patient Review and Examination Form
1. Identification information Id number [__J
1.1 What is the patient's name: First name
Surname
1.2 Name of the patient's consultant:





Patient's hospital record number
1.4 Who is the patient's G.P.? Surname+initial




1.6 Patient's NHS number: old:
new:
1.7 Date of examination (dd/mm/yyyy): / /
1.8 Examination performed by:
iv
Clinical history
(note the source ofthe information: e.g. hospital notes, relative, etc.)
3. State of patient at admission/first examination by a neurologist
3.1 General appearance:












4. Previous medical history
Complete this section oftheform using the medical notes available. All questions refer to the
patient's history prior to the onset ofthe current illness.
4.1 Does the patient have a record of
previous hospital admissions
unrelated to the present illness? (l=yes,
2=no)
{Ifyes), on how many occasions has
the patient been admitted to hospital?
(88=not applicable)
{Ifyes) record the hospital's name, the








Has the patient ever had a diagnosis of inflammatory
bowel disease? (l=yes, 2=no)
{Ifyes) record date of first diagnosis (dd/mm/yyyy)
Has the patient ever been diagnosed as diabetic?
(l=yes, 2=no)
{Ifyes) record date of first diagnosis (dd/mm/yyyy)
{Ifyes) has the patient received insulin? (l=yes, 2=no)
{Ifpatient has received insulin) record date of first and
last prescription (dd/mm/yyyy)
Has the patient ever undergone surgery requiring a
general anaesthetic? (l=yes, 2=no)
{Ifyes) record the date of the surgery, the procedure(s)
performed, and the name of the hospital where the
procedure(s) took place.
Has the patient ever undergone surgery without
general anaesthetic? (l=yes, 2=no)
{Ifyes) record the date of the surgery, the procedure(s)
performed, and the name of the hospital where the
procedure(s) took place.
On how many occasions in all has the patient








4.7 Has the patient ever received an organ transplant
(including corneal or bone marrow transplant)? (l=yes,
2=no)
{Ifyes) record the date, organ received and name of
hospital.
4.8 Has the patient ever received blood or blood products?
(l=yes, 2=no)
{Ifyes) record the date, type of product, name of
hospital and reason.
4.9 Has the patient ever received a treatment involving a
course of injections (excluding any treatments related
to the current illness)? (l=yes, 2=no)
{Ifyes) record the year of the treatment, the
medication(s) involved and the reason.
ix
4.10 Non-injectable treatments lasting more than 4 weeks: record the start date of the





















4.11 Has the subject ever been exposed to one of the medications
of bovine origin withdrawn in 1990? (l=yes, 2=no)
X




































6. Recording/coding of history and examination
6.1 What were the first symptoms of illness noted by the
patient or their family?
When did these symptoms first occur? (dd/mm/yyyy)
6.2 When did the patient first seek medical attention for
the illness? (dd/mm/yyyy)
6.3 When was the patient first referred to a neurologist?
(dd/mm/yyyy)
6.4 When was the patient first admitted for the current
illness? (dd/mm/yyyy)
6.5 Since the start of the illness, until the current time,
has the patient exhibited the following neurological



















Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but



















6.6 Since the start of the illness, until now, has the
patient exhibited the following clinical symptoms/






6.7 Since the start of the illness, has the patient been
seen by a psychiatrist? (l=yes, 2=no)
{Ifyes) record the date of the first consultation
(dd/mm/yyyy)
6.8 Since the start of the illness until now, has the patient
exhibited the following psychiatric symptoms/signs:

















Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but











Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but











7.1 Has the patient undergone an EEG? (l=yes, 2=no)
(Ifyes), on how many occasions?
(Ifyes), record date ofmost recent EEG (dd/mm/yyyy) / /
Are EEG records/copies available in the Unit? (l=yes
all, 2=yes some, 3=no, 8=not applicable)
Have the EEGs been examined by a Unit staff
member? (l=yes all, 2=yes some, 3=no, 8=not applicable)
7.2 Has the patient recorded an EEG characteristic of
CJD (generalized triphasic periodic complexes with
frequency about l/s)?(l=yes, confirmed by Unit staff,
2=yes, reported by local staff, EEG not available for
confirmation by Unit staff, 3=no, 8=no EEG performed)
What was the basis for the classification of the EEG?
(l=informaI, 2=Oxford criteria, 3=Gottingen criteria,
4="WHO" criteria, 8= no EEG performed)
(Ifyes) record the date on which the first
characteristic EEG was recorded (dd/mm/yyyy)
7.3 Has the patient ever had a CT scan? (l=yes, 2=no)
(Ifyes), on how many occasions?
(Ifyes), record date ofmost recent scan (dd/mm/yyyy) /'""*/
Are CT scan results available in the Unit (l=yes all,
2=yes some, 3=no, 8=not applicable)
Have the CT scans been examined by a Unit staff
member? (l=yes all, 2=yes some, 3=no, 8=not applicable)
7.4 Has the patient ever had an abnormal CT scan?
(l=yes, confirmed by Unit staff, 2=yes, reported by local staff,
scan not available for confirmation by Unit staff, 3=no, 8=no
scans performed)
(Ifyes) record the date on which the first abnormal
scan was performed (dd/mm/yyyy)
(Ifyes) specify what abnormalities have been
observed
xv
7.5 Has the patient ever had an MRI scan? (l=yes, 2=no)
{Ifyes), on how many occasions?
{Ifyes), record date ofmost recent scan (dd/mm/yyyy)
Are MRI scan results available in the Unit (l=yes all,
2=yes some, 3=no, 8=not applicable)
Have the MRI scans been examined by a Unit staff
member? (l=yes all, 2=yes some, 3=no, 8=not applicable)
□
□
7.6 Has the patient ever had an abnormal scan? (l=yes,
confirmed by Unit staff, 2=yes, reported by local staff, scan not
available for confirmation by Unit staff, 3=no, 8=no scans
performed)
{Ifyes) record the date on which the first abnormal
scan was performed (dd/mm/yyyy)
{Ifyes) specify what abnormalities have been observed
7.7 {Ifan abnormalMRI scan has been reported by





7.8 CSF findings (fill coding boxes with 8s if test results are not
available)








Ig oligoclonal bands in: CSF
blood




































7.9 Has the patient had any abnormal liver function test
results recorded? (l=yes, 2=no)
(Ifyes) specify abnormality and give date of first
abnormal test:
7.10 Does the patient have any abnormalities on other
routine biochemical/haematological investigations?
(l=yes, 2=no)






7.11 Has the patient undergone a brain biopsy? (l=yes,
2=no)
(Ifyes) what was the result? (l=no evidence of
spongiform change, 2=spongiform change without florid
plaques, 3=spongiform change with florid plaques, 4=result not
yet available, 8=no biopsy performed)
Name of neuropathologist:
7.12 Has the patient undergone a tonsil biopsy? (l=yes,
2=no)
(Ifyes) what was the result? (l=no evidence of PrP
immunostaining, 2=equivocal, 3=PrP positive, 4=result not yet
available, 8=no biospy performed)
8. Specimens collected
8.1 Blood: frozen for general use




9.1 On the basis of the available information, what is the
classification of the patient? (l.O=definite CJD,
2.0=probable CJD, 3.0=possible CJD, 4.1=diagnosis unclear,
4.2=CJD thought unlikely, 4.3=definitely not CJD, 5=GSS)
(Ifpatient is classified as at least possible CJD or
GSS) which category of disease is suspected?
(S=sporadic CJD, N=nvCJD, F=familial CJD, I=iatrogenic











2.Original CJD study questionnaire
1. Patient number
2. a) Case Source:
b) Control
3. Date of interview
4. Place of interview















10. Country of origin
11. Skin Colour
PRODROMAL PHASE








13. Had the patient, prior to this admission been:
a) Depressed
b) Tired and exhausted
c) Unable to sleep











e) Other illness; specify:





16. Has the patient every been in hospital prior to this illness?





17. Does the patient either regularly attend hospital or GP?
Date Practitioner Reason
18. Has the patient ever had an operation?











19b. Has the patient ever been tested for glaucoma?
20. Has the patient ever had a head injury (with loss of consciousness or skull
fracture)?
If so: Details:
21. Has the patient ever been jaundiced?
If so: Details:
22. Has the patient ever had an epileptic fit?
If so: Details




24a. Has the patient ever had a blood transfusion?
If so: Details:
24b. Has the patient ever been a blood donor?
If so: Details:
xxiii
25. Has the patient ever had an organ transplant
If so: Specify organ and give details:
26. Has the patient ever been in contact with any person with a serious
dementing illness?
If so, details
27. Is the patient left or right handed?





















30a. What injectable therapy, or vaccinations has the patient received in the past?
Name Date Reason Frequency
30b. Has the patient ever had an EMG
If yes, age at first EMG:
If yes, age at last EMG:
If yes, specify reason:
(eg myopathy, neuropathy etc)
31 Smoking habits:
Never = 1
Ex (>12/12) = 2
Current cigs = 3
Current pipe/cigar = 4
Not Known = 9
Drinking habits:
Never = 1
Ex drinker (>12/12) = 2
XXV
Current = 3





32.1 Father Mother Spc
a) Country of birth?
b) Is relative alive now?
c) If no: Age at death:
Cause of death
Place of death
Prior to death was relative
confused or unconscious?
Did relative suffer any
other disease or illness?
32.2 Paternal Paternal Maternal Maternal
Grandfather Grandmother Grandfather Granc
a) Country of birth?
b) Is relative alive now?




Prior to death was relative
confused or unconscious?
Did relative suffer any other disease or illness?
33. Siblings






34. Patient's marital status








Age Sex Alive/Dead Cause of Death
SOCIAL HISTORY
37. Residential history
Address Dates Local characteristics (eg





















39. Occupation of partner:








a) How often does the patient eat the following
Never = 1
< 1 yr =2
Several times/year = 3
> 1/12 = 4
> 1 /week = 5









Ever After 1 985
(i) Sausages
(ii) Tripe















c) Does the patient ever eat rare or undercooked meat?
d) Does the patient have any dietary restrictions or eccentricities?
(NB: If vegetarian, did they ever eat meat, and if so, for how long?)
e) Does the patient consume dairy products?




43. Has the patient ever had personal contact with the following animals:
Age first Ever Age











44. Has the patient had contact with fur or leather other than normal contact with every
45. Has the patient ever lived or worked on a farm?
46. Hobbies:
xxxii
47. Has the patient ever had contact with the following:
(a) Fertiliser
(b) Bonemeal
(c) Hoof and Horn
(d) Dried blood
48. Has the patient any domestic animals now or has he/she had any in the past?
a) Species
b) Was animal allowed to
mix freely with other
animals outside the
house?






d) Did animal ever have a
serious illness?
e) Age of patient when
animal in house
xxxiii
49. Has the patient ever travelled abroad?
If so: Location and dates
50. Does the patient regularly travel within Britain?
If so: Location, frequency and reasons
51. Has any other relative had a similar disease? (OMIT THIS











REVIEW OF PROGRESSION OF PHYSICAL SIGNS
EXAMINATION
1. General appearance:


















a) Date of death:
Place of death:
Cause of death:
b) Review of clinical course:
c) EEG progression:


























1. Identification information Id number
1.1 What was the patient's name: First name
Surname
1.2 Who was patient's consultant:





Patient's hospital record number
1.4 Name of preceding hospital/hospice (if any)
Patient's hospital record number
Other preceding hospital/hospice (if any)
Patient's hospital record number
1.5 Patient's G.P. (surname & initial)





1.6 NHS number of patient: old:
new:
1.7 Date of death of patient (dd/mm/yyyy)









1.10 Date this review closed (dd/mm/yyyy)








(note the source ofthe information: e.g. hospital notes, relative, etc.)
xli
3. State ofpatient at admission/first examination by a neurologist
3.1 General appearance:












4. Previous medical history
Complete this section of the form using the medical notes available. All questions refer to the
patient's history prior to the onset of the final illness. If notes are not available then enter 8s
in coding boxes
4.1 Did the patient have a record of
previous hospital admissions
unrelated to the last illness? (l=yes,
2=no)
{Ifyes), on how many occasions was
the patient admitted to hospital?
(88=not applicable)
{Ifyes) record the hospital's name, the







Was the patient ever diagnosed as having
inflammatory bowel disease? (l=yes, 2=no)
{Ifyes) record date of first diagnosis (dd/mm/yyyy)
Was the patient ever diagnosed as diabetic? (l=yes,
2=no)
{Ifyes) record date of first diagnosis (dd/mm/yyyy)
{Ifyes) did the patient receive insulin? (l=yes, 2=no)
{Ifpatient received insulin) record date of first and last
prescription (dd/mm/yyyy)
Did the patient ever undergo surgery requiring a
general anaesthetic? (l=yes, 2=no)
{Ifyes) record the date of the surgery, the procedure(s)
performed, and the name of the hospital where the
procedure(s) took place.
Did the patient ever undergo surgery without general
anaesthetic? (l=yes, 2=no)
{Ifyes) record the date of the surgery, the procedure(s)
performed, and the name of the hospital where the
procedure(s) took place.
4.6 On how many occasions in all did the patient undergo




4.7 Did the patient ever receive an organ transplant
(including corneal or bone marrow transplant)? (l=yes,
2=no)
{Ifyes) record the date, organ received and name of
hospital.
4.8 Did the patient ever receive blood or blood products?
(l=yes, 2=no)
{Ifyes) record the date, type of product, name of
hospital and reason.
4.9 Did the patient ever receive a treatment involving a
course of injections (excluding any treatments related
to the final illness)? (l=yes, 2=no)
{Ifyes) record the year of the treatment, the
medication(s) involved and the reason.
xlv
4.10 Non-injectable treatments lasting more than 4 weeks, excluding treatments related to
the final illness: record the start date of the treatment, the duration, the medicine and





















4.11 Was the subject ever exposed to one of the medications of
bovine origin withdrawn in 1990? (l=yes, 2=no)
xlvi
5. Recording/coding of history and examination
5.1 What were the first symptoms of illness noted by the
patient or their family?
When did these symptoms first occur? (dd/mm/yyyy)
5.2 When did the patient first seek medical attention for the
illness? (dd/mm/yyyy)
5.3 When was the patient first referred to a neurologist?
(dd/mm/yyyy)
5.4 When was the patient first admitted for the current
illness? (dd/mm/yyyy)
5.5 Did the patient, at any time during the course of the
illness, exhibit the following neurological


















Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but



















5.6 Did the patient, at any time during the course of the
illness, exhibit the following clinical






5.7 Since the start of the illness, was the patient seen by
a psychiatrist? (l=yes, 2=no)
{Ifyes) record the date of the first consultation
(dd/mm/yyyy: enter 08/08/0808 if not applicable)
5.8
v.
Since the start of the illness until death, did the
patient exhibit the following psychiatric




low mood and apathy " " • *-• v."'
anxiety
delusions
hallucinations , * .;ft
aggression
Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but










Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but
date unknown record as 09/09/0909:
if no enter date as 08/08/0808
xlviii
6. Investigations
6.1 Did the patient undergo an EEG? (l=yes, 2=no)
{Ifyes), on how many occasions?
{Ifyes), record date ofmost recent EEG (dd/mm/yyyy)
Are EEG records/copies available in the Unit? (l=yes
all, 2=yes some, 3=no, 8=not applicable)
Have the EEGs been examined by a Unit staff
member? (l=yes all, 2=yes some, 3=no, 8=not applicable)
6.2 Did the patient record an EEG characteristic ofCJD
(generalized triphasic periodic complexes with
frequency about l/s)?(l=yes, confirmed by Unit staff,
2=yes, reported by local staff, EEG not available for
confirmation by Unit staff, 3=no, 8=no EEG performed)
What was the basis for the classification of the EEG?
(l=informal, 2=Oxford criteria, 3=Gottingen criteria,
4="WHO" criteria, 8= no EEG performed)
{Ifyes) record the date on which the first
characteristic EEG was recorded (dd/mm/yyyy)
6.3 Did the patient ever have a CT scan? (l=yes, 2=no)
{Ifyes), on how many occasions?
{Ifyes), record date ofmost recent scan (dd/mm/yyyy)
Are CT scan results available in the Unit (l=yes all,
2=yes some, 3=no, 8=not applicable)
Have the CT scans been examined by a Unit staff
member? (l=yes all, 2=yes some, 3=no, 8=not applicable)
6.4 Did the patient ever have an abnormal CT scan?
(l=yes, confirmed by Unit staff, 2=yes, reported by local staff,
scan not available for confirmation by Unit staff, 3=no, 8=no
scans performed)
{Ifyes) record the date on which the first abnormal
scan was performed (dd/mm/yyyy)








6.5 Did the patient ever have an MRI scan? (l=yes, 2=no)
{Ifyes), on how many occasions?
{Ifyes), record date ofmost recent scan (dd/mm/yyyy)
Are MRI scan results available in the Unit (l=yes all,
2=yes some, 3=no, 8=not applicable)
Have the MRI scans been examined by a Unit staff
member? (l=yes all, 2=yes some, 3=no, 8=not applicable)
□
6.6 Did the patient ever have an abnormal scan? (l=yes,
confirmed by Unit staff, 2=yes, reported by local staff, scan not
available for confirmation by Unit staff, 3=no, 8=no scans
performed)
{Ifyes) record the date on which the first abnormal
scan was performed (dd/mm/yyyy)
{Ifyes) specify what abnormalities have been observed
6.7 {Ifan abnormalMRI scan has been reported by





6.8 CSF findings (fill coding boxes with 8s if test results are not
available)











Date of second CSF collection (dd/mm/yyyy)
Results:





































6.9 Did the patient have any abnormal liver function test
results recorded? (l=yes, 2=no)
{Ifyes) specify abnormality and give date of first
abnormal test:
6.10 Did the patient have any abnormalities on other
routine biochemical/haematological investigations?
(l=yes, 2=no)
{Ifyes) give describe the investigation(s) and the
abnormalities
lii
6.11 Did the patient undergo a brain biopsy during life?
(l=yes, 2=no)
(Ifyes) what was the result? (l=no evidence of
spongiform change, 2=spongiform change without florid
plaques, 3-spongiform change with florid plaques, 4=resu!t not
yet available, 8=no biopsy performed)
Name of neuropathologist:
6.12 Did the patient undergo a tonsil biopsy? (l=yes, 2=no)
(Ifyes) what was the result? (l=no evidence ofPrP
immunostaining, 2=equivocal, 3=PrP positive, 4=result not
available, 8=no biopsy performed)
7. Material available
7.1 Blood: frozen for general use
separated and frozen for transmission studies
7.2 Urine
7.3 CSF
7.4 Was a post mortem performed? (l=yes, 2=no)
(Ifyes) is neuropathological material available?
(l=yes, 2=no, 8=not applicable)
(Ifmaterial is available) is material available in
Edinburgh? (l=yes, 2=no, 8=not applicable)
7.5 Are post mortem results available? (l=yes, 2=no, 8=no
post mortem performed)
(Ifyes) what is the result? (l=no evidence of spongiform
change, 2=spongiform change without florid plaques,
3=spongiform change with florid plaques, 4=result not yet
available, 8=no post mortem performed)
Name of neuropathologist:
7.6 Are PrP genotype data available? (l=yes, 2=no)
(Ifyes) did the patient carry a mutation? (l=yes
(specify), 2=no)












8.1 At notification to the CJDSU, what was the patient's
classification? (1.0=definite CJD, 2.0=probable CJD,
3.0=possible CJD, 4.1=diagnosis unclear, 4.2=CJD thought
unlikely, 4.3=definitely not CJD, 5=GSS)
{Ifpatient was classified as at least possible
CJD/GSS) which category of disease was suspected?
(S=sporadic CJD, N=nvCJD, F=familial CJD, I=iatrogenic
CJD, G=GSS, 8=not applicable)
8.2 What was the highest classification on the basis of
clinical information alone? (2=probable CJD, 3=possible
CJD, 4=neither probable nor possible CJD, 5=GSS)
8.3 At the time of completion of this review, what is the
patient's classification? (1.0=definite CJD, 2.0=probable
CJD, 3.0=possible CJD, 4.1=diagnosis unclear, 4.2=CJD
thought unlikely, 4.3=definitely not CJD, 5=GSS)
{Ifpatient was classified as at leastpossible
CJD/GSS) which category of disease is suspected?
(S=sporadic CJD, N=nvCJD, F=familial CJD, I=iatrogenic
CJD, G=GSS, 8=not applicable)
8.4 {Ifpatient was classified as at leastpossible
CJD/GSS) what was the clinical presentation of
subject at onset of symptoms? (1= rapidly progressive
dementia, 2= Heidenhain, 3=pure psychiatric onset, 4=slowly
progresive dementia, 5= pure cerebellar onset, 6=
extrapyramidal onset, 6=stroke like onset, 7=other, 8=not
applicable, 9= unable to ascertain/missing)
.
liv









NHS Number, if known:
Family, carer or independent representative details (if appropriate*)
* This may be appropriate if the approach is made via a iead family member, carer or independent

























Brief clinical details: (please attach recent letter or discharge summary)
Consent:
*please delete as appropriate
I have been provided with the patient information
leaflet which explains the role of the National
CJD Surveillance Unit and the National Prion
Clinic.
I agree to my/the patient's* details being
forwarded to the National CJD Surveillance Unit




I agree that staff from the National CJD
Surveillance Unit in Edinburgh and the National
Prion Clinic in London can visit myself/the
patient* and my/their* relatives at a mutually
convenient time for clinical assessment and
surveillance purposes and to provide the
opportunity, should we wish, to discuss ongoing
research, including clinical trials of potential
treatments.
I understand that this may mean providing
further information to help in the organisation of
my/the patient's* care, and to contribute to a






On completion, please fax to NCJDSU 0131 343 1404, NPC 0207 061 9889
and also to your local CCDC
lvii
E. Tables of frequencies of symptoms and signs in Definite, Probable and




Definites 1993/4 Definites 2003/4 Significance
Forgetful 43.9 % (36) 39.5 % (30) NS
Unsteady 35.4 % (29) 22.4% (17) NS
Sleep 25.6% (21) 22.4% (17) NS
Visual 19.5% (16) 22.4% (17) NS
Weight loss 18.3% (15) 11.8% (9) NS
Psychiatric 15.9% (13) 11.8% (9) NS
Speech 9.8 % (8) 7.9 % (6) NS
Dizzy 12.2 % (10) 11.8% (9) NS
Weakness 4.9 % (4) 6.6 % (5) NS
Sensory symptoms 3.7 % (3) 3.9 % (3) NS
Headache 2.4 % (2) 2.6 % (2) NS
Hallucinations 1.2 % (1) 2.6 % (2) NS
Symptoms
suggesting seizure




Probables 1993/4 Probables 2003/4 Significance
Forgetful 53.8 % (7) 39.3 % (22) NS
Unsteady 23.1 % 3 25.0 % (14) NS
Sleep 15.4 5(2) 16.1 % (9) NS
Visual 15.4% (2) 21.4% (12) NS
Weight loss 15.4% 92) 7.1 % (4) NS
Psychiatric 7.7 % (1) 17.9% (10) NS
Speech 23.1 % (3) 8.9 % (5) NS
Dizzy 15.4% (2) 14.3 % (8) NS
Weakness 0 % (0) 0 % (0) NS
Sensory symptoms 0 % (0) 3.6 % (2) NS
Headache 38.5 % (5) 10.7 % (6) NS
Hallucinations 7.7 % (1) 3.6 % (2) NS
Symptoms
suggesting seizure










Forgetful 50% (13) 59.4 % (19) NS
Unsteady 23.1 % (6) 25% (8) NS
Sleep 11.5 % (3) 9.4 % (3) NS
Visual 7.7 % (2) 0 % (0) NS
Weight loss 15.4% (4) 9.4 % (3) NS
Psychiatric 15.4% (4) 12.5 % (4) NS
Speech 0 % (0) 6.3 % (2) NS
Dizzy 23.1 % (6) 3.1 %(1) NS
Weakness 7.7 % (2) 3.1 % (1) NS
Sensory symptoms 3.8 % (1) 3.1 %(1) NS
Headache 3.8 %(1) 3.1 %(1) NS
Hallucinations 7.7 % (2) 6.3 % (2) NS
Symptoms
suggesting seizure




Definites 1993/4 Definites 2003/4 Significance
Forgetful 95.1 % (78) 97.4 % (74) NS
Unsteady 89.0 % (73) 94.7 % (72) NS
Sleep 73.2 % (60) 55.3 % (42) p = 0.02
Visual 61.0% (50) 65.8 % (50) NS
Weight loss 45.1 % (37) 25.0% (19) p = 0.01
Psychiatric 41.5 % (34) 31.6% (24) NS
Speech 80.5 % (66) 84.2 % (64) NS
Dizzy 25.6% (21) 27.6% (21) NS
Weakness 34.1 % (28) 35.5 % (27) NS
Sensory symptoms 4.9 % (4) 17.1 % (13) p = 0.02
Headache 12.2 % (10) 23.7% (18) NS
Hallucinations 36.6 % (30) 52.6 % (40) NS
Symptoms
suggesting seizure





Probables 1993/4 Probables 2003/4 Significance
Forgetful 100% (13) 100 % (53) NS
Unsteady 92.3 % (12) 98.1 % (52) NS
Sleep 46.2 % (6) 41.5 % (22) NS
Visual 53.8 % (7) 67.9 % (36) NS
Weight loss 53.85 (7) 22.6% (12) p = 0.04
lix
Psychiatric 30.8 % (4) 26.4% (14) NS
Speech 84.6% (11) 92.5 % (49) NS
Dizzy 23.1 % (3) 32.1 % (17) NS
Weakness 15.4% (2) 26.4 5 (14) NS
Sensory symptoms 38.5 % (5) 18.9% (10) NS
Headache 15.4% (2) 30.2 % (16) NS
Hallucinations 38.5 % (5) 49.1 % (26) NS
Symptoms
suggesting seizure









Forgetful 92.3 % (24) 96.9% (31) NS
Unsteady 84.6 % (22) 65.6% (21) NS
Sleep 46.2% (12) 43.8 % (14) NS
Visual 26.9 % (7) 18.8% (6) p = 0.003
Weight loss 30.8 % (8) 25.0 % (8) NS
Psychiatric 23.1 % (6) 31.3 %(10) NS
Speech 57.7% (15) 56.3% (18) NS
Dizzy 30.8 % (8) 9.4 % (3) p = 0.04
Weakness 46.2 % (12) 15.6% (5) p = 0.008
Sensory symptoms 19.2 % (5) 15.6% (5) NS
Headache 23.1 % (6) 18.8% (6) NS
Hallucinations 19.2 % (5) 53.1 % (17) NS
Symptoms
suggesting seizure
3.8 % (1) 9.4 % (3) NS
Table G
Signs on 1st exam. Definites 93/4 Definites 03/4 Significance
Dementia 56.1 % (46) 63.2% (48) NS
Cerebellar 40.2 % (33) 48.7 % (37) NS
Pyramidal 11.0% (9) 19.7% (15) NS
Extrapyramidal 4.9 % (4) 2.6 % (2) NS
Myoclonus 9.8 % (8) 19.7% (15) NS
Other movt
disorder
9.8 % (8) 9.2 % (7) NS
Oculomotor 11.0% (9) 25.0% (19) NS
Cortical blindness 1.2 % (1) 0 % (0) NS
Dyspraxia 8.5 % (7) 11.8% (9) NS
Akinetic mutism 0 % (0) 0 % (0) NS
Primitive reflexes 4.9 % (4) 3.9% (3) NS
Sensory signs 14.6% (12) 9.2 % (7) NS
Neurogenic muscle
wasting
1 % (1.2) 1.3 % (1) NS
lx
Urinary 7.3 % (6) 7.9 % (6) NS
incontinence /
catheterised
Mean time to 1st examination for pathologically confirmed cases was 3.3 months for
1993/4 referrals and 4.4 months for 2003/4 referrals.
Table H
Signs on 1st exam. Probables 1993/4 Probables 2003/4 Significance
Dementia 92.3 % (12) 62.3 % (33) p = 0.05
Cerebellar 61.5 % (8) 56.6 % (30) NS
Pyramidal 30.8 % (4) 13.2% (7) NS
Extrapyramidal 0 % (0) 1.9 % (1) NS
Myoclonus 15.4% (2) 18.9% (10) NS
Other movt 0 % (0) 11.3% (6) NS
disorder
Oculomotor 7.7 % (1) 9.4 % (5) NS
Cortical blindness 0 % (0) 1.9 % (1) NS
Dyspraxia 7.7 % (1) 17.0% (9) NS
Akinetic mutism 0 % (0) 0 % (0) NS
Primitive reflexes 7.7 %(1) 5.7 % (3) NS
Sensory signs 0 % (0) 7.5 % (4) NS
Neurogenic muscle 0 % (0) 0 % (0) NS
wasting
Urinary 0 % (0) 5.7 % (3) NS
incontinence /
catheterised
Mean time to exam for Probable sCJD was 1.3 months in 1993/4 and 3.0 months in
2003/4.
Table I





Dementia 65.4 % (17) 53.1 % (3) NS
Cerebellar 46.2% (12) 21.9% (7) p = 0.007
Pyramidal 7.7 % (2) 6.3 % (2) NS
Extrapyramidal 0 % (0) 9.4 % (3) NS
Myoclonus 19.2% (5) 12.5 % (4) NS
Other movt
disorder
7.7 % (2) 3.1 %(1) NS
Oculomotor 7.7 % (0) 9.4 % (3) NS
Cortical blindness 0 % (0) 0 % (0) NS
Dyspraxia 0 % (0) 3.1 %(1) NS
Akinetic mutism 0 % (0) 0 % (0) NS
lxi
Primitive reflexes 3.8 % (1) 9.4 % (3) NS
Sensory signs 15.4% (4) 9.4 % (3) NS
Neurogenic muscle 0 % (0) 0 % (0) NS
wasting
Urinary 15.4% (4) 9.4 % (3) NS
incontinence /
catheterised
Mean time to first exam for Possible / Unclear diagnosis cases was 2.7 months in
1993/4 and 4.2 months in 2003/4
Table J
Clinical signs ever Definite 1993/4 Definite 2003/4 Significance
Dementia 93.9 % (77) 97.4 % (74) NS
Cerebellar 62.2% (51) 68.4 % (52) NS
Pyramidal 56.1 % (46) 51.3% (39) NS
Extrapyramidal 22.0% (18) 17.1 % (13) NS
Myoclonus 85.4 % (70) 88.2 % (67) NS
Other movt
disorder
37.8% (31) 30.3 % (23) NS
Oculomotor 36.6 % (30) 46.1 % (35) NS
Cortical blindness 24.4 % (20) 9.2 % (7) p = 0.02
Dyspraxia 28.0 % (23) 43.4 % (33) p = 0.05
Akinetic mutism 69.5 % (57) 35.5 % (27) p< 0.001
Primitive reflexes 59.8 % (49) 51.3% (39) NS
Sensory signs 22.0% (18) 10.5% (8) NS
Neurogenic muscle
wasting




54.9 % (45) 81.6% (62) p< 0.001
Table K
Clinical signs ever Probable 1993/4 Probable 2003/4 Significance
Dementia 100% (13) 100 % (53) NS
Cerebellar 69.2 % (9) 79.2% (42) NS
Pyramidal 53.8 % (7) 69.8 % (37) NS
Extrapyramidal 0 % (0) 5.7 % (3) NS
Myoclonus 92.3 % (12) 98.1 % (52) NS
Other movt
disorder
23.1 % (3) 34.0% (18) NS
Oculomotor 30.8 % (4) 45.3 % (24) NS
Cortical blindness 53.8 % (7) 22.6 % (12) p = 0.04
Dyspraxia 30.8 % (4) 35.8 % (19) NS
Akinetic mutism 76.9% (10) 37.7 % (20) T—HOOII(X
lxii
Primitive reflexes 61.5 % (8) 58.5% (31) NS
Sensory signs 0 % (0) 3.8 % (2) NS
Neurogenic muscle 0 % (0) 1.9 % (1) NS
wasting









Dementia 92.3 % (24) 93.8 % (30) NS
Cerebellar 61.5% (16) 46.9% (15) p = 0.02
Pyramidal 42.3% (11) 25.0 % (8) NS
Extrapyramidal 11.5% (3) 21.9% (7) NS
Myoclonus 76.9 % (20) 78.1 % (25) NS
Other movt 19.2% (5) 25.0 % (8) NS
disorder
Oculomotor 30.8 % (8) 25.0 % (8) NS
Cortical blindness 11.5 % (3) 0 % (0) NS
Dyspraxia 19.2% (5) 15.6 % (1) NS
Akinetic mutism 38.5 %(10) 37.7 % (20) p = 0.04
Primitive reflexes 42.3 %(11) 40.6 % (13) NS
Sensory signs 15.4% (4) 12.5 % (4) NS
Neurogenic muscle 0 % (0) 3.1 %(1) NS
wasting
Urinary 57.7% (15) 50.0% (16) NS
incontinence /
catheterised
lxiii
